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In this Special Issue entitled “Rare Kidney Diseases: New Translational Research Approach to
Improve Diagnosis and Therapy”, of the International Journal of Molecular Sciences, that includes
original articles and reviews, authors have underlined the role of biomedical research in providing
new insights into the pathologies of complex kidney diseases.
Rare kidney diseases comprise a group of more than one hundred different life-threatening or
chronically debilitating disorders affecting a small number of patients worldwide (approximately <1
in 2000 individuals in Europe and <200,000 in USA) [1] with different local and/or systemic clinical
manifestations/complications. Most of them have a genetic basis, often affecting patients early in
childhood, and are frequently progressive, disabling and life-threatening [2]. These features can have
an overwhelming psychological impact on the families of children affected by these diseases.
However, although often perceived by the public opinion and media as a prime target of national
health care systems, the research in this area has been, for many years, neglected in favor of more
common diseases. Main reasons for the lack of interest in this field could be due to the small number of
patients available and the consequent limited epidemiological data regarding many of these disorders.
Additionally, rare diseases can affect people in different ways. Even patients with the same
disorder can exhibit very different signs and symptoms, or there may be many subtypes of the same
condition. This diversity comprises a significant challenge to healthcare practitioners and scientists
alike in terms of being able to gain sufficient experience for the most proper and timely definition,
diagnosis and management.
A step forward in this field has been obtained by the advances in biotechnologies and ”omics”
methodologies [3–6] that have led to the discovery of previously unrecognized disease-associated
biological processes and identified new potential diagnostic biomarkers and drug targets.
In this issue Bruschi et al. [7], by using a comprehensive comparative proteomic analysis (by mass
spectrometry) of urinary microvesicles and exosomes, reported, for the first time, that several urinary
proteins (some of them implicated in complement pathway regulation) may be able to clearly identify
patients with medullary sponge kidney (MSK) disease, a rare kidney condition often associated with
nephrocalcinosis/nephrolithiasis and cystic anomalies in the precalyceal ducts, from idiopathic calcium
nephrolithiasis (ICN) as a control group.
The analysis of urinary extracellular vesicles is ideal because they can be easily obtained without
invasive procedures, and they contain elevated levels of cell-specific proteins from every segment
of the nephron, representing diverse cellular processes including metabolic, immunity-related and
coagulation responses [8,9]. These intrinsic characteristics of extracellular vesicles could, therefore,
provide a panel of informative marker proteins that not only allow the diagnosis and monitoring of
MSK but could also provide insight into the underlying pathophysiological and biochemical processes.
Gianesello et al. [10] investigated allelic and locus heterogeneity in Dent disease (DD), an X-linked
renal tubulopathy mainly caused by loss-of-function mutations in CLCN5 (DD1) and OCRL genes,
Int. J. Mol. Sci. 2020, 21, 4244; doi:10.3390/ijms21124244 www.mdpi.com/journal/ijms1
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and analyzed ClC-5, megalin, and cubilin expression in DD1 kidney biopsies. They further expanded
the spectrum of CLCN5 mutations in DD by describing 23 novel mutations. In DD1 kidney biopsies,
they showed that the loss of ClC-5 tubular expression caused defective megalin and cubilin trafficking.
In DD3 patients (who have neither CLCN5 nor OCRL gene mutations) whole exome sequencing (WES)
did not detect a new disease-causing gene. Instead, it revealed the concomitant presence of likely
pathogenic variants in genes encoding proximal tubular endocytic apparatus components, suggesting
that they may have had a role in determining the DD3 phenotype.
Furthermore, Muhle-Goll C et al. [11] investigated the accuracy of nuclear magnetic resonance
(NMR)-based urine metabolomics for the diagnosis of acute kidney injury (AKI) in a pilot cohort study
of neonates and children with established Kidney Disease: Improving Global Outcomes (KDIGO) AKI
of heterogeneous etiology. They further explored if metabolomic fingerprints and biomarkers allow
for a differentiation of specific AKI subtypes.
Multivariate analysis identified a panel of four metabolites that allowed diagnosis of AKI with an
area under the receiver operating characteristics curve (AUC-ROC) of 0.95 (95% confidence interval
0.86–1.00). Especially urinary citrate levels were significantly reduced whereas leucine and valine
levels were elevated. Metabolomic differentiation of AKI causes appeared promising but these results
need to be validated in larger studies.
De Rasmo D et al. [12] analyzed molecular aspects of nephropathic cystinosis, a rare inherited
metabolic disease characterized by an impaired transport of the amino acid cystine out of lysosomes
due to the reduced or absent function of the specific carrier cystinosin, which is encoded by the
CTNS gene.
In particular, authors investigated mitochondrial dynamics in CTNS−/− conditionally immortalized
proximal tubular epithelial cells (ciPTEC) carrying the classical homozygous 57-kb deletion with the
intent of identifying new therapeutic targets and biomarkers for treatment follow-up.
Interestingly, their results clearly demonstrated that CTNS−/− cells showed an overexpression
of parkin associated with the deregulation of ubiquitination of mitofusin 2 and fission 1 proteins,
an altered proteolytic processing of optic atrophy 1 (OPA1) and a decreased OPA1 oligomerization.
According to molecular findings, the analysis of electron microscopy images showed a decrease in
the mitochondrial cristae number and an increase in the cristae lumen and cristae junction width.
Cysteamine treatment restored mitochondrial size, cristae number and lumen, but had no effect on
cristae junction width, making tubular cells more susceptible to apoptotic stimuli.
Based on their results, authors concluded that several cellular mediators of mitochondrial dynamics
could be useful to develop new therapeutic interventions in this disease. This could be assessed by a
future multicenter translational study.
The retrospective analysis of John C. Lieske group [13] investigated plasma oxalate (POx) as a
potential predictor of end-stage kidney disease (ESKD) among primary hyperoxaluria (PH) patients.
PH is a rare inherited autosomal recessive genetic disease caused by defects in genes that encode
proteins important for glyoxylate metabolism [14].
Notably, results of this study demonstrated that in patients with PH, higher POx concentration
was a risk factor for ESKD, particularly in advanced chronic kidney disease stages.
Together with the aforementioned original articles, this issue also includes five literature reviews.
Andrighetto et al. [15] reviewed the role of the complement cascade in a wide spectrum of
rare renal diseases (including antibody-related glomerulopathies and non-antibody-mediated kidney
diseases, such as C3 glomerular disease, atypical hemolytic uremic syndrome and focal segmental
glomerulosclerosis) and the potential therapeutic effects of new selective complement-targeting drugs.
Schena FP group [16], describing recent research findings on C3 glomerulopathy, emphasized the
importance of a multidisciplinary approach (that involves nephrologists, renal pathologists, molecular
biologists and geneticists) to optimize the diagnosis and the treatment of this rare and neglected disease.
Fay J. Dickson and John A. Sayer [17] elegantly reviewed recent literature evidences regarding the
employment of a novel precision-medicine approach to ensure patients affected by nephrocalcinosis
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and their families receive prompt diagnosis (that may slow down the progression to CKD), tailored
treatment and accurate prognostic information (it is also useful to screen other family members).
Next, Sallustio et al. [18], based on recent literature evidences, have suggested a new vision of IgA
Nephropathy, a primary glomerulonephritis that affects people mainly in the 2nd and 3rd decade of life.
Whole-genome genomic studies revealed that this disorder is influenced by several environmental and
behavioral factors that, if promptly corrected, may change the course of the disease.
Finally, Letavernier E et al., in an interesting narrative review [19], summarized recent discoveries
concerning the pathophysiology of Pseudoxanthoma elasticum, a rare mendelian disease responsible
for both cardiovascular and renal papillary calcifications, and discussed the potential implications
of pyrophosphate deficiency as a promoter of vascular calcifications in kidney stone formers and in
patients affected by CKD.
Overall, the 10 contributions have clearly shown that, in the future, molecular biology will certainly
impact clinical decision making in nephrology and will become part of the day-to-day clinical practice.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Medullary sponge kidney (MSK) disease is a rare and neglected kidney condition often
associated with nephrocalcinosis/nephrolithiasis and cystic anomalies in the precalyceal ducts. Little
is known about the pathogenesis of this disease, so we addressed the knowledge gap using a
proteomics approach. The protein content of microvesicles/exosomes isolated from urine of 15 MSK
and 15 idiopathic calcium nephrolithiasis (ICN) patients was investigated by mass spectrometry,
followed by weighted gene co-expression network analysis, support vector machine (SVM) learning,
and partial least squares discriminant analysis (PLS-DA) to select the most discriminative proteins.
Proteomic data were verified by ELISA. We identified 2998 proteins in total, 1764 (58.9%) of which
were present in both vesicle types in both diseases. Among the MSK samples, only 65 (2.2%)
and 137 (4.6%) proteins were exclusively found in the microvesicles and exosomes, respectively.
Similarly, among the ICN samples, only 75 (2.5%) and 94 (3.1%) proteins were exclusively found
in the microvesicles and exosomes, respectively. SVM learning and PLS-DA revealed a core panel
of 20 proteins that distinguished extracellular vesicles representing each clinical condition with
an accuracy of 100%. Among them, three exosome proteins involved in the lectin complement
pathway maximized the discrimination between MSK and ICN: Ficolin 1, Mannan-binding lectin
serine protease 2, and Complement component 4-binding protein β. ELISA confirmed the proteomic
results. Our data show that the complement pathway is involved in the MSK, revealing a new range
of potential therapeutic targets and early diagnostic biomarkers.
Keywords: medullary sponge kidney; idiopathic calcium nephrolithiasis; complement system; proteomics
1. Introduction
In the last decade, great efforts have been undertaken to characterize the biological networking
associated with medullary sponge kidney (MSK) disease, a rare clinical condition (prevalence of
approximately 5 cases per 100,000 in the general population) often associated with nephrocalcinosis
and nephrolithiasis, urinary acidification and concentration defects, and cystic anomalies in the
precalyceal ducts [1]. Most of these studies, based on clinical observations, as well as molecular
Int. J. Mol. Sci. 2019, 20, 5517; doi:10.3390/ijms20215517 www.mdpi.com/journal/ijms5
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analysis, have provided evidence that supports the genetic transmission of MSK and an association
with metabolic disorders (such as hyperparathyroidism) and bone diseases [2–11].
More recently, we used proteomic analysis to catalog the MSK-specific protein profile, as well as the
protein content of urinary extracellular vesicles [12]. This revealed the presence of several key regulators
of epithelial cell differentiation, kidney development, cell migration/adhesion, and extracellular
matrix organization, providing a new insight into the pathophysiology of MSK [12]. The most
abundant protein found in MSK urinary extracellular vesicles was laminin subunit α2 (LAMA2,
Merosin), a well-characterized member of the laminin family of at least 15 αβG heterotrimeric
proteins, which contributes to the extracellular matrix and is a major component of the basement
membrane [12,13]. This protein is thought to promote cyst formation [14–16]. It also regulates
extracellular laminin assembly, and the laminin then determines the orientation of the apical pole [17].
In our most recent publication [18], we compared the protein content of extracellular vesicles
(exosomes and microvesicles) from MSK and autosomal dominant polycystic kidney disease (ADPKD)
patients by mass spectrometry (MS) and identified a profile including 34 proteins that discriminate
between the two clinical conditions. The most abundant protein in MSK vesicles was SPP1, also known
as osteopontin, which is implicated in physiological/pathological bone mineralization and kidney
stone formation [19]. This protein is synthesized in the kidney and secreted into the urine by epithelial
cells, including those lining the loop of Henle, distal convoluted tubule, and papillary duct [20].
SPP1 inhibits the nucleation, growth, and aggregation of calcium oxalate crystals [21] and the binding
of these crystals to kidney epithelial cells [22]. Although it has been recently found that osteopontin
was up-regulated in the kidney from established rat models for polycystic kidney disease compared
with wild-type mice [23,24], no data are available for MSK (no animal model is available for this
disease). Therefore, based on our in vivo data, we can assume that in MSK patients, osteopontin could
be also more up-regulated than ADPKD. A reason could be that in MSK, this biological element may
be implicated not only in cystic development, but also in nephrolithiasis, a major clinical condition
associated with medullary sponge kidney.
The diagnostic accuracy for MSK is currently low because it depends on personal experience
(MSK is often confused with other causes of nephrocalcinosis or with papillary ductal plugging)
and diagnosis requires invasive radiation and/or nephrotoxic contrast agents for medical imaging.
Although the studies described above have shed light on the biological mechanisms associated with
MSK, the pathogenesis of this disorder is only partially defined and further studies are necessary to
identify suitable diagnostic biomarkers. To address this knowledge gap, we carried out a comprehensive
comparative proteomic analysis of urinary microvesicles and exosomes to identify biological differences
between MSK and idiopathic calcium nephrolithiasis (ICN) as a control group. The analysis of urinary
extracellular vesicles is ideal because they can be obtained without invasive procedures and they
contain elevated levels of cell-specific proteins from every segment of the nephron, representing
diverse cellular processes including metabolic, immunity-related, and coagulation responses [25,26].
These intrinsic characteristics of extracellular vesicles could, therefore, provide a panel of informative
marker proteins that not only allow the diagnosis and monitoring of MSK but could also provide
insight into the underlying pathophysiological and biochemical processes.
2. Results
2.1. Characterization of Exosomes and Microvesicles
The size and purity of the microvesicles and exosomes isolated by ultracentrifugation were
confirmed by dynamic light scattering (DLS), revealing a Gaussian distribution profile with peak
means at 1000 ± 65 and 90 ± 5 nm, the typical size for microvesicles and exosomes, respectively
(Figure S1A). There was no difference in size between the MSK and ICN patients for either type of
vesicle. Western blot analysis revealed that the exosomes were positive for CD63 and CD81 but not
CD45, whereas the microvesicles showed the opposite antigen profile (Figure S1B).
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2.2. Protein Composition of Exosomes and Microvesicles
The protein composition of microvesicles and exosomes from the urine of ICN and MSK patients
was determined by MS analysis. We identified 2998 proteins in total, 1764 (58.9%) of which were
present in all four sample types. Among the ICN samples, only 75 (2.5%) and 94 (3.1%) proteins were
exclusively found in the microvesicles and exosomes, respectively. Similarly, among the MSK samples,
only 65 (2.2%) and 137 (4.6%) proteins were exclusively found in the microvesicles and exosomes,
respectively (Figure 1).
Figure 1. Venn diagram showing all the proteins identified in exosomes and microvesicles isolated from
the urine of idiopathic calcium nephrolithiasis (ICN) and medullary sponge kidney (MSK) patients.
Venn diagram shows common and exclusive proteins in the ICN and MSK groups. The numbers
(and percentages) of proteins in the overlapping and non-overlapping areas are indicated.
About 2% of the total proteins found in extracellular vesicles were associated with one or both
kidney diseases according to the DisGeNET database [27]. Among these associated proteins, 40% were
found in the ICN and 100% in the MSK samples (Figure S2). The cellular origins of the proteins in the
microvesicles were very similar in the ICN and MSK disease samples, with 35% of proteins originating
from membranes, 25% from the cytoplasm, 7% from the nucleus, and 33% from other organelles. Similar
results were observed for the exosome proteins, with 19% originating from membranes, 31% from the
cytoplasm, 11% from the nucleus, and 38% from other organelles.
The overlapping protein content of each sample was confirmed by constructing a two-dimensional
scatter plot of the multidimensional scaling (MDS) analysis (Figure S3). No samples were excluded
during the quality check, performed by non-hierarchical clustering. We used weighted-gene
co-expression network analysis (WGCNA) to identify proteins associated with each type of extracellular
vesicle and disease, revealing a total of 14 modules comprising proteins with similar expression profiles.
To distinguish between modules, we chose an arbitrary color for each module. The number of proteins
included in each module ranged from 31 (salmon) to 950 (turquoise). The lime, pink, violet, and tan
modules showed closer relationships with the microvesicles or exosomes from the ICN samples,
whereas the gray, yellow, and green modules showed closer relationships with the microvesicles from
the MSK samples (Figure 2).
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Figure 2. Module identification and relationships with clinical traits. Heat map of the relationships
between module eigengenes and the trait indicator of each sample. The grade of the relationship
ranges from −1 (blue) to 1 (red), where blue represents a perfect negative correlation and red a perfect
positive correlation.
Next, we applied the Mann–Whitney U-test to identify the proteins that best distinguish the type
of disease in the microvesicles or exosomes (Figure 3A,B).
This revealed a total of 142 discriminatory proteins (Tables S1 and S2): 105 distinguished between
ICN and MSK microvesicles and 43 distinguished between ICN and MSK exosomes, with six featuring
in both vesicle types (Figure S4A). Their expression profiles after Z-score analysis are shown in Figure
S4B. support vector machine (SVM) learning and partial least squares discriminant analysis (PLS-DA)
were then used to highlight the proteins that maximize the discrimination between different sample
types, revealing a core panel of 20 proteins that identified the four sample types with an accuracy of
100% (Figure 4A). Following the Z-score analysis, we built a heat map of the corresponding expression
profiles (Figure 4B).
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Figure 3. Volcano plot showing the univariate statistical analysis of urinary exosome (A) and
microvesicle (B) fractions from ICN and MSK patients. The plot is based on the fold change (log2) and
p-value (–log10) of all proteins identified in all samples. White circles indicate proteins with statistically
significant differences in abundance between the two groups of patients.
The diversity of expression profiles among the proteins that showed significant and high levels
of sample discrimination indicated an equally diverse range of functions, so we assigned Gene
Ontology (GO) functional annotations to build a network of biochemical pathways among the different
groups (Figure S5). In this network, circles and lines represent the biochemical pathways and their
interconnections, respectively. In addition, the different pathways were clustered into 12 functional
groups based on their GO annotations (ellipses): immune system, production of reactive oxygen
species, IL-8 regulation, transport, regulation of ERBB signaling, tyrosine phosphorylation, receptor
activity, peptidyl serine modification, hydrolase activity, DNA regulation, nucleoside metabolism,
and cell and organ development. These 12 clusters were grouped into four macro-areas: regulation
of metabolism, signal transduction, inflammation, and regulation of cell development. To generate
a more concise picture of the biochemical process associated with the three proteins that maximize
the discrimination between the exosomes of ICN and MSK samples [Mannan-binding lectin serine
protease 2 (MASP2), Ficolin 1 (FCN1), and Complement component 4-binding protein β (C4BPB)],
we explored the enrichment of GO annotations in greater detail. This highlighted the lectin-based
complement activation pathway as the perturbed biochemical process most likely associated with
all three potential biomarkers (Figure 5). The diagram shows the pathway mapped as a network
of proteins (nodes) and their interactions (edges). Node color represents the fold change in protein
abundance in the urinary exosome fraction of MSK (red) versus ICN (blue) patients, and the node size
represents the corresponding p-values.
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Figure 4. Proteins that achieve maximum discrimination between the exosome and microvesicle
fractions of ICN and MSK patients. (A) Heat map of 20 core proteins identified through the combined
use of univariate statistical analysis, machine learning, and partial least squares discriminant analysis.
In the heat map, each row represents a protein, and each column corresponds to a sample type
(exosome and microvesicle fractions from ICN and MSK patients). Normalized Z-scores of protein
abundance are depicted by a pseudocolor scale with red indicating positive expression, white equal
expression, and blue negative expression compared to each protein value, whereas the dendrogram
displays the outcome of unsupervised hierarchical clustering, placing similar proteome profile values
near each other. (B) Two-dimensional scatter plot representing the partial least squares discriminant
analysis of exosomes (white symbols) and microvesicles (gray symbols) from MSK (circle) and ICN
(square) patients, using the 20 core proteins. The ellipsis indicates 95% confidence interval. Visual
inspection of the dendrogram, heat map, and scatter plot confirm the ability of these proteins to clearly
distinguish among the four different sample types.
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Figure 5. Complement lectin pathway activation. The diagram shows the zoom-in of the immune
system enrichment results mapped as a network. Nodes and edges represent, respectively, the proteins
and their interaction in the pathway of complement lectin activation. The color intensity of each protein
(node) indicates the fold change increment in the urinary exosome fraction of MSK (red) versus ICN
(blue) patients and the node size is representative of their p-value. The gray nodes represent unidentified
proteins (circle) and protein complexes (diamonds) in the lectin pathway. The hexagons indicate the
three proteins that maximize the discrimination between ICN and MSK samples as highlighted by the
combined use of univariate/multivariate statistical analysis and machine learning algorithms.
2.3. ELISA Analysis of MASP2, FCN1, and C4BPB to Confirm the MS Data
The mass spectrometry (MS) results were verified by ELISA for all patients enrolled in the study
using an in-house assay setup (Figure 6). We found that MASP2 was expressed more strongly in
ICN patients compared to MSK patients (Figure 6A, black circle). The median (and interquartile
range) values for ICN and MSK were 1.05 (0.41–1.4) and 0.2 (0.1–0.4), respectively (p < 0.0001).
Received operating characteristic (ROC) analysis revealed that the expression of MASP2 in the urinary
exosome can distinguish between ICN and MSK patients (Figure 6B, black line). The area under the
curve (AUC), 95% confidence interval (CI), and p-value for the ROC analysis were 0.89, 0.81–0.97,
and p < 0.0001, respectively. The cutoff, sensitivity, specificity, and likelihood ratio were 0.62, 67%, 97%,
and 20, respectively.
In contrast to MASP2, FCN1 (Figure 6A, red circle) and C4BPB (Figure 6A, green circle) were more
strongly expressed in MSK patients compared to ICN patients. For FCN1, the median (and interquartile
range) values for ICN and MSK were 0.34 (0.28–0.47) and 1.06 (0.59–1.5), respectively (p < 0.0001).
ROC analysis revealed that the expression of FCN1 in the urinary exosome can distinguish between
ICN and MSK patients (Figure 6B, red line). The AUC, 95% CI and p-values for the ROC analysis were
0.9, 0.82–0.98, and p < 0.0001, respectively. The cutoff, sensitivity, specificity, and likelihood ratio were
0.55, 77%, 87%, and 5.7, respectively. For C4BPB, the median (and interquartile range) values for ICN
and MSK were 0.45 (0.3–0.59) and 1.2 (0.67–1.67), respectively (p < 0.0001). ROC analysis revealed
that the expression of C4BPB in the urinary exosome can distinguish between ICN and MSK patients
(Figure 6B, green line). The AUC, 95% CI, and p-values for the ROC analysis were 0.9, 0.82–0.98,
11
Int. J. Mol. Sci. 2019, 20, 5517
and p < 0.0001, respectively. The cutoff, sensitivity, specificity, and likelihood ratio were 0.62, 77%, 87%,
and 5.7, respectively.
Figure 6. ELISA experiments to verify the proteomic data. (A) Box plot showing the median and
interquartile range values of MASP2 (black), FCN1 (red), and C4BPB (green) in the urinary exosome of
all patients. In particular, MASP2 was strongly expressed in the urinary exosome of ICN compared
to MSK patients, whereas FCN1 and C4BPB showed the opposite profile. (B) Received operating
characteristic (ROC) curve analysis confirming that the expression of all three proteins discriminates
between ICN and MSK patients.
3. Discussion
MSK is a rare kidney disease that is currently difficult to diagnose because the molecular basis of
pathogenesis is unclear and robust diagnostic biomarkers are not available in the clinic. We, therefore,
carried out a comprehensive comparative proteomic analysis of urinary microvesicles and exosomes
from MSK patients and a control group with the distinct kidney disorder ICN. We defined the protein
profiles of both vesicles in both diseases and applied innovative statistical methods (including SVM
learning and PLS-DA) to identify specific proteins (and the corresponding biological networks) that
can accurately discriminate between patients with each disease. These proteins and networks not only
represent a source of novel biomarker candidates and potential therapeutic targets but should also
shed light on the molecular basis of MSK.
Statistical analysis identified a core panel of 20 highly discriminative proteins, the most promising
were FCN1, MASP2, and C4BPB, all of which are major functional or regulatory components of
the lectin complement pathway. These three proteins were not associated with either MSK or ICN
according to the DisGeNET, a database containing one of the largest publicly available collections of
genes and variants associated with human diseases [27]. FCN1 and C4BPB were more abundant in the
exosomes of MSK patients compared to ICN controls, whereas MASP2 showed the opposite profile.
It is possible that all three proteins, because of their molecular weight and the absence of proteinuria
and/or renal impairment in our enrolled patients, did not pass through an intact glomerular membrane
but were instead derived from renal epithelial cells [28].
12
Int. J. Mol. Sci. 2019, 20, 5517
FCN1 (also known as M-ficolin) is an oligomeric pattern-recognition protein consisting of an
N-terminal collagen-like domain and a C-terminal globular fibrinogen-like domain [29,30]. It can
form complexes with MASP2 to activate the lectin complement pathway [31]. FCN1 may also interact
with C-reactive protein (CRP) via a conformational change induced by mild acidosis at the local site
of infection [32,33], and with pentraxin 3 (PTX3) in a Ca2+-dependent manner [34]. The high level
of FCN1 in urinary exosomes isolated from our MSK patients suggests that the lectin complement
pathway may be involved in the complex biological process leading to the growth of cysts. This agrees
with previous studies based on mouse models deficient in complement factors, which develop fewer
kidney cysts and suffer less severe pericystic tissue inflammation, helping to preserve normal renal
functions [35]. Further evidence that the complement pathway is involved in cystic disorders has been
gathered from patients affected by ADPKD, whose urine and cyst fluids were found to be enriched for
complement proteins [36–38].
The downregulation of MASP2 in our MSK patients was accompanied by the upregulation of
C4BPB, a multimeric protein that inhibits the activation of the complement cascade by preventing
the formation of the classical C3 and C5 convertases [39]. This may reflect the physiological attempt
of the kidneys to mitigate the activation of the lectin complement pathway. This could also explain
the contra-regulation of FCN1 and MASP2. However, additional studies are necessary to confirm
this effect. Indeed, the hyperactivation of complement may induce glomerular and tubulointerstitial
injury [40].
Taken together, our data suggest for the first time that the lectin complement pathway may be
involved in the complex biological machinery associated with MSK, but it is clearly not associated with
nephrolithiasis. Extracellular vesicles may, therefore, be part of the pathological machinery leading to
the growth of cysts. Although we cannot exclude that the complement system could be a secondary
response to the disease, this might offer a therapeutic option for progression blockade. Additionally,
urinary vesicles may provide a source of valuable clinical biomarkers allowing MSK to be distinguished
from other cystic disorders (including ADPKD) and types of nephrolithiasis.
However, our results must be validated using a larger cohort of patients, and additional functional
studies are required to better define the biological role of the lectin complement cascade in the
pathogenesis of MSK.
4. Materials and Methods
4.1. Patients
Having obtained informed written consent, we enrolled 15 adult MSK patients and 15 adult ICN
patients matched for age, gender, and geographical origin, followed up at our renal unit. The inclusion
criteria for the MSK group were the same as described in our previous study [12]. Particularly, patients
had both kidneys involved, nephrocalcinosis and/or cysts in at least 2 papillae in each kidney. For MSK,
patients had papillary precalyceal ectasias on films obtained at least 10 min after contrast medium
injection in the absence of compression maneuvers and signs of obstruction. The X-ray films were
reviewed by an independent radiologist to confirm the diagnosis. For ICN patients the inclusion
criteria were calcium stone disease, normal serum creatinine and electrolyte concentrations, and
urinary pH ≤ 5.5 measured in spot morning urine (after overnight fasting) to exclude tubular acidosis.
Exclusion criteria for ICN patients were: the presence of endocrine diseases and cystic kidney disorders,
nephrocalcinosis, and obstructive nephropathy. In all ICN patients, the MSK disease was ruled out by
careful clinical examination.
Clinical data were registered in an electronic database. Informed consent was obtained from all
patients in accordance with the Declaration of Helsinki and the ethical board of the University Hospital
of Verona approved the study (1312CESC, 24 May 2017).
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4.2. Isolation of Microvesicles and Exosomes
Second morning urine samples were obtained from all patients. Microvesicles and exosomes were
isolated by centrifugation as previously reported [18]. Briefly, 16 ml aliquots of urine were centrifuged
at 16,000× g for 30 min at 16 ◦C in order to remove alive and dead cells and organelles. The obtained
supernatant was centrifuged for 120 min at 22,000× g at 16 ◦C to obtain the microvesicle fraction.
The microvesicle-containing pellet was washed in phosphate-buffered saline (PBS) and repelleted as
above for a total of five wash cycles to obtain a clean microvesicle fraction. To obtain the exosome,
the supernatant was centrifuged for 120 min at 100,000× g at 16 ◦C. Then one-step sucrose cushion
ultracentrifugation for 120 min at 100,000× g at 16 ◦C was performed to further purify exosomes
according to their density. The exosome-containing pellet was washed in PBS and repelleted as above
for a total of five wash cycles to obtain a clean exosome fraction. This procedure was carried out for
each sample and the microvesicle and exosome fractions were stored at –80 ◦C until use.
4.3. Dynamic Light Scattering
The size of the exosomes and microvesicles was determined by dynamic light scattering (DLS)
using a Zetasizer nano ZS90 particle sizer (Malvern Instruments, Worcestershire, UK) at a 90◦ fixed
angle. The particle diameter was calculated using the Stokes–Einstein equation. For particle sizing in
solution, exosome and microvesicle aliquots were diluted in 10% PBS and analyzed at a constant 25 ◦C.
4.4. Western Blot
Microvesicle and exosome fractions from 16 ml urine samples were separated by SDS-PAGE
(8–16% acrylamide gradient) and then transferred to a nitrocellulose membrane. The membrane was
blocked with 1% bovine serum albumin (BSA) in PBS plus 0.1% Tween-20 (PBST), rinsed in PBST,
and labeled with one of the following primary human antibodies diluted in 1% BSA in PBST: anti-CD63
(Novus Biological, Littleton, CA, USA), anti-CD81 (Novus Biological, Littleton, CA, USA), or anti-CD45
(LifeSpan BioSciences, Seattle, WA, USA) [41]. After rinsing again in PBST, the membrane was
incubated with horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibodies (Novus
Biological, Littleton, CA, USA). Chemiluminescence was detected and quantified using the ChemiDoc
Touch Imaging System and Image Lab software (Bio-Rad, Hercules, CA, USA).
4.5. Mass Spectrometry
Samples were processed with in-StageTip (iST) method with two poly (styrene divinylbenzene)
reversed-phase sulfonate (SDB-RPS) disks. The microvesicle- and exosome-containing pellets were
solubilized with a solution containing 10 mM Tris(2-carboxyethyl)phosphine, 40 mM chloro-acetamide,
100 mM Tris (pH 8.5), and 2% sodium deoxycholate. Lysis, reduction, and alkylation of the samples
were performed in a single step and then loaded into the StageTip. The samples were then diluted
with a buffer containing 25 mM Tris (pH 8.5) and 1 μg of trypsin. After the acidification step with 1%
trifluoroacetic acid (TFA), the samples were washed with 0.2% TFA three times. The proteins were
eluted in 60 μl 5% v/v ammonium hydroxide containing 80% v/v acetonitrile. The desalted peptides
were dried in a speed vacuum and resuspended in 2% acetonitrile containing 0.2% formic acid (FA).
They were then separated on a 50-cm reversed-phase Easy Spray column (75-μm internal diameter ×
50 cm; 2 μm/100 Å C18) on an Ultimate 3000 RSLCnano device (Thermo Fisher Scientific, Waltham,
MA, USA) with a binary buffer system comprising buffer A (0.1% FA) and buffer B (80% acetonitrile,
5% dimethylsulfoxide, 0.1% FA). The program consisted of a 70-min gradient (2–45% buffer B) at a flow
rate of 250 μl/min, with the column temperature maintained at 60 ◦C. The chromatography system
was coupled to an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific, Waltham,
MA, USA), acquiring data in Charge Ordered Parallel Ion aNalysis (CHOPIN) mode. The precursors
were ionized using an EASY-spray source held at +2.2 kV and the iICNet capillary temperature was
held at 300 ◦C. Single MS survey scans were performed over the mass window 375–1500 m/z with
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an AGC target of 250,000, a maximum injection time of 50 ms, and a resolution of 120,000 at 200 m/z.
Monoisotopic precursor selection was enabled for peptide isotopic distributions, precursors of z = 2–5
were selected for 2 s of cycle time, and dynamic exclusion was set to 25 s with a ± 10 ppm window set
around the precursor. The following CHOPIN conditions were applied: a) if the precursor charge state
is 2, then follow with collision-induced dissociation (CID) and scan in the ion trap with an isolation
window of 1.8, CID energy of 35%, and a rapid ion trap scan rate; b) if the precursor charge state is 3–5
and precursor intensity >500,000, then follow with higher-energy C-trap dissociation (HCD) and scan
in the Orbitrap with an isolation window of 1.8, HCD energy of 28%, and a resolution of 15,000; c) if
the precursor charge state is 3–5 and precursor intensity < 500,000, then follow with CID as described
for option (a). For all MS2 events, the following options were set: “Injection Ions for All Available
Parallelizable Time” with an AGC target value of 4000 and a maximum injection time of 250 ms for
CID, or an AGC target value of 10,000 and a maximum injection time of 40 ms for HCD.
4.6. MS Data Analysis
Raw MS files were processed in the MaxQuant v1.6.0.16 environment using the MaxLFQ algorithm
for label-free quantification and Andromeda search engine. Peptide and protein false discovery rate
(FDRs) were both set at < 0.01. The search contained variable modifications for the oxidation of
methionine (M), N-terminal protein acetylation (protein N-terminus), and fixed carbamidomethyl
modifications (C). For protease digestion, up to two missed cleavages were allowed. Peptides of length
greater than six amino acids have been considered for the identification. The “match between runs”
algorithm with a setting of 1 min time window was used for the quantification of MS missed data in
each individual measurement. UniProt FASTA Homo sapiens database (access August 2017) was used
for the identification of peptides and proteins.
4.7. ELISA
MASP2, FNC1, and C4BPB levels were determined using an in-house ELISA setup.
Briefly, polyclonal antibody anti-MASP2, anti-FCN1, or anti-C4BPB (LifeSpan Biosciences) was
used to coat overnight at 4 ◦C 96-well MaxiSorp Nunc plates (Thermo Fisher Scientific, Waltham, MA,
USA). The plates were then blocked with 3% BSA in PBS. Exosome fractions were solubilized in 10 μl
of mild detergent solution (1% Nonidet P-40, 0.5% Tween-20 in PBS), supplemented with 90 μl 3% BSA
in PBST and incubated at 4 ◦C overnight. After three washes in PBST, the plates were incubated for
4h with the corresponding monoclonal antibody (anti-MASP2, anti-FCN1, or anti-C4BPB, all from
LifeSpan Biosciences, Seattle, WA, USA) diluted 1:1000 with 1% BSA in PBST. After three washes with
PBST, the plates were incubated with HRP-conjugated anti-mouse IgG diluted 1:5000 in 1% BSA in
PBST for 1h. After washing, the peroxidase substrate (TMB, Bio-Rad, Hercules, CA, USA) was added.
The reaction was stopped with an H2SO4 solution. The absorbance at 450 nm was measured using an
iMark microplate reader (Bio-Rad, Hercules, CA, USA). To standardize the response of the antibodies,
we used a pool of strongly positive controls. The optical density results were expressed as relative
units per milliliter (RU/ml).
4.8. Statistical Analysis
After normalization, unsupervised hierarchical clustering and multidimensional scaling (MDS)
with Spearman’s rank correlation and k-means were used to recognize outliers and sample dissimilarity.
Weighted-gene co-expression network analysis (WGCNA) package in R was used for building the
co-expression network with the normalized expression profiles of the identified proteins. A weighted
adjacency matrix was constructed using the power function. After choosing the appropriate beta
parameter of power (with the value of independence scale set to 0.8), the adjacency matrix was
transformed into a topological overlap matrix (TOM), which measures the network connectivity of
all the proteins. To classify proteins with co-expression profiles into protein modules, hierarchical
clustering analysis was conducted according to the TOM dissimilarity with a minimum size of
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30 proteins per module. To identify the relationship between each module and clinical trait, we used
module eigengenes (MEs) and calculated the correlation between MEs and each clinical trait and their
statistical significance corrected for multiple interactions. A heat map was then used to visualize the
degree and significance of each relationship.
A non-parametric Mann–Whitney U-test, machine learning methods, such as non-linear support
vector machine (SVM) learning, and partial least squares discriminant analysis (PLS-DA) were used to
identify the hub proteins of modules that maximize the discrimination between the selected clinical
traits. For the Mann–Whitney U-test, proteins were considered to be significantly differentially
expressed between the two conditions with power of 80% and an adjusted p-value ≤ 0.05 after
correction for multiple interactions (Benjamini–Hochberg) and a fold change of ≥2. In addition, the
proteins needed to show at least 70% identity in the samples in one of two conditions. Volcano plots
were used to visualize this analysis. In SVM learning, a fourfold cross-validation approach was applied
to estimate the prediction and classification accuracy. The whole matrix was also randomly divided
into two parts, one for learning (65%) and the other to verify the accuracy of the prediction (35%).
Finally, the resulting core panel of hub proteins was uploaded to Cytoscape using the EnrichmentMap,
ClusterMaker2, and AutoAnnotate apps to construct a protein–protein interaction network and identify
the principal biological processes and pathways involved in each condition. Gene Ontology (GO)
annotations were extracted from the Gene Ontology Consortium (http://www.geneontology.org/).
For ELISA data analysis, the Mann–Whitney U-test was used to assess differences in MASP2,
FCN1, or C4BPB protein levels between the two study groups, and the results were expressed as
medians and interquartile ranges. A value of p < 0.05 was considered to be statistically significant.
Received operating characteristic (ROC) curves were generated to assess the diagnostic efficiency of
each assay. Youden’s index and likelihood ratio were used, to identify the cutoff and the diagnostic
performance of the tests, respectively. All statistical tests were performed using the latest version of
the software package R available at the time of the experiments.
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MSK medullary sponge kidney
ICN idiopathic calcium nephrolithiasis
LAMA2 laminin subunit α2
SVM support vector machine
PLS-DA partial least squares discriminant analysis
ADPKD autosomal dominant polycystic kidney disease
MS mass spectrometry
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SPP1 osteopontin
PBS phosphate-buffered saline
DLS dynamic light scattering
iST in-StageTip
SDB-RPS poly (styrene divinylbenzene) reversed-phase sulfonate
TFA trifluoroacetic acid
BSA bovine serum albumin
PBST PBS plus 0.1% Tween-20
HRP horseradish peroxidase
ROC Received operating characteristic
AUC area under the curve
CI confidence interval
FCN1 Ficolin 1
MASP2 Mannan-binding lectin serine protease 2
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Abstract: Dent disease (DD), an X-linked renal tubulopathy, is mainly caused by loss-of-function
mutations in CLCN5 (DD1) and OCRL genes. CLCN5 encodes the ClC-5 antiporter that in proximal
tubules (PT) participates in the receptor-mediated endocytosis of low molecular weight proteins.
Few studies have analyzed the PT expression of ClC-5 and of megalin and cubilin receptors in DD1
kidney biopsies. About 25% of DD cases lack mutations in either CLCN5 or OCRL genes (DD3), and no
other disease genes have been discovered so far. Sanger sequencing was used for CLCN5 gene analysis
in 158 unrelated males clinically suspected of having DD. The tubular expression of ClC-5, megalin,
and cubilin was assessed by immunolabeling in 10 DD1 kidney biopsies. Whole exome sequencing
(WES) was performed in eight DD3 patients. Twenty-three novel CLCN5 mutations were identified.
ClC-5, megalin, and cubilin were significantly lower in DD1 than in control biopsies. The tubular
expression of ClC-5 when detected was irrespective of the type of mutation. In four DD3 patients,
WES revealed 12 potentially pathogenic variants in three novel genes (SLC17A1, SLC9A3, and PDZK1),
and in three genes known to be associated with monogenic forms of renal proximal tubulopathies
(SLC3A, LRP2, and CUBN). The supposed third Dent disease-causing gene was not discovered.
Keywords: dent disease; CLCN5 gene mutations; proximal tubular ClC-5 expression; megalin; cubilin;
kidney biopsies; immunohistochemistry; whole exome sequencing
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1. Introduction
The term Dent disease (DD) identifies a group of X-linked renal disorders characterized by features
of incomplete Fanconi syndrome including low-molecular-weight proteinuria (LMWP), and more or
less severe hypercalciuria, nephrocalcinosis and/or nephrolithiasis. This triad of symptoms has been
variously named in the past as X-linked recessive nephrolithiasis with renal failure (OMIM 310468),
X-linked recessive hypophosphatemic rickets (OMIM 300554), or the idiopathic LMWP of Japanese
children (OMIM 308990), testifying to the disease’s phenotypic variability [1,2]. DD usually presents in
children or young adults, progressing to chronic kidney disease (CKD) between the third and fifth
decades of life in 30–80% of cases [3,4].
The most common genetic cause of DD is a mutated CLCN5 gene encoding the ClC-5 chloride
channel Cl-/H+ antiporter (DD1; MIM#300009) [5–9]. In the kidney, ClC-5 is expressed primarily in
the proximal tubular cells (PTCs) located mainly in the subapical endosomes. Together with megalin
and cubilin synergistic receptors, it is involved in the endocytic reabsorption of albumin and LMW
proteins [10,11]. ClC-5 expression levels are lower in the α intercalated cells of the cortical collecting
duct and in the cortical and medullary thick ascending limb of Henle’s loop [12].
DD1 features a marked allelic heterogeneity, with more than 200 CLCN5 mutations described so
far [9]. Functional investigations in Xenopus Levis oocytes and mammalian cells enabled these CLCN5
mutations to be classified. The most common mutations lead to a defective protein folding and processing,
resulting in endoplasmic reticulum (ER) retention of the mutant protein for further degradation by the
proteasome [13–17]. Few studies have investigated ClC-5 expression in DD1 kidney biopsies.
OCRL gene mutations, which are usually associated with Lowe syndrome (OMIM #309000), have
been identified in about 10–15% of DD patients (DD2; MIM#300555). Approximately 25% of DD patients
(DD3) have neither CLCN5 nor OCRL gene mutations [18–21].
This study aimed to investigate allelic and locus heterogeneity in DD and to analyze ClC-5,
megalin, and cubilin expression in DD1 kidney biopsies. We further expanded the spectrum of CLCN5
mutations in DD by describing 23 novel mutations. In DD1 kidney biopsies, we showed that the loss
of ClC-5 tubular expression caused defective megalin and cubilin trafficking. In DD3, whole exome
sequencing (WES) did not detect a new disease-causing gene. Instead, it revealed the concomitant
presence of likely pathogenic variants in genes encoding proximal tubular (PT) endocytic apparatus
components, suggesting that they may have had a role in determining the DD3 phenotype.
2. Results
2.1. CLCN5 Gene Mutation Analysis
The 85% of the 158 patients analyzed for the presence of CLCN5 mutations were of Italian origin,
6% were non-Italian European (Balcanic and English), and the remaining 9% were extra-European
(Figure 1).
DNA sequence analysis of the CLCN5 gene revealed 50 different mutations in 56 unrelated patients.
Six different mutations were found twice. Among the detected mutations, the most common types
were missense mutations (21 cases), followed by frameshift mutations (14 cases), nonsense mutations
(13 cases), and splicing mutations (eight cases) (Figure 2).
Twenty-three mutations were not previously described, which were judged potentially pathogenic
by in silico tools and classified as pathogenic or likely pathogenic according to American College
of Medical Genetics and American College of Pathologists (ACMG/AMP) guidelines [22] (Table 1).
The novel frameshift, nonsense, and missense mutations were mapped onto ClC-5 protein domains
(Table 1). Table S1 summarizes the clinical details of 20 patients with novel CLCN5 mutations (clinical
data were unavailable for three). LMWP and hypercalciuria were the most common signs at the time
of their molecular diagnosis, and their clinical phenotypic variability reflected that of patients with
known CLCN5 mutations [9].
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Figure 1. Ethnical distribution of the 158 analyzed patients.
Figure 2. Percentages of mutations of CLCN5 gene by type.







Frameshift c.100_101insG Exon 2 p.(Glu35fs) Pathogenic (Ib) A helix, stop in Loop A-B
Frameshift c.125delA Exon 3 p.(Glu42fs) Pathogenic (Ib) Loop A-B
Frameshift c.266_267insT Exon 4 p.(Ile89fs) Pathogenic (Ib) B helix, stop in Loop B-C
Frameshift c.518delT Exon 6 p.(Ile173fs) Pathogenic (Ib) D helix, stop in Loop D-E
Frameshift § c.691delA Exon 6 p.(Lys231fs) Pathogenic (Ia)
Loop F-G, stop at the end of
helix G
Frameshift c.1164_1165insAG Exon 8 p.(Lys388fs) Pathogenic (Ib) L helix, stop in helix M
Frameshift c.1635_1638delCAAG Exon 10 p.(Ser545fs) Pathogenic (Ib) Q helix, stop in cytoplasmic
Frameshift c.1657delG Exon 10 p.(Arg554fs) Pathogenic (Ib)
Cytoplasmic, stop at the
beginning of CBS1
cytoplasmic domain
Frameshift c.1920delC Exon 10 p.(Ile641fs) Pathogenic (Ib) CBS1 cytoplasmic domain,stop in cytoplasmic
Nonsense c.1287G>A Exon 8 p.(Trp429*) Pathogenic (Ib) M helix
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Nonsense c.2016C>G Exon 11 p.(Tyr672*) Pathogenic (Ib) Cytoplasmic
Nonsense c.2128C>T Exon 11 p.(Gln710*) Pathogenic (Ib) Cytoplasmic-beta strand inCBS2 domain
Missense c.262G>A Exon 4 p.(Gly88Ser) Likelypathogenic (IV) B helix
Missense c.305G>T Exon 4 p.(Cys102Phe) Likelypathogenic (V) Loop B-C
Missense c.518T>A Exon 6 p.(Ile173Lys) Likelypathogenic (V) D helix
Missense § c.608C>G Exon 6 p.(Ser203Trp) Pathogenic (II) E helix
Missense c.809G>A Exon 8 p.(Ser270Asn) Likelypathogenic (IV) Loop H-I
Missense § c.922G>A Exon 8 p.(Val308Met)
Pathogenic
(IIIb) Loop I-J
Missense c.1565T>A Exon 10 p.(Val522Asp) Likelypathogenic (V) P helix
Missense c.1619C>T Exon 10 p.(Ala540Val) Likelypathogenic (IV) Q helix
Missense c.2192A>C Exon 12 p.(His731Pro) Likelypathogenic (V) Cytoplasmic-CBS2 domain
Splicing c.105+5G>C Intron 2-splicesite p.?
Likely
pathogenic (II)
Splicing c.1348-1G>A Intron 8-splicesite p.? Pathogenic (Ic)
§ CLCN5 mutations also analyzed in patients’ kidney biopsies.
2.2. ClC-5, Megalin, and Cubilin Immunolabeling in DD1 Kidney Biopsies
Renal tubular ClC-5 expression was analyzed by immunohistochemistry (IHC) in 10 patients
carrying CLCN5 stop codon (frameshift and nonsense mutations) or missense mutations (Table 2).
In control biopsies, ClC-5 immunostaining was mainly apical and subapical (Figure 3). Our antibody
has around 66% overall epitope sequence similarity to ClC-3 and ClC-4, which are both expressed in
the membranes of intracellular organelles [23], so cross-reactivity can be expected. Immunolabeling
for ClC-3, ClC-4, and ClC-5 in serial sections of a control sample showed that tubular apical staining
was almost exclusively attributable to ClC-5 expression, while cytoplasmic staining was due largely to
ClC-3 and ClC-5, and much less to ClC-4 (Figure S1).
In DD1 biopsies, ClC-5 apical immunolabeling was negligible in most tubules, whatever the
type of mutation (Figure 3). As expected, ClC-5 expression was very significantly downregulated
(Figure 4) in DD1 biopsies compared with control biopsies (median CTRL 8.69% [Interquartile range
(IQR) 1.94–15.97%], DD1 0.01% [IQR 0.00–0.12%]; p < 0.01).
Table 2 shows the morphometric findings on ClC-5 immunostaining for each mutation. Notably,
two patients (Pt3 and Pt4) carried the same very premature nonsense mutation p.(Arg34*), but with
a completely different pattern of expression: ClC-5 immunolabeling was completely absent in one,
while in the other, it stained 0.12% of the whole biopsy area, which was more than in any of the other
biopsies analyzed (Figure 3).
Analyzing megalin and cubilin immunofluorescence (IF) in the same patients (Figure 5) revealed
that both receptors were significantly downregulated by comparison with control biopsies (median
megalin: CTRL 4.52% [IQR 3.64–8.39%], DD1 1.67% [IQR 0.09–3.91%], p = 0.019; median cubilin: CTRL
10.87% [IQR 1.54–19.85%], DD1 1.01% [IQR 0.83–2.67%], p = 0.003) (Figure 4).
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1 p.(Thr44fs) 2 Proteinuria Minimal changes 0.01
2 p.(Lys231fs)(novel) 14 Proteinuria Normal 0.00
3 p.(Arg34*) 11 Nephroticsyndrome
Chronic interstitial nephritis with
global glomerulosclerosis 0.12
4 p.(Arg34*) 6 Proteinuria Global glomerulosclerosis andIgM nephropathy 0.00
5 p.(Gln600*) 6 Proteinuria Tubulointerstitial injury with focalglomerulosclerosis 0.05
6 p.(Ser203Trp)(novel) 3 Proteinuria Normal 0.01
7 p.(Ser261Arg) 4 Heavyproteinuria
Proliferative mesangial
glomerulonephritis 0.07
8 p.(Tyr272Cys) NA Proteinuria Normal 0.01
9 p.(Val308Met)(novel) 9
Proteinuria
and hematuria Normal 0.08
10 p.(Trp547Arg) 1 Proteinuria Normal 0.00
NA: not available.
Figure 3. ClC-5 immunolabeling in control and DD1 kidneys. Representative images disclosing ClC-5
positivity in control and DD1 kidneys. In CTRL, ClC-5 staining was located mainly in tubular apical
and subapical positions. In DD1 patients, some tubules presented basolateral or cytoplasmic ClC-5
positivity (Pt9), and very few showed apical staining (Pt9, Pt3). ClC-5 immunostaining was negligible
in most DD1 tubules (Pt4), whatever the type of mutation. The asterisk indicates a cytoplasmic signal,
arrows indicate apical and subapical signals, the arrowhead indicates a basolateral signal. Scale bar =
50 μm. CTRL= control, Pt = patient.
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Figure 4. ClC-5, cubilin, and megalin quantitative analysis. Morphometric analysis showed a significant
decrease in the percentage of positive area in kidneys of DD1 patients than in control kidneys for all
molecules examined. Data were analyzed using the Mann–Whitney U-test. CTRL = control.
 
Figure 5. Megalin and cubilin immunolabeling in control and DD1 kidneys. Representative images
disclosing megalin and cubilin positivity in control and DD1 kidneys. In CTRL, megalin (red) and
cubilin (green) staining was located mainly in tubular apical and subapical positions. Immunolabeling
for both receptors was rarely apical in DD1 patients (Pt3), while it was more frequently found in
the cytoplasm (Pt1 and Pt5). The asterisk indicates a cytoplasmic signal, arrows indicate apical and
subapical signals. Blue indicates counter-staining of nuclei with 4′,6-diamidino-2-phenylindole (DAPI).
Scale bar = 50 μm. CTRL = control, Pt = patient.
26
Int. J. Mol. Sci. 2020, 21, 516
2.3. Whole Exome Sequencing (WES) Study
Among CLCN5 negative patients, 34 underwent mutational screening of the OCRL gene, and 19
patients were found to not carry mutations. In eight out of 19 CLCN5 and OCRL-negative patients
(four children and four adults), we performed WES.
We first searched for mutations in phenocopy genes. Known monogenic forms of nephrolithiasis
and nephrocalcinosis as well as of proximal and distal tubulopathy, for a total of 62 genes including
known genes of the PT endocytic pathway (Table S2), were firstly evaluated in these patients.
Furthermore, the first 100 genes prioritized for their association with CLCN5 or OCRL genes using the
Scalable kernel-based gene prioritization (SCUBA) were investigated [24] (Table S3).
Unexpectedly, in two children, we detected CLCN5 or OCRL known disease-causing mutations,
p.(Lys231fs) and p.(Arg318Cys), respectively. If on one hand this finding was disturbing because it
meant that by previous Sanger sequencing we had missed two causative mutations in the two known
genes, on the other hand, it confirmed that our pool of DD3 cases was well representative of DD
patients based on disease phenotype.
In four patients (three adults and one child), we detected 12 variants in three genes known to be
associated either with monogenic forms of proximal renal tubulopathy (SLC3A1) or with monogenic
syndromes involving proximal tubule dysfunction (LRP2, CUBN), as well as in novel genes not related
to monogenic nephropathies (SLC17A1, SLC9A3, and PDZK1). These last genes could be candidates
for DD-like phenotypes for their function in PT, and detected variants were predicted to be pathogenic
or likely pathogenic by in silico tools (although with a different degree of concordance), except for one
in the SLC17A1 gene (Table 3). Table S4 summarizes the four patients’ clinical phenotypes.
In two adults patients (AMS and BDA), we detected biallelic likely pathogenic variants in SLC3A1
and LRP2 genes whose mutations are responsible for the recessive diseases Cystinuria (MIM#220100)
and Donnai–Barrow/Facio-oculo-acoustico-renal syndrome (DB/FOAR, MIM#222448), respectively.
In AMS, we also identified a very rare missense variant classified as a variant of uncertain
significance (VUS) in the SLC17A1 gene encoding sodium/phosphate cotransporter 1 (NPT1), which
occurs at the apical pole of PTCs [25] and participates in renal urate export [26,27]. The same patient
was found to be homozygous for the very rare nonsense variant p.(Arg8*) in the PDKZ1 gene. This gene
encodes the Na(+)/H(+) exchange regulatory cofactor NHE-RF3, which is a PDZ domain-containing
scaffolding protein and one of the key molecules of the urate transportsome [28,29].
The already known pathogenic LRP2 mutation p.(Asp2054Asn) [30] was detected in AMV. In this
patient, we also found an in-frame indel variant of the CUBN gene encoding for cubilin. CUBN
gene mutations are known to cause Imerslund–Gräsbeck syndrome (IGS, MIM#261100), which is an
autosomal recessive disorder involving selective intestinal vitamin B12 malabsorption and LMWP.
The p.(Val2347del) variant in CUBN is very rare (TOPmed 0.0000001); Mutation Taster (MT) and
PROVEAN predicted its pathogenicity, and it was classified as VUS according to ACMG/AMP
guidelines [22].
Among eight different LRP2 uncommon coding variants with a minor allele frequency (MAF)
< 0.05 detected in our DD3 patients, four were identified in one patient (AMT) of which two were
predicted to be pathogenic by in silico tools (Table 3). Similar to AMV, this patient carried an uncommon
CUBN missense variant that was considered pathogenic by MT, PROVEAN, and DANN, but classified
as benign according to ACMG/AMP guidelines. He also harbored a very rare variant in the SLC9A3
gene, which was predicted as pathogenic by in silico tools, and classified as VUS. The SLC9A3 gene
encodes sodium/hydrogen exchanger 3 (NHE3), which is the main apical Na+/H+ exchanger in adult
kidneys [31], and part of the macromolecular endocytic complex at the brush border of PTCs [32,33].
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3. Discussion
Dent disease 1 is a worldwide disease, and this is further confirmed by our cohort of patients
which included persons from all over the word. More than 220 CLCN5 pathogenic mutations have been
reported so far. Mutations were found scattered along all exons of the gene and in different protein
domains [9,34–45]. Mansour-Hendili et al. [9] reported that the majority were missense and frameshift
mutations (33.33% and 29.05% respectively) followed by nonsense mutations (17.52%), splicing
mutations (12.39%), and large deletions (4.70%). In our cohort of patients, missense and frameshift
mutations were also the most frequent, but with a lower proportion (38% and 25% respectively), while
we observed more nonsense mutations compared to the previously reported data (23%).
In our study, DNA sequence analysis of the CLCN5 gene revealed 50 different mutations, 23 of
which have never been described before. ACMG/AMP guidelines classify the nine missense novel
mutations in CLCN5 as likely pathogenic. They were mapped onto ClC-5 protein domains (Table 1).
The p.(Ile173Lys) missense mutation is in the D helix, which is one of the four helixes (D, F, N,
and R) brought together near the channel center to form the Cl-selectivity filter [46] and consequently
believed to alter ClC-5 conductance.
The p.(His731Pro) missense mutation affects the ClC-5 carboxy-terminus cytoplasmic domain.
All eukaryotic ClCs have a large cytoplasmic C-terminus containing a pair of cystathionine beta-synthase
(CBS) domains. Several authors have shown that CBS domains are involved in regulating the activity
of ClCs, including ClC-5 [47–49]. Mutations affecting the two CBS domains were reported correctly
targeted to the plasma membrane and early endosomes, but with altered ClC-5 electrical activity [14].
The nonsense mutation p.(Arg718*) truncating the ClC-5 protein near the C-terminus reportedly
results in ER retention, underscoring the importance of the C-terminus in passing protein quality
control in ER [50]. These findings suggest that truncated ClC-5 proteins at the C-terminus could cause
function loss through defective protein processing. However, three different truncated mutations at
the C-terminus—p.(Tyr617*), p.(Arg648*), and p.(Arg704*)—targeted the cell surface (albeit only one
with residual activity) [50], so we cannot say whether our stop codon mutations at the C-terminus of
ClC-5 protein (Table 1) could exhibit residual activity targeting the plasma membrane.
The p.(Ser203Trp) missense mutation affects the E helix, whose role in ClC-5 function is still
unclear. The nearby p.(Leu200Arg) mutation reportedly produced a loss of Cl- conductance [1], and the
p.(Ser203Leu) was found to cause current failures due to ER retention [50]. Taken together, these
findings indicate that the p.(Ser203Trp) mutation is probably pathogenic.
Six missense mutations map in the major helixes (B, H, I, O, P, and Q) involved in dimer interface
formation [9,46], or in the intervening loops, suggesting an impaired physical contact between the
two subunits that might disrupt proper pore configuration [50,51]. In addition, for the p.(Ala540Val),
a pathogenic missense in the same position in a Dent family from New Zealand has already been
reported [38], confirming the possible damaging role of the alteration of this residue. The p.(Ser270Asn)
missense mutation maps in the loop between helixes H and I, near the “proton glutamate” (Glu 268),
which is crucial to the Cl-/H+ transport function [9]. Since the p.(Ser270Arg) mutation was reportedly
associated with chloride current abolition [52], we hypothesize a similar effect of this new mutation.
Very few studies investigated ClC-5 expression in kidney biopsies [10,53]. We analyzed ClC-5
protein expression in kidney biopsies from 10 patients carrying three novel and seven known CLCN5
mutations and in eight control biopsies. In controls, ClC-5 immunolabeling was mainly apical and
subapical in tubular cells, and it was not co-localized with ClC-3 or ClC-4 staining. The few studies on
ClC-5 expression in human kidney reported similar staining findings [10,53], which are justified by the
well-accepted ClC-5 localization in early and recycling endosomes and the plasma membrane [54,55].
Our study is the first to demonstrate the loss of ClC-5 protein expression in DD1 kidneys. However,
an apical staining was detected in very few tubules in 7/10 DD1 biopsies, including those with the
novel p.(Val308Met) and p.(Ser203Trp) mutations. Therefore, we speculate that the expression of
these ClC-5 mutants is regulated post-translationally, and mutated proteins can very rarely reach the
plasma membrane. This is consistent with previous findings in ClC-5 mutant models. Both missense
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and nonsense ClC-5 mutants could be either targeted to early endosomes or plasma membrane, but
with a limited activity, or confined to the ER [50]. In fact, some DD1 tubules were only labeled at the
basolateral pole (probably a sign of ER retention) (Figure 3 Pt 9).
Apical staining was unexpectedly detected for the very premature truncated ClC-5 protein at codon
34. Premature stop codons (PSCs) account for one in two CLCN5 mutations, and cause three distinct
molecular alterations: (1) the production of a truncated, usually non-functional, protein; (2) degradation
of the transcripts containing PSCs via the nonsense-mediated decay (NMD) pathway; and (3) exon
skipping due to alternative cryptic acceptor or donor sites being used in the exon encompassing the
stop codon [56]. The first molecular change can be excluded, because our ClC-5 antibody recognized
an epitope at the C-terminus of the protein. The second and third might apply because (1) NMD
may occasionally be bypassed when translational read-through allows the decoding of stop codons as
sense codons, thus enabling protein translation; (2) PSCs can also prompt exon skipping by altering
exonic splicing enhancer (ESE) or exonic splicing silencer (ESS) motifs. PSCs have even been found
to be statistically inclined to induce exon skipping more than other exon mutations [57]. If this is
true of the p.(Arg34*) mutation, we can expect exon skipping to be in frame, thus enabling complete
protein synthesis and allowing the mutated protein to be detected by immunolabeling. However, such
explanations for this ClC-5 mutant protein’s presence in one biopsy should be considered with caution,
as the ClC-5 protein was not found in most tubules, nor in another biopsy carrying the same mutation.
This could mean that how PSCs are processed by cell transcriptional and translational apparatus might
depend on the context (meaning the cell environment and/or the genomic context).
As in Clcn5 knock-out (KO) animal models [58], ClC-5 loss in human kidney causes defective
cubilin and megalin recycling, leading to LMWP. All the ClC-5 mutants studied here triggered both
their defective expression at the brush border of PTCs and their downregulation. The presence of a
megalin signal at the apical border of some tubules in the biopsy carrying the p.(Arg34*) mutation
(Figure 5, Pt3) suggests a residual ClC-5 activity enabling a normal endocytic process and consequent
megalin recycling.
Few studies have examined megalin and cubilin expression in DD1. Urinary megalin excretion
was found to be significantly lower in DD1 patients than in normal individuals [59]. IHC on kidney
biopsies from two patients carrying different CLCN5 mutations revealed a defective megalin, cubilin,
and Dab2 expression in PTCs [60,61]. Studies on megalin recycling in conditionally immortalized
proximal tubular epithelial cell lines from three patients with CLCN5 mutations showed defects in
cell surface expression and internalization [62]. Our data definitively corroborate previous findings
and suggest that a reduced intracellular megalin and cubilin synthesis may also contribute to their
defective apical exposure.
Approximately one in four DD patients have no CLCN5 or OCRL gene mutations. Whether mutations
in a third, as yet unknown gene can cause DD3 remains to be seen, but—judging from our WES study on
six DD3 patients—this seems unlikely. Instead, as we previously suggested [63], WES data point to
DD3 patients having atypical phenotypes of known hereditary nephropathies or blended phenotypes.
In fact, we identified in two patients (AMS and BDA) biallelic likely pathogenic variants in two
genes (SLC3A1, LRP2) whose mutations are known to cause cystinuria and DB/FOAR. Our findings
suggest that probably these patients were misdiagnosed as DD because of the presence renal Fanconi
syndrome. Indeed, several disorders are caused by mutations of genes coding for components of
the endolysosomal system in the PT. Besides CLCN5 (DD1) and OCRL (Lowe syndrome and Dent
disease type 2) genes, they include LRP2 (DB/FOAR), CUBN, AMN (Imerslund–Gräsbeck syndrome),
and CTNS (nephropathic cystinosis). Typically, these recessive disorders cause proximal tubular
dysfunction and lead to inappropriate urinary loss of LMW proteins and solutes (e.g., phosphate,
glucose, amino acids, urate), and they often lead to renal failure. The clinical entity of generalized
proximal tubular dysfunction is referred to as renal Fanconi syndrome.
However, apart from BDA who was found to carry biallelic pathogenic variants in the LRP2 gene
and, for this reason, and after a careful clinical revaluation, was assessed to suffer from an atypical form
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of DB/FOAR syndrome [64], the other patient (AMS) did not suffer from cystinuria, despite carrying
biallelic variants in the SLC3A1 gene that were classified as likely pathogenic according to ACMG/AMP
variant interpretation. Indeed, in this patient, the urinary level of cysteine was found to be normal
even after repeated measurements. Two hypotheses may explain these findings: (1) the variants may
be hypomorphic, thereby allowing a limited gene product activity, and (2) the two variants are in the
same allele (complex allele), although their MAF was highly different, suggesting the absence of a
linkage disequilibrium.
Instead, what appears relevant from this study is finding in three patients (comprising AMS)
possible pathogenic variants in more than one gene connected in functional networks (PDZK1, SLC17A1,
CUBN, SLC3A9, and LRP2), which we considered important for explaining patients’ phenotypes, thus
suggesting digenic or oligogenic disorders.
The major finding of WES study is the discovery in AMS of a homozygous truncating mutation in
the PDZK1 gene. This is a new gene that has never been related before to human diseases, although it
is one of the loci of strongest effect on serum urate level and gut [65–67]. NHE-RF3 encoded by PDZK1
is a major scaffolder protein in the brush border of kidney PTCs [68], interacting through its PDZ
domain with key molecules of urate transport, including NPT1 [29]. Furthermore, NHE-RF3 is one of
the several proteins interacting with the type-2a sodium phosphate cotransporter (NaPi-2a), which is
the major inorganic phosphate cotransporter of the PTCs [69]. Targeted disruption of the Pdzk1 gene
by homologous recombination in mice induced modulation of the expression of selective ion channels
in the kidney, including NaPi-2a. The steady-state levels of NaPi-2a were found to be reduced under a
phosphorus (Pi)-rich diet, and this was paralleled by higher urinary total and fractional Pi excretion [69].
In these KO mice, serum urate was not measured, nor were urate transporters investigated. However,
urine and serum analysis did not reveal any significant difference between KO and wild-type mice
except for a significant increase in the cholesterol levels [69]. Interestingly, in Pdzk1 KO mice under
a high-Pi diet, the PDZ scaffolding protein NHE-RF1 was increased at the bush border of proximal
tubules. NHE-RF1 was demonstrated to localize with megalin in the brush border, because it bounds
to its internal C-terminal PDZ binding motif [70]. It was also showed that NHE-RF1 silencing in PTCs
increased megalin expression [70].
In the same patient, we also detected a very rare missense variant in the SLC17A1 gene, which
is classified as VUS due to its extreme rarity in the human population (data from gnomAD: 1 allele
out of 250846). The SLC17A1 gene is one of the loci associated with serum urate level and gout [71]
and encodes NPT1, which is a Cl-dependent urate transport interacting with NHE-RF3 encoded
by the PDZK1 gene [26]. The clinical phenotype of patient AMS involves multiple tubular defects
(particularly hyperphosphaturia, hypercalciuria, and severe hypouricemia), which might be consistent
with a partial renal Fanconi syndrome and had led to a clinical suspicion of renal hypouricemia
(MIM#220150 and 612076) and atypical DD. By WES, we excluded the presence of pathogenic variants
in both SLC22A12 and SLC2A9 genes encoding URAT1 and GLUT9, respectively. It is tempting to
speculate that the PDZK1 and the SLC17A1 gene variants might have had a role in determining AMS
clinical phenotype for their direct interaction with urate and phosphate transport. Family studies will
help clarify these aspects.
Since megalin and cubilin PTC expression is altered in DD1, it is conceivable that LRP2 and/or
CUBN mutations can cause or contribute to a DD-like nephropathy. WES results seem to support this
hypothesis. In addition to BDA, who has already been described as carrying biallelic mutations in the
LRP2 gene [64], AMV was also found to carry a known pathogenic LRP2 allele and a very rare inframe
deletion in the CUBN gene. CUBN variants have recently been associated with proteinuria with no
signs of IGS. It was shown that a homozygous frameshift mutation in exon 53 of CUBN (p.Ser2785fs)
only caused proteinuria [72]. Moreover, a missense variant in exon 57 (p.Ile2984Val) was associated
with albuminuria [73]. Mutations in the CUBN gene cause IGS apparently only when they affect the
cubilin–amnionless interaction domain (exons 1–20) or the IF-Cbl binding site (exons 21–29) [74]. In our
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patient, CUBN mutation is localized in exon 46. Follow-up showed that our patient’s LMWP was
intermittent while his proteinuria started at 1 year old and ranged between 0.4 and 1 g/24 h.
True digenic inheritance (DI) is the simplest form for oligogenic disease [75], but it is also encountered
when pathogenic mutations responsible for two different diseases are co-inherited, leading to a blended
phenotype [76]. The two heterozygous mutations in the LRP2 and CUBN genes, encoding proteins
working close together on the same endocytic pathway, might plausibly be responsible for patient
AMV’s disease phenotype. Further studies on his kidney biopsy and/or urinary proteoma might
confirm this hypothesis. Family studies may help to solve these questions.
We detected two LRP2 coding variants associated with two likely pathogenic missense variants in
the CUBN and SLC9A3 genes in the genome of a single patient (AMT). It is noteworthy that these genes
respectively encode megalin, cubilin, and NHE3, which are located—together with ClC-5, amnionless,
and Dab2—at the cell surface of PTCs, forming its endocytic apparatus [54,55].
SLC9A3 homozygous or compound heterozygous disease-causing mutations have recently been
reported in nine patients from eight families with congenital secretory sodium diarrhea (MIM#616868) [77].
No association has been found as yet between SLC9A3 variants and renal proximal tubulopathies, but
a defective Nhe3 exposure was found in Clcn5 KO mice [55,78]. Studies by Gekle et al. [33] support a
crucial role for NHE3 in proximal tubular receptor-mediated endocytosis by demonstrating in Nhe3
KO mice that Nhe3 deficiency led to a reduced protein reabsorption: the urinary protein patterns
resembled those of mice deficient in megalin or ClC-5. Recent evidence also highlights the importance
of NHE3 for calcium reabsorption. Nhe3 KO mice revealed significant urinary calcium wasting and a
low cortical bone mineral density and trabecular bone mass [79].
The genetic data of the AMT patient are puzzling and raise some questions. With the advent
of high-throughput sequencing, we are bound to discover more patients suffering from oligogenic
diseases and learn more about how complex interactions between allelic and locus heterogeneity
affect disease phenotypes [80]. The presence of multiple coding variants in the same gene, either in
cis or in trans, may also conceivably cause defective protein functioning, although this needs to be
demonstrated in animal and in vitro models [81]. The genotype–phenotype correlation in the AMT
patient is worth investigating, because it seems to reveal such an impact on disease phenotype. This
patient was 26 years old when referred to a nephrologist for kidney stones. His height (158 cm)
and weight (42 kg) were below the third percentile. His renal phenotype mainly featured proximal
tubulopathy manifesting as Fanconi syndrome with LMWP, hypercalciuria, hyperphosphaturia,
glycosuria, natriuresis, and hypercitraturia. Therefore, the patient’s presenting phenotype was mainly
related to an impaired renal calcium and phosphate metabolism. WES detected no relevant variants in
genes known to be responsible for monogenic forms of nephrolithiasis and renal tubulopathies. We
hypothesized that the AMT patient’s phenotype was due to the variants in LRP2, CUBN, and SLC9A3,
whose products work on the same cellular pathways as ClC-5, or pathways related thereto, but this
hypothesis needs to be evaluated by in vitro studies. From the point of view of the referring clinicians,
tubular abnormalities might be a real challenge: indeed, clinical characteristics of different diseases
sometimes overlap, and a full-blown classical phenotype (in the case of AMS, a renal Fanconi syndrome)
is rare. Therefore, when multiple tubular defects (i.e., alteration in tubular handling of 2–4 different
solutes) coexist, the chance of a blended phenotype becomes more plausible, and a next-generation
sequencing (NGS) approach might be a good strategy to identify multiple (and possibly interacting)
genetic defects that may explain each individual phenotype.
4. Material and Methods
4.1. Patients
4.1.1. DNA Samples
From 2006 to 2018, DNA samples were collected from 158 unrelated pediatric and adult males with
clinically suspected DD according to the criteria described in our previous study [82]. Patients should
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have encountered at least two of the above-mentioned criteria for being referred to our laboratory
for a molecular diagnosis. Since proteinuria was recently reported as one of the DD symptoms in
concomitance with signs of incomplete Fanconi tubulopathy [83], and because of the cost of urinary
assessment of LMW proteins, we decided to include in the diagnostic workflow also patients presenting
with proteinuria, although in the absence of documented LMWP. Informed consent to the genetic study
was obtained from all probands or their parents.
DNA samples from eight patients (four children and four adults) with no detectable CLCN5
or OCRL gene mutations underwent WES. The selection was based on the presence of a likely DD
phenotype (i.e., the presence of LMWP and/or proteinuria, hypercalciuria, and at least one of the
following: nephrocalcinosis, kidney stones, hypophosphataemia, renal failure, aminoaciduria, rickets,
or a positive family history) with or without extra-renal symptoms. The study was approved by Padua
University Hospital’s Ethical Committee, protocol 0028285 (11 May 2016)
4.1.2. Biopsies
Ten kidney biopsies were collected from patients carrying nine different CLCN5 mutations (Table 2).
All biopsies were performed for diagnostic purposes and available for immunolabeling studies subject
to informed consent.
Eight control cortical tissues were obtained from nephrectomies for renal cancer (sites remote
from the tumor-bearing renal tissue), disclosing a normal morphology and no immunofluorescence.
The study was approved by Padua University Hospital’s Ethical Committee, protocol 0007452 (1
February 2018).
4.2. Sanger Sequencing
CLCN5 gene mutation analysis was performed by Sanger sequencing. Genomic DNA was extracted
from peripheral blood using the QIAamp DNA Blood Minikit (Qiagen, Milan, Italy) according to the
manufacturer’s instructions. The primers and PCR conditions for amplifying the CLCN5 gene-coding
region and intron–exon boundaries are described elsewhere [82]. The PCR products were analyzed
using the Bioanalyzer 2100 (Agilent Technologies, Milan, Italy) and purified with the MinElute PCR
Purification Kit (Qiagen, Milan, Italy). Sanger sequencing was done with the BigDye Terminator v1.1
Cycle Sequencing Kit (ThermoFisher Scientific, Milan, Italy) and the ABI-PRISM 3100 Genetic Analyzer
(ThermoFisher Scientific, Milan, Italy). The nomenclature of mutations is based on the CLCN5 cDNA
sequence NM_0000844. Missense and splicing mutations were interpreted using the Mutation Taster
(MT) [84], and classified according to the American College of Medical Genetics and American College
of Pathologists (ACMG/AMP) variant classification guidelines [22]. Mutations were confirmed by
sequencing a second independent PCR product.
4.3. Whole-Exome Sequencing (WES)
WES was performed at Padua University’s Centro di Ricerca Interdipartimentale per le
Biotecnologie Innovative (CRIBI) sequencing center using the Ion Proton System (ThermoFisher
Scientific, Milan, Italy), obtaining an average reads coverage of 80X for each sample. Data were
analyzed as suggested by the manufacturer, with read alignment using TMAP and variant calling with
TSVC, which are both included in the Ion Proton Suite (v 5.0). QueryOR (http://queryor.cribi.unipd.it,
accessed on 27 November 2019) [85] was used to analyze and prioritize short-nucleotide variants (SNV).
This web-based query platform enables quick, easy, in-depth variant prioritization by aggregating
several functional annotations of both genes and variants. The prioritization strategy entails a ranking
that sorts results by the number and weight of the criteria met (see below).
Two main approaches were initially used to identify the most promising variants: (1) a gene-
centered search, considering known details of genes and associated pathways, and information about the
disease and related disorders; and (2) a variant-centered search, focusing on the intrinsic characteristics
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of variants, such as type (indel, snp, mnp), codon effect (frameshift, missense, and nonsense variants),
and genomic position.
In a subsequent prioritization step, variants were ranked by sequencing coverage, minor allele
frequency (MAF) values ≤ 0.05, and predicted possible–probable deleteriousness. For this purpose,
QueryOR provides coding variant predictions based on several tools, including the well-known SIFT,
PolyPhen2, and MT, and the more recent PROVEAN, CADD, and DANN scores [84,86–90]. Sanger
sequencing was used to validate variants identified by the in silico prioritization strategy during WES.
Table S5 shows the gene names, NCBI reference sequences, primers, and PCR amplification conditions.
Identified variants were checked against relevant database such as Clinvar (https://www.ncbi.
nlm.nih.gov/clinvar/, accessed on 27 November 2019) and The Human Gene Mutation Database
(HGMD) (http://www.hgmd.cf.ac.uk/ac/index.php, accessed on 27 November 2019), and were classified
according to ACMG/AMP guidelines [22].
4.4. Immunohistochemistry (IHC)
IHC was conducted on formalin-fixed, paraffin-embedded sections using an indirect immunoperoxidase
method. Specimens were treated as previously described [91], and incubated overnight with rabbit
anti-human ClC-5 (Sigma-Aldrich, Milan, Italy, cat. HPA000401) diluted 1:200, goat anti-human ClC-3
(Santa Cruz Biotechnologies, Heidelberg, Germany, cat. sc-17572) diluted 1:150, and rabbit anti-human
ClC-4 (Sigma-Aldrich, Milan, Italy, cat. HPA063637) diluted 1:50 in PBS at 4 ◦C in a humidified
chamber. A donkey anti-goat IgG-HRP secondary antibody (Santa Cruz Biotechnologies, Heidelberg,
Germany, cat. sc-2020) diluted 1:100 was used for ClC-3. Immunolabeling specificity was confirmed by
incubating without any primary antibody. Images were acquired with the Diaplan light microscope
(Leitz, Como, Italy) and 20X/0.45 objective using a Micropublisher 5.0 RTV camera (Teledyne QImaging,
Surrey, BC, Canada).
4.5. Immunofluorescence (IF)
IF analyses were performed on serial sections of kidney biopsies. Samples were treated as previously
described [92] and incubated overnight with primary antibody (sheep anti-human cubilin [R&D
Systems, Minneapolis, MN, USA, cat. AF3700], rabbit anti-human megalin [LS-Bio, Seattle, WA, USA,
cat. LS-B105]) diluted 1:100 in PBS 5% BSA at 4 ◦C. Sections were incubated with the appropriate
fluorescent secondary antibody [92]. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI). Negative controls were run by omitting the primary antibody. Images were acquired with
a DMI6000CS-TCS SP8 fluorescence microscope (Leica Microsystems, Milan, Italy) with a 20X/0.4
objective using a DFC365FX camera (Leica Microsystems, Milan, Italy) and analyzed with the LAS-AF
software (Leica Microsystems, Milan, Italy).
4.6. Morphometric Analysis
ClC-5, megalin, and cubilin signals on kidney biopsies were quantified by morphometric analysis
using Image-Pro Plus 7.0 (Media Cybernetics, Abingdon, United Kingdom). Signals were acquired
at 200X with the same time exposure, gain, and intensity for all patients, and quantified excluding
the glomerular compartment. For ClC-5, only apical or subapical tubular staining was considered as
positive. Quantities were expressed as the mean area covered by pixels (%).
4.7. Statistical Analysis
Non-parametric tests (Mann–Whitney U-test) were used due to the small sample size. Results
with p < 0.05 were considered significant and given as median ± IQR. All analyses were performed
with R software version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) [93].
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5. Conclusions
By describing 23 novel CLCN5 mutations, this study extends the allelic heterogeneity of DD1.
Our results on DD1 kidney biopsies provide evidence that ClC-5 is lost in PTCs, and this, in turn, leads
to a defective trafficking of megalin and cubilin in these cells.
Using WES to investigate DD3 patients, we did not identify the supposed third Dent disease-
causing gene. Instead, our study suggests that likely pathogenic variants in genes encoding components
of the endocytic apparatus of tubular cells (megalin, cubilin, NHE3, and NHE-RF3) may have determined
DD3 phenotypes. However, except for one patient in whom we identified a known monogenic disease,
in the other patients, the presence of variants in more than one gene related in functional networks
suggest that we are probably facing oligogenic disorders. Furthermore, our study suggests that DD3
patients are a pool of patients with DD-like phenotypes, which may present atypical phenotypes of
known hereditary nephropathies or blended phenotypes.
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Figure S1: ClC-5, ClC-4 and ClC-3 immunolabeling in serial sections of a control kidney. Tubular staining
was almost exclusively apical (arrows) for ClC-5, while cytoplasmic staining (arrowheads) was seen for ClC-3,
and ClC-5 and much less for ClC-4. Scale bar = 50 μm. Table S1: Clinical phenotypes of 20 patients carrying novel
CLCN5 mutations. Table S2: List of phenocopy genes. Table S3: List of the genes prioritized according to scalable
kernel-based gene prioritization (SCUBA) [24]. Table S4: DD-like phenotype of patients carrying likely pathogenic
variants as detected by whole exome sequencing. Table S5: PCR primer sequences and amplification conditions.
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Abstract: Acute kidney injury (AKI) in critically ill children and adults is associated with significant
short- and long-term morbidity and mortality. As serum creatinine- and urine output-based definitions
of AKI have relevant limitations, there is a persistent need for better diagnostics of AKI. Nuclear
magnetic resonance (NMR) spectroscopy allows for analysis of metabolic profiles without extensive
sample manipulations. In the study reported here, we examined the diagnostic accuracy of NMR
urine metabolite patterns for the diagnosis of neonatal and pediatric AKI according to the Kidney
Disease: Improving Global Outcomes (KDIGO) definition. A cohort of 65 neonatal and pediatric
patients (0–18 years) with established AKI of heterogeneous etiology was compared to both a group
of apparently healthy children (n = 53) and a group of critically ill children without AKI (n = 31).
Multivariate analysis identified a panel of four metabolites that allowed diagnosis of AKI with an
area under the receiver operating characteristics curve (AUC-ROC) of 0.95 (95% confidence interval
0.86–1.00). Especially urinary citrate levels were significantly reduced whereas leucine and valine
levels were elevated. Metabolomic differentiation of AKI causes appeared promising but these results
need to be validated in larger studies. In conclusion, this study shows that NMR spectroscopy yields
high diagnostic accuracy for AKI in pediatric patients.
Keywords: acute kidney injury; metabolomics; urine; NMR spectroscopy; multivariate analysis
1. Introduction
Acute kidney injury (AKI) is associated with poor outcomes, including increased morbidity (e.g.,
days on ventilator, length of hospital and intensive care unit stay) and mortality, and an increased risk
for the development of chronic kidney disease [1–3]. The prevalence of neonatal and pediatric AKI
among critically ill and high-risk cohorts is high, and AKI incidence is still increasing. Based on recent
consensus definitions, AKI occurs in 27% and 29.9% of patients of the pediatric (PICU) and neonatal
intensive care unit (NICU), respectively [4,5]. Remarkably, in non-critically ill hospitalized children and
adolescents, AKI incidence is still as high as 5% [6]. The current gold standard for the diagnosis of AKI
relies upon serum creatinine and urine output measurements, both of which, however, reveal relevant
drawbacks. As such, serum creatinine is a late and indirect marker of reduced glomerular filtration
rate that does not allow for differentiation of the specific cause of renal impairment. Urine output
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measurements, on the other hand, demand longer-term evaluations and are influenced, e.g., by diuretic
medication. Of note, an earlier and more specific identification of patients with AKI and especially
of those who are at highest risk for adverse outcome can influence physicians’ decision-making and
medical treatment and may ultimately improve patient outcome.
In recent years, several urinary proteins including neutrophil gelatinase-associated lipocalin
(NGAL), kidney injury molecule-1 (KIM-1), tissue inhibitor of metalloprotease-2 (TIMP-2), insulin-like
growth factor-binding protein 7 (IGFBP7), and others have been proposed as useful biomarkers for
early diagnosis, differentiation, and/or prediction of patient outcome in adult and pediatric AKI [7–10].
Unfortunately, the specificity of the above protein biomarkers for kidney injury and their clinical
performance are insufficient for clinical implementation [11,12]. Hence, there is an unmet need for
novel markers of AKI alone or in combination that i) improve patient risk stratification, ii) optimize
early and precise detection of renal damage, iii) enable an early etiological classification of AKI, iv)
monitor and target clinical management, and v) predict clinical outcome following AKI.
Untargeted metabolomics provides a functional fingerprint of the physiological and
pathophysiological state of an organism and can be used both for pattern recognition and
metabolite identification [13]. Nuclear magnetic resonance (NMR) and gas chromatography or
liquid chromatography, together with mass spectrometry, are generally used to separate and identify
metabolites. Metabolic approaches, i.e., by mass spectrometry, have been adopted to uncover new
small molecule biomarkers or biochemical mechanisms as well as signaling pathways in chronic
kidney disease, diabetic nephropathy, AKI, renal cancer, kidney transplantation, and polycystic kidney
diseases [14,15]. These studies were performed in either rodents or humans and investigated blood,
urine, or kidney tissue samples. In an experimental pig model of sepsis-induced AKI, NMR-based
metabolomics was a potentially useful tool for biomarker identification [16]. Characteristic urine
NMR spectra were also demonstrated in murine renal ischemia-reperfusion injury models [17,18].
Archdekin et al. using mass spectrometry of urine samples demonstrated the potential of a urine
metabolite classifier to detect non-rejection kidney injury in pediatric kidney transplant patients and
non-invasively discriminated non-rejection kidney injury from rejection [19]. While metabolomic
profiles have been investigated in prematurity, low birth weight neonates, perinatal asphyxia, pediatric
respiratory and neurological diseases, gastrointestinal diseases and inborn errors of metabolism, only
very few clinical studies have been published that investigated the application of a metabolomic
approach in pediatric AKI [20,21].
This prompted us to investigate the accuracy of NMR-based urine metabolomics for the diagnosis
of AKI in a pilot cohort study of neonates and children with established Kidney Disease: Improving
Global Outcomes (KDIGO) AKI of heterogeneous etiology. We further aimed to investigate if
metabolomic fingerprints and biomarkers allow for a differentiation of specific AKI subtypes.
2. Results
2.1. Characteristics of the Study Population
Subject characteristics are shown in Table 1. As the urine heavily reflects environmental influences,
two different control groups were included into the study in order to reduce the risk of a selection bias.
While the first control group consisted of apparently healthy children (“healthy controls”), the second
control group comprised neonatal and pediatric ICU patients without AKI (“non-AKI patients”).
In brief, there was no significant difference regarding age, gender, proportion of neonates, and body
mass index (BMI) standard deviation score (SDS) between AKI patients, non-AKI patients, and healthy
controls. The etiology of AKI was heterogeneous including both prerenal and intrinsic causes. The more
frequent AKI etiologies included dehydration (n = 15), hemolytic uremic syndrome (n = 13), septic
shock (n = 12), perinatal asphyxia (n = 7), hemodynamic instability (n = 4), and interstitial nephritis
(n = 4). Serum creatinine on study enrollment was significantly (p < 0.001) higher in AKI patients
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compared to non-AKI patients and, accordingly, estimated creatinine clearance (eCCl) was significantly
reduced (p < 0.001).
Table 1. Characteristics of the study population. Numeric data are presented as median with
interquartile range (IQR) in parenthesis. Categorical data are presented as a number with the
percentage in parenthesis. Statistical tests used for the individual parameters are described in the
section Statistical Analysis. p < 0.05 was regarded as statistically significant. Abbreviations: AKI, acute
kidney injury; BMI, body mass index; eCCl, estimated creatinine clearance; KDIGO, Kidney Disease:







Controls (n = 53) p-Value









Neonates 12 (18.5%) 6 (19.4%) 11 (20.8%) 0.95
BMI SDS −0.5 (−1.2 to 0.5) −0.8 (−1.9 to 0.6) 0.25
AKI etiology
Dehydration 15 (23.0%)
Hemolytic uremic syndrome 13 (20.0%)
Septic shock 12 (18.5%)
Perinatal asphyxia 7 (10.8%)
Hemodynamic 4 (6.2%)
Interstitial nephritis 4 (6.2%)
Other 10 (15.4%)
Serum creatinine on study
enrollment (mg/dL) 1.60 (0.9 to 3.5) 0.3 (0.2 to 0.5) <0.001
eCCl on study enrollment
(mL/min per 1.73 m2) 19.2 (11.0 to 42.0) 123.0 (80.9 to 170) <0.001
KDIGO staging of AKI
Stage 1 5 (7.7%)
Stage 2 9 (13.8%)
Stage 3 51 (78.5%)
Proteinuria (g/L) 0.6 (0.2 to 1.5) 0.1 (0.0 to 0.1) <0.001
Urinary protein-to-creatinine
ratio (mg/g) 239 (48.6 to 955) 34.6 (24.6 to 49.3) <0.001
Urinary leukocytes (per μL) 22.0 (4.5 to 93.0) 5.0 (0.0 to 26.5) <0.01
Urinary erythrocytes (per μL) 15.0 (2.0 to 136.0) 5.0 (2.0 to 37.3) <0.05
Squamous epithelium (per μL) 0.0 (0.0 to 1.5) 0.0 (0.0 to 0.0) 0.074
C-reactive protein (mg/L) 30.9 (7.5 to 98.8) 2.4 (0.0 to 19.0) 0.001
Renal replacement therapy 27 (41.5%) 0 (0%) 0 (0%) <0.001
3-month mortality 11 (16.9%) 0 (0%) 0 (0%) <0.05
Maximum KDIGO stage during the clinical course was Stage 3 in 51 patients (78,5%), Stage 2 in nine patients (13.8%),
and Stage 1 in five patients (7.7%). Proteinuria (p < 0.001), urinary protein-to-creatinine-ratio (p < 0.001), urinary
leukocytes (p = 0.002), urinary erythrocytes (p < 0.05), and C-reactive protein (p = 0.001) were significantly increased
in AKI patients compared to non-AKI patients. Twenty-seven AKI patients (41.5%) required renal replacement
therapy during the clinical course, 11 AKI patients (16.9%) deceased within 3 months following study enrollment.
2.2. Nuclear Magnetic Resonance (NMR) Spectroscopy Analysis
Ten typical spectra of the urines of AKI patients, non-AKI patients, and healthy controls,
respectively, are shown in Supplemental Figure S1. Whereas spectra of healthy children had a uniform
appearance, corresponding to the typical urine spectra of healthy people [22], AKI spectra revealed a
different picture. Not only did the spectra show increased intensities due to the reduced urine volume,
but metabolite composition varied between the different individuals. In addition, some AKI spectra
revealed a background of broad unresolved resonances most likely originating from large protein
or lipid/steroid signals. Non-AKI patient spectra were in-between the two other groups, showing
variation in their metabolite composition, but not to the same extent as the AKI spectra. Because of the
observed spectral diversity, we performed variable bucketing and selected preferably those peaks that
were common among all three groups.
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2.3. Multivariate Analysis
When performing a principle component analysis (PCA), the AKI group could be clearly separated
from the healthy control group (Figure 1A). However, the separation between the AKI and the non-AKI
group was less apparent. Principal components 1 (PC1) and 2 (PC2) explained 13.4% and 12.4% of the
variation. Quality control (QC) samples clustered tightly within the healthy control group and showed
that measurements were highly reproducible. Neonatal spectra appeared to have more negative PC1
values. Especially among the healthy control group, neonatal spectra clustered in the upper left corner.
Thus, the subsequent analyses were performed twice, with neonates either included or excluded.
When neonates were excluded from the analysis (12 AKI patients, 11 healthy control subjects, six
non-AKI control patients), separation was more pronounced (Figure 1B).
Figure 1. Principle component analysis of the urine spectral bucket table. Variable bucketing was
employed leading to 129 buckets. Metabolites were assigned, whenever possible, based on comparison
with database entries or literature and were confirmed by spiking experiments. (A) All spectra (AKI
patients, n = 65; healthy controls, n = 53; non-AKI patients, n = 31; QC, n = 15), * denotes neonatal
spectra, (B) neonatal spectra excluded (AKI patients, n = 53; healthy controls, n = 42; non-AKI patients,
n = 25; QC, n = 15). Outliers were not detectable. AKI, acute kidney injury; QC, quality control.
Partial least squares discriminant analysis (PLS-DA) was performed to separate within group
variation from class-related differentiation (Figure 2A). Quality control parameters showed that AKI
patients could be reliably separated from the control group (quality of prediction Q2: 0.55, explained
variance R2: 0.76). Omitting neonatal samples (Figure 2B) only slightly improved the separation and
predictive power (Q2: 0.64, R2: 0.82). A 1000-fold permutation analysis confirmed that this result was
not fortuitous in both cases (p < 0.001). Separation into prerenal and intrinsic causes of AKI based on
previously published criteria [23] was explored, but did not lead to improved clustering in the PCA or
PLS-DA (Supplemental Figure S2) and was consequently abandoned.
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Figure 2. Partial least squares discriminant analysis of the urine spectral bucket table. Neonatal spectra
(A) included (AKI patients, n = 65; healthy controls, n = 53; non-AKI patients, n = 31), (B) excluded
(AKI patients, n = 53; healthy controls, n = 42; non-AKI patients, n = 25). AKI, acute kidney injury.
As mentioned before, non-AKI patient spectra separated less well from AKI spectra than healthy
control spectra. We questioned whether the analysis preferentially selected general traits of morbidity
like markers of increased catabolic pathways or drug metabolism. To rule out this argument, we
performed both PCA and PLS-DA in healthy controls and non-AKI controls (Supplemental Figure S3).
Metabolites that separated the two groups were identified in a PLS-DA (Supplemental Table S1)
and those with variable importance in projection (VIP) values higher than 1.5 were excluded in the
following analyses. For further analyses, the healthy control group and the non-AKI patient group
were combined. This led to a visibly better separation already in a PCA (Supplemental Figure S4A). A
PLS-DA model could be obtained with three components and quality parameters Q2 of 0.66 and R2 of
0.79 (Supplemental Figure S4B, Table 2). Omitting neonates further improved the separation between
the groups to a Q2 value of 0.73 and a R2 value of 0.89 (Supplemental Figure S5A and S5B, Table 2).
The VIP plot (Supplemental Figures S4C and S5C) revealed that citrate, bile acid signals, leucine,
valine, general lipid signals, cis-aconitic acid, formate, as well as non-assigned aliphatic (unk_al/x)
compounds were mainly responsible for the separation.
Table 2. Explained variance and predictability for AKI and subgroups when compared to the combined








AKI (total) 3 0.63 0.78 < 0.001
AKI (neonates excluded in AKI and CTL) 4 0.73 0.89 < 0.001
Dehydration 3 0.44 0.80 < 0.001
Perinatal asphyxia 2 0.26 0.61 0.159
Septic shock 4 0.73 0.95 < 0.001
Hemolytic uremic syndrome 4 0.69 0.90 < 0.001
* resulting from 1000 times permutation analysis.
2.4. Biomarker Analysis
To analyze whether the spectral information or a combination of several metabolites could be
used as biomarker, 20% of randomly selected spectra (11 AKI, six non-AKI, and eight healthy control
spectra) were not used for initial analysis and served as validation cohort. Neonates were excluded
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as the previous analysis had shown that their spectral characteristics differ to a certain degree. We
developed a diagnostic model based on the metabolites with the highest VIP values in the PLS-DA
analysis (Supplemental Figure S5C, Table 3). They all demonstrated AUC-ROC values > 0.70 and
confidence intervals that did not cross 0.5. Yet a logistic regression model with these 15 markers did
not converge. Thus, we successively reduced the number of potential markers based on the calculated
z values and Pr(>|z|) to a set of four markers: Citrate with its resonance at 2.69 ppm, leucine (0.96 ppm),
valine with its resonance at 1.00 ppm, and bile acid (0.69–0.81 ppm).
Table 3. Top 15 metabolites according to PLS-DA of AKI compared to the combined control group
(non-AKI patients plus healthy control subjects), neonatal spectra excluded. AKI, acute kidney injury;
PLS-DA, partial least squares discriminant analysis.
Metabolite Importance Number Metabolite VIP Score AUC * 95% CI **
1 Citrate1 *** 2.73 0.94 0.88–0.98
2 Bile acid 2.52 0.91 0.84–0.97
3 Citrate2 *** 2.50 0.92 0.85–0.96
4 Unk_al1 2.49 0.90 0.83–0.96
5 unk_al28 2.19 0.84 0.75–0.91
6 Leucine 2.13 0.83 0.73–0.90
7 unk_al24 2.07 0.83 0.74–0.92
8 unk_al26 2.07 0.82 0.73–0.91
9 Valine 1.89 0.79 0.70–0.89
10 unk_al10 1.86 0.80 0.70–0.89
11 cis-Aconitic acid 1.86 0.79 0.69–0.88
12 Formate 1.80 0.84 0.75–0.91
13 LipidCH2 1.65 0.82 0.72–0.90
14 Glycine 1.50 0.71 0.61–0.81
15 Asparagine 1.48 0.76 0.65–0.85
* ROC AUC values from univariate testing. ** 95% confidence interval was calculated using 500 bootstrappings.
*** Citrate is characterized by two separate buckets, one for each proton of the degenerate CH2 group.
We obtained a regression equation with a best threshold (or cut-off) for the predicted p (= Pr(y=1|x))
of 0.34 (Table 4A).
Table 4. Logistic regression model—summary of each feature: (A) With four, (B) with six features.
(A) logit(p) = log(p/(1 − P)) = −0.667 − 2.723 citrate + 2.538 leucine − 3.42 valine + 3.164 bile acid
Estimate Std. Error z Value Pr(>|z|) Odds
(Intercept) −0.667 0.571 −1.167 0.243 -
citrate (2.69 ppm) −2.723 0.83 −3.281 0.001 0.07
leucine 2.538 1.089 2.33 0.02 12.65
valine −3.42 1.374 −2.489 0.013 0.03
bile acid 3.164 1.096 2.887 0.004 23.67
(B) logit(P) = log(P/(1 − P)) = 0.034 − 3.193 citrate + 4.859 leucine − 6.191 valine + 4.207 bile acid - 2.694
unk_al1 − 2.489 unk_al28
Estimate Std. Error z value Pr(>|z|) Odds
(Intercept) 0.034 0.998 0.034 0.973 -
citrate (2.69 ppm) −3.193 1.682 −1.898 0.058 0.04
leucine 4.859 2.182 2.227 0.026 128.88
valine −6.191 2.617 −2.366 0.018 0
bile acid 4.207 1.774 2.372 0.018 67.18
unk_al1/3.16 ppm 2.694 1.414 −1.906 0.057 0.07
unk_al28/2.15 ppm −2.489 1.093 −2.278 0.023 0.08
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p-values above this threshold classified samples as AKI. The area under the receiver operating
characteristics curve (AUC-ROC) was 0.95 with a 95% confidence interval of 0.86–1.00 (Figure 3A).
When the classification performance was tested on the validation cohort, one AKI test sample (out of
11) was wrongly classified, but no control spectra. A modified marker set including two additional
unidentified aliphatic compounds, one with a resonance at 3.16 ppm (unk_al1) and one overlapping
with glutamine (2.12–2.17 ppm, unk_al28), classified all spectra of the validation set correctly, but had
a slightly lower AUC-ROC value of 0.93 (95% CI: 0.82–0.99) (Table 4B and Figure 3B). Details about
each feature are listed in Table 4A,B.
Figure 3. ROC curve for the diagnostic accuracy of selected metabolites from NMR spectroscopy for
the diagnosis of KDIGO AKI obtained from a linear regression analysis using (A) four selected features
(citrate (2.69 ppm), leucine (0.96 ppm), valine (1.00 ppm), and bile acid (0.69–0.81 ppm)) and (B) six
selected features (citrate (2.69 ppm), leucine (0.96 ppm), valine (1.00 ppm), bile acid (0.69–0.81 ppm),
unk_al1 (3.16 ppm), and unk_al28 (2.12–2.17 ppm)). AKI, acute kidney injury; KDIGO, Kidney Disease:
Improving Global Outcomes; NMR, nuclear magnetic resonance; ROC, receiver operating characteristic.
2.5. Differentiation of Acute Kidney Injury (AKI) Etiologies
We next analyzed whether NMR spectroscopy allows for etiologic differentiation of underlying
AKI causes (Figure 4). Four AKI subgroups had sufficient patient numbers for statistical analysis
(n > 5). Here we used a reduced set of buckets and excluded all buckets of the original set that had
variable importance in projection (VIP) values < 1.1 when the AKI group was compared against the
combined control group. This led to a reduced set of 48 buckets. The logic behind this choice was to
remove potential noise as the number of variables by far exceeded the number of spectra.
We performed PLS-DA with each of the subgroups (i.e., dehydration, hemolytic uremic syndrome,
septic shock, perinatal asphyxia) against the combined control group to search for distinct group
specific patterns. Quality control values were good for two subgroups (septic shock and hemolytic
uremic syndrome) and acceptable for the dehydration subgroup (Table 2). A moderate Q2-value and a
high empirical p-value for a 1000-fold permutation test showed that the subgroup perinatal asphyxia
was less well identifiable with the employed metabolite set.
Figure 4 displays the VIP values of the most important metabolites (VIP > 1.1 in at least one
group) together with their fold change calculated for each subgroup. The VIP patterns (Figure 4A)
showed that in addition to metabolite buckets that were important for general AKI identification in
all AKI subjects, AKI subtype-specific metabolite buckets appeared to be identifiable. Fold changes
analysis displayed an even more distinct picture (Figure 4B). A fold change in citrate was common in
all groups. Others seemed to be specific for the underlying AKI etiology. For example, gluconate and
lactate-to-threonine ratio had large fold changes in perinatal asphyxia and septic shock, but were less
informative for dehydration and hemolytic uremic syndrome.
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Figure 4. (A) Overview of discriminant identified metabolites according to variable importance in
projection (VIP) values analyzed separately for each etiology. VIP values were obtained from a PLS-DA
analysis. Only metabolite buckets are shown that had VIP values > 1.1 for at least one of the different
groups. (B) The respective fold changes (log2(FC)) for the same metabolites are given for comparison.
Black bars denote fold changes with an associated p-value < 0.01, grey bars those with a p-value > 0.01.
PLS-DA, partial least squares discriminant analysis.
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3. Discussion
Several metabolomic studies investigating various renal diseases have been published in the past
decade, however, metabolomics data on pediatric AKI is scarce (for an overview see [14,15,24]). In the
present study, 1H-NMR profiling was applied to urinary samples of neonatal and pediatric patients
with established AKI and compared to healthy children and to hospitalized children without AKI. By
multivariate analysis, we identified a panel of metabolites that enabled AKI diagnosis by yielding an
AUC-ROC of 0.95. The identified metabolites that enabled the diagnosis of AKI (KDIGO) included,
among several unknown compounds, increases in leucine, valine, bile acid and decreases in citrate
(Figure 4B). In addition, in our rather small pilot study population NMR-fingerprints seemed to allow
for differentiation between different AKI etiologies.
A crucial point in our analysis was the selection of the control group. The AKI cohort was very
heterogeneous with respect to the underlying cause of AKI, and patients were treated with a variety
of medications. As urine reflects all these impacts as well as nutritional influences, comparing the
AKI children only to a healthy control cohort would enhance the risk for the selection of markers not
related to AKI but rather to general morbidity. Creatinine may be such an example, as it is not only
used to determine renal clearance but is also a marker of muscle mass. For that reason, we decided to
further include a control group of critically ill ICU patients without AKI that were also exposed to
diverse medical treatments. PCA and PLS-DA analysis proved that this grouping was possible and
that AKI spectra showed their own distinct pattern. Moreover, in this way we identified metabolites
like mannitol, lactose, and creatinine as crucial for the general distinction between healthy children
and hospitalized patients without AKI. Mannitol and lactose are applied as additive drug components,
whereas creatinine may be a common sign of catabolic metabolism or a sign of a minor reduction in
renal clearance (Supplemental Table S1). By omitting these metabolites, we are confident that the
distinction of AKI from non-AKI patients was not based on common medication or general signs of
morbidity. Strikingly, some markers that were excluded from analysis after comparison of healthy
control and non-AKI patient control spectra (hippurate, indoxylsulfate, creatinine) were among those
that were previously classified as markers for AKI in animal models [25–27]. However, in animal
models, only healthy untreated animals served as control. This does not allow a distinction between
general signs of morbidity and specific ones for AKI.
Previous human AKI studies resulted in the identification of a variety of potential metabolite
biomarkers [14,24]. Interestingly, almost no overlap exists between the respective metabolites [28–34]
and the metabolites identified in our study. For example, Beger et al. identified homovanillinic acid
sulfate, a dopamine metabolite as the most important marker in the urine of children who developed
AKI after cardiac surgery [21]. This finding was confirmed by Mercier et al. investigating the urine of
neonates with AKI [29]. By contrast, aromatic compounds other than 3-indoxylsulfate and hippurate
are not among the important metabolites in our study.
Animal studies present a somewhat more homogeneous picture of putative biomarkers. In the
majority, AKI was induced in healthy animals through application of drugs or surgery [25–27,34–38].
Although the identified biomarkers rarely fully matched between the different studies, metabolites of the
citric acid cycle (TCA) cycle, branched-chain amino acids, creatinine, hippurate, and 3-indoxylsulfate
emerged as common markers of drug-induced AKI [25–27,34–38]. Some prospective markers in
rodent models of drug-induced AKI (e.g., by cisplatin or gentamicin) were already altered in early
phases of drug-induced nephrotoxicity [25]. Strikingly though, the metabolite selection mentioned
above overlaps with the markers identified in our study. Especially citrate, leucine, and valine were
among the most relevant metabolites responsible for AKI diagnosis and were main components of our
developed logistic regression model.
Why do our results match better to studies on animals than on humans? Previous human studies
generally examined very homogeneous groups of patients with respect to AKI etiology. In our study,
AKI patients comprised a broad etiologic spectrum of AKI which is reflected by the diverse peak
patterns in the aromatic area (Figure 1). This diversity may have helped in identifying a robust common
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denominator. Enhanced branched-chain amino acids and a reduction in citrate excretion has been
reported previously, but for other nephropathies including chronic kidney disease, [39,40], diabetic
nephropathy [41] and polycystic kidney disease [42]. They may be signs of early kidney damage, as a
reduction of citrate can be a sign for mitochondrial dysfunction of the proximal tubular cell [24].
In fact, a reduction of TCA cycle metabolites as reflected in our study presumably mirrors tubular
dysfunction due to inadequate energy supply. This dysfunction might originate from missing driving
forces of the tubular cell membrane due to a lack of adenosine triphosphate (ATP) that ultimately
impairs transcellular transport of dicarbonic acids by organic anion transporters (OAT), i.e., OAT4 [43].
The reason for the reduction of urinary formic acid in pediatric AKI patients can only be speculated on.
Energy deficiency might cause a reduced outwardly directed electrochemical gradient for formate, a
metabolite that was also significantly reduced in AKI patients. This, in consequence, is a driving force
for tertiary active Cl- absorption via the Cl-/formate anion exchange transporter [44].
In our study, the percentage of spectra originating from neonates was 18.5% in the AKI group,
19.4% in the non-AKI patient group, and 20.8% in the healthy control group. Omitting these from
the statistical analyses further improved the separation between the AKI group and the combined
control group comprising both healthy children and critically ill ICU patients without AKI. Similar
observations were made previously when investigating novel protein biomarkers of renal damage
in mixed neonatal and pediatric cohorts [23]. This observation might be attributed, at least in part,
to the relatively high percentage of low KDIGO AKI stages in neonates. As such, four neonates
(33.3%) were classified as Stage 1 KDIGO AKI, three neonates (25%) were classified as Stage 2 and
only five patients (41.7%) were classified as Stage 3 AKI. By contrast, 46 (86.8%) pediatric AKI patients
fulfilled Stage 3 KDIGO AKI criteria, six (11.3%) fulfilled Stage 2 criteria and only one pediatric AKI
patient (1.9%) fulfilled Stage 1 criteria. In addition, several metabolomics studies demonstrated that
the urine of neonates shows characteristic differences compared to older children. Scalabre et al.
stressed the differential impact of age, height, and weight in metabolomic studies on urinary metabolic
profiles in children aged < 1 year [45]. Among the metabolites identified as markers of age, they also
identified citrate as an important marker. In that study, it was correlated with an increase in weight
and height, and showed a negative correlation with age like succinate, which was confirmed in two
other studies [20,46,47]. In comparison, in our study AKI patients of all ages showed a decrease of
citrate levels compared to non-AKI subjects. Other age-related metabolites identified in these studies
showed no significant effect in our analysis. Thus, we are confident that in our study age-related effects
were marginal compared to the metabolic changes caused by AKI.
There are several limitations to our study. First, the number of patients participating in our
single-center pilot study was low, hence requiring larger population studies. Nevertheless, robust
identification of AKI patients by 1H-NMR spectroscopy was feasible despite the wide variety of AKI
etiologies. Second, due to the low number of study participants investigated, this study was not
appropriate for analyzing the impact of AKI severity as reflected by KDIGO stage on NMR spectra.
Third, the presented study primarily focuses on the diagnosis of established AKI using the serum
creatinine- and urine output-based KDIGO AKI criteria as gold standard. However, due to a variety of
reasons both parameters can be problematic for AKI diagnosis, especially in children. Future studies
will have to deal with the implementation of 1H-NMR spectroscopy for early detection of imminent
AKI, for differentiation of varying AKI subtypes and for therapy monitoring and prognosis of AKI
outcome. In fact, early identification of patients at highest risk for AKI and for adverse outcome can
help physicians in early decision-making, e.g., with respect to the timely insertion of dialysis catheters
and initiation of renal replacement therapy.
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4. Materials and Methods
4.1. Ethics Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the
ethics committee of the Heidelberg Medical Faculty (Protocol S-133/2011, permission: 15 July 2011,
amendment: 13 June 2016). Legal guardian of each patient gave written informed consent and, when
appropriate, assent from the patient was obtained as well.
4.2. Study Design and Participants
A prospective pilot cohort study was conducted at the University Children’s Hospital Heidelberg.
Patients aged 0 to 18 years who developed AKI during their hospital stay and patients who were
referred to our Children’s Hospital with established AKI were enrolled in the study from October 2011
to March 2019. Of note, the study population has partly been published before [23,48,49]. Criteria for
study exclusion were (i) prematurity, (ii) postrenal AKI as examined by initial renal ultrasound, and
(iii) children undergoing cardiac surgery. AKI was classified either according to the Kidney Disease:
Improving Global Outcomes (KDIGO) AKI definition [50] for pediatric patients or according to the
modified KDIGO definition for neonatal patients aged ≤ 28 days of life [51]. When serum creatinine
and urine output criteria resulted in different KDIGO stages, the higher stage was chosen. The revised
Schwartz formula (k = 0.413 × height / serum creatinine) was used for calculation of eCCl [52]. Baseline
serum creatinine was defined as last value within the previous three months before study enrollment.
In the case of missing baseline data, the eCCl was assumed to be 120 mL per minute per 1.73 m2 in
pediatric patients and 40 mL per minute per 1.73 m2 in neonates [4,48]. Control subjects without AKI
were taken from two different cohorts [23]. While the “non-AKI patients” group (n = 31) consisted of
neonatal and pediatric ICU patients without AKI, the “healthy controls” group (n = 53) comprised
apparently healthy neonates, children, and adolescents aged 0–18 years. Diagnoses of inpatients
without AKI were postoperative care (n = 25 including neurosurgery, n = 11; pediatric surgery, n = 6;
maxillofacial surgery, n = 6; orthopedics, n = 1; otorhinolaryngology, n = 1), seizures (n = 1), respiratory
diseases (n = 1), perinatal asphyxia (n = 1), infectious diseases (n = 2), and cardiovascular diseases
(n = 1). Exclusion criteria for the healthy control group have been previously published [48]. Patients’
characteristics are given in Table 1.
4.3. Sample and Data Collection
Urine samples were collected immediately following KDIGO AKI diagnosis or after admission to
our hospital. In case of anuria, urine samples were obtained after restoration of diuresis. Following
centrifugation, the supernatants of the urine samples were frozen, stored at −80 ◦C and thawed prior
to analysis. After thawing urine samples were centrifuged for 10 min at 15,871 g. A total of 500 μL
of samples were mixed with 100 μL sodium phosphate buffer (150 mM final concentration in D2O,
pH 7.2) containing 2 mM trimethylsilylpropanoic acid for spectral referencing. D2O was used as lock
substance. Measurement of SCr was performed using an IDMS-traceable enzymatic method.
4.4. 1H-NMR Spectroscopy of Urine Samples
A 600 MHz Avance II spectrometer (Bruker Biospin, Rheinstetten, Germany) with a double
resonance 5-mm BBI probe was used to acquire the 1H NMR spectra at 300 K. Temperature calibration
was performed on a daily basis. Quality control (QC) samples consisting of urine aliquots of a healthy
male volunteer were included every 10 h of measurement. One-dimensional spectra were acquired
with the Bruker pulse sequence noesygppr1D using a relaxation delay of 10 s, 32 transients of 64 K data
points, and a spectral width of 20 ppm. Water suppression was achieved through presaturation with a
bandwidth of 25 Hz. Automatic phase- and baseline-correction was employed. Spectra were calibrated
to the signal of TSP. Prior to Fourier transformation, spectra were multiplied with an exponential
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function with a 0.3 Hz line broadening factor. Topspin3.2 (Bruker Biospin, Rheinstetten, Germany) was
used for data acquisition and processing.
Variable bucketing was employed leading to 129 buckets. Metabolites were assigned on the basis
of comparison with data bases entries or literature whenever possible. Spiking experiments, where
specific metabolites were added to a representative, already measured sample, were used to confirm
the assignments in cases of doubt. Two windows were excluded: 4.74–4.84 ppm and 6.0–5.56 ppm,
where water or urea resonances, respectively, appear. Missing values did not occur.
4.5. Statistical Analysis
As clinical data was non-normally distributed, median and interquartile range are presented. For
statistical analysis of intergroup differences of numeric parameters, the Kruskal–Wallis test with post
hoc Dunn’s test or the Mann–Whitney U-test were used. Categorical parameters were compared by
Pearson’s Chi-squared test. For age-independent estimates, BMI was converted to SDS values, related
to age- and gender-specific means and SD of European reference populations.
PCA and PLS-DA were performed with R (version 3.5.3) using the package MetaboanalystR and
default parameters [53]. Probabilistic quotient normalization [54] was employed prior to statistical
analysis using the healthy control samples as reference to take into account that the urine of AKI patients
is as such more often concentrated leading to higher peak intensities. Data distribution showed that
the data were skewed. To take this into account, data were log transformed and scaled to unit variance.
To assess the quality of the resulting statistical models, 10-fold internal cross-validation as well as
permutation tests were performed. To judge the predictive power of PLS-DA, quality parameters Q2
(quality of prediction) and R2 (explained variance) were calculated. In a second round, metabolites that
separated healthy controls and non-AKI controls were identified in a PLS-DA (Supplemental Table S1)
and those with VIP values higher than 1.5 (18 buckets) were excluded from the subsequent analyses.
Biomarker analysis was performed with the respective module of MetaboanalystR using PLS-DA
for identification of a set of marker peaks, support vector machines, and logistic regression to assess
the suitability of a reduced set for class prediction of unknown spectra and univariate ROC curve
analysis for the calculation of individual metabolite AUC values.
For etiological analysis a reduced set of metabolites was used. All buckets were taken out that had
variable importance in projection (VIP) values < 1.1 when the AKI group was compared against the
combined control group. This led to a reduced set of 48 buckets. Metabolite fold changes between the
groups were assessed with the non-parametric Mann-Whitney U-test using the Fold-Change Analysis
Module of MetaboanalystR.
5. Conclusions
In conclusion, the present study underlines the value of 1H-NMR spectroscopy for the identification
of novel biomarkers of renal damage in pediatric AKI. By use of this elegant technique, we were able
to identify a panel of four metabolites that in linear regression analysis yielded an excellent accuracy
for the diagnosis of AKI. In addition, detailed breakdown of signaling pathways being involved in the
AKI cascade might further pave the way for the development of new therapeutic options for AKI.
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AKI (Non-AKI), Figure S4: PCA and PLS-DA after taking out buckets separating healthy control group from
hospitalized patients without AKI, Figure S5: Same as Figure S4, with neonatal spectra excluded. Table S1:
Variable importance in projection (VIP) –Values from PLS-DA of healthy control group vs. hospitalized patients
without AKI (Non-AKI).
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Abstract: Nephropathic cystinosis is a rare lysosomal storage disorder caused by mutations in
CTNS gene leading to Fanconi syndrome. Independent studies reported defective clearance of
damaged mitochondria and mitochondrial fragmentation in cystinosis. Proteins involved in the
mitochondrial dynamics and the mitochondrial ultrastructure were analyzed in CTNS−/− cells
treated with cysteamine, the only drug currently used in the therapy for cystinosis but ineffective
to treat Fanconi syndrome. CTNS−/− cells showed an overexpression of parkin associated with
deregulation of ubiquitination of mitofusin 2 and fission 1 proteins, an altered proteolytic processing
of optic atrophy 1 (OPA1), and a decreased OPA1 oligomerization. According to molecular findings,
the analysis of electron microscopy images showed a decrease of mitochondrial cristae number and
an increase of cristae lumen and cristae junction width. Cysteamine treatment restored the fission
1 ubiquitination, the mitochondrial size, number and lumen of cristae, but had no effect on cristae
junction width, making CTNS−/− tubular cells more susceptible to apoptotic stimuli.
Keywords: Fanconi syndrome; nephropathic cystinosis; mitochondrial dynamics; cysteamine;
mitochondrial fusion; mitochondrial fission; mitochondrial cristae
1. Introduction
Nephropathic cystinosis (MIM 219800) is a rare inherited metabolic disease characterized by an
impaired transport of the amino acid cystine out of lysosomes due to reduced or absent function of the
specific carrier cystinosin, which is encoded by CTNS gene [1–3]. Kidneys are affected at the initial
stage of the disease, leading to early onset Fanconi syndrome, which is characterized by polyuria,
glycosuria, phosphaturia, aminoaciduria, and urinary loss of electrolytes and low-molecular-weight
proteins [4]. The cystine-depleting agent, cysteamine (MEA), significantly delays symptoms [5,6],
but does not treat Fanconi syndrome and is ineffective to prevent the progression of kidney disease.
Fanconi syndrome has also been reported in children with specific mitochondrial syndromes [7]. Renal
Int. J. Mol. Sci. 2020, 21, 192; doi:10.3390/ijms21010192 www.mdpi.com/journal/ijms57
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tubular cells are very rich in mitochondria due to the intense reabsorption and excretion processes
that occur in this district. We recently reported, in CTNS−/− cells derived from proximal tubules,
mitochondrial fragmentation associated with respiratory chain dysfunction and low mitochondrial
3′,5′-cyclic adenosine monophosphate (cAMP) levels [8]. Furthermore, enhanced apoptosis [9,10],
defect of autophagic flux [11,12], and endo-lysosomal dysfunction [13,14] were observed.
Communication between mitochondria and the endo-lysosomal system is complex. Increasing
evidences show close relationship between these two cellular compartments [15,16]. Mitochondria
constantly undergo fission and fusion processes to adapt to environmental changes in a continuous
and balanced way, in order to maintain morphology and regulate cellular ATP levels. Mitochondrial
fission regulates the production of new mitochondria and the segregation of damaged mitochondria.
In this process, receptor proteins such as mitochondrial fission factor (Mff), mitochondrial fission
1 protein (Fis1), mitochondrial dynamics protein of 49 kDa (MiD49), and mitochondrial dynamics
protein of 51 kDa (MiD51) recruit the large GTPase dynamin-related protein 1 (Drp1) from the cytosol
to the outer mitochondrial membrane (OMM), which forms a multimeric complex with mitochondrial
membrane adaptors [17,18]. Mitochondrial fusion is mediated by three key regulatory fusion proteins:
the dynamin-related GTPases mitofusin 1 (MFN1) and mitofusin 2 (MFN2), responsible for the
fusion of OMM and the dynamin-related GTPases optic atrophy 1 (OPA1), which mediates fusion
of the inner mitochondrial membrane (IMM) and contributes to the maintenance of mitochondrial
potential, to control respiratory chain activity and apoptosis [19,20]. When mitochondrial dynamics are
impaired, dysfunctional mitochondria are selectively eliminated through mitophagy, which is initiated
by ubiquitin-dependent or ubiquitin-independent signals [21]. The lysosomal alterations in cystinosis
lead to defective autophagic clearance of damaged mitochondria [12], therefore the purpose of our
study was to investigate mitochondrial dynamics in CTNS−/− conditionally immortalized proximal
tubular epithelial cells (ciPTEC) carrying the classical homozygous 57-kb deletion in the intent of
identifying new therapeutic targets and biomarkers for treatment follow-up.
2. Results
2.1. CTNS−/− ciPTEC Showed Deregulation of Proteins Involved in Mitochondrial Fission/Fusion Processes
Recruitment of the GTPase dynamin-related protein 1 (Drp1) to mitochondria is a key step
required for mitochondrial fission and its reversible phosphorylation was implicated in the regulation
of this process. The analysis of phosphorylated Drp1 at Ser-637 (Drp1pS637) showed high variability
of protein phosphorylation with no significant differences in wild type and CTNS−/− ciPTEC, also
24 h treatment with 100 μM cysteamine (MEA) did not affect Drp1pS637phosphorylation (Figure 1).
The western blotting of the pro-fission mitochondrial protein Fis1 revealed the ubiquitinated and
not-ubiquitinated forms of protein. CTNS−/− ciPTEC showed increased level of Fis1 (2.47 ± 0.27 vs.
1.08 ± 0.08, p = 0.0027). Treatment with 100 μM MEA for 24 h further increased total Fis1 protein level
(2.47 ± 0.27 vs. 3.59 ± 0.15, p = 0.011) but almost completely reduced the ubiquitinated counterpart by
96.3% (p < 0.001) (Figure 1). Third key regulatory protein analyzed was mitochondrial fission factor
(Mff), which localizes on OMM and promotes the recruitment of DRP1 to the mitochondrial surface.
This protein, shown in its four isoforms, was not modified in CTNS−/− ciPTEC and the expression was
unchanged after MEA treatment (Figure 1).
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Figure 1. Analysis of proteins involved in fission process of mitochondrial dynamics in untreated
and cysteamine (MEA)-treated CTNS−/−compared to CTNS+/+. Cell cultures were treated with
100 μM cysteamine (MEA) or DMSO (vehicle) for 24 h as specified in the figure. (a) Representative
immunoblotting analysis in cellular lysate of conditionally immortalized proximal tubular epithelial
cells (ciPTEC) from a healthy subject (CTNS+/+) and cystinotic patient (CTNS−/−). (b–e) The histograms
(Drp1pS637, panel (b), n = 8; mitochondrial fission factor (Mff), panel (c), n = 3; mitochondrial fission 1
protein (Fis1), panel (d), n = 4; ubiquitinated Fis1 (Ub-Fis1), panel (e), n = 3) represent the means values
± SEM of the relative expression normalized on actin level. Densitometric analysis was performed by
Versa-Doc imaging system BioRad, using Quantity One software. p-value less than 0.05 was considered
as statistically significant, (Student’s t test, *** p < 0.001; ** p < 0.01; * p < 0.05). For further details see
under “materials and methods” section.
The inner mitochondrial membrane GTPase OPA1 undergoes constitutive processing leading to
the conversion of the un-cleaved long OPA1 (L-OPA1) in cleaved short variants (S-OPA1). Various stress
conditions, including apoptotic stimuli, trigger the complete conversion of L-OPA1 into S-OPA1. In this
regard, CTNS−/− ciPTEC were characterized by a significant increase of short variants (52.4%, p < 0.05),
but 24 h treatment with 100 μM MEA did not show significant effects (Figure 2). In agreement with
higher S-OPA1 levels, we found that the active form of mitochondrial metallo-endopetidase OMA1,
which catalyze conversion of OPA1 into short isoforms and triggers mitochondrial fragmentation, was
increased by 79.8% in CTNS−/− ciPTEC (p < 0.001), and not rescued by MEA treatment (Figure 2).
OPA1 can oligomerize at the inner mitochondrial membrane to keep the cristae junction tight, therefore
cell fresh pellets were treated with the cross-linker bis-maleimidohexane (BMH) 1 mM or with vehicle
to test the oligomeric state of OPA1. The OPA1 oligomer, immune-revealed as a high molecular-weight
band (≈250 kDa), decreased in CTNS−/− cells by 23.5% compared to CTNS+/+ cells and was not
affected by MEA treatment. The absence of OPA1 oligomerization in cells treated with vehicle (DMSO)
confirmed the specificity of cross-linking (Figure 2).
The expression of MFN2, an outer mitochondrial membrane GTPase involved in fusion processes,
was not changed in CTNS−/− ciPTEC with respect to control cells (Figure 3). However, the higher
molecular weight band, corresponding to ubiquitinated MFN2, indicated an increase of ubiquitination in
CTNS−/− ciPTEC by 70.8% (p < 0.001). Treatment with MEA showed 37.8% reduction of ubiquitination
but the effect was not statistically significant (Figure 3).
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Figure 2. Processing and oligomerization of optic atrophy 1 (OPA1) fusion protein in untreated and
MEA-treated CTNS−/− compared to CTNS+/+. (a) Representative immunoblotting analysis of ciPTEC
obtained from CTNS+/+ and CTNS−/−. Where indicated, the cells were treated with MEA or DMSO
(vehicle) for 24 h. The histograms of OPA1 (b) represent the percentage of relative expression of L and
S forms of OPA1 in each lane (n = 3). The histograms of OMA1 (c) represent the means values ± SEM
of the relative expression normalized on actin level (n = 3). (d) The fresh collected cells were treated
with the cross-linker 1,6-bismaleimidohexane (BMH) 1 mM or with vehicle (DMSO) for 30 min at 37 ◦C,
then centrifuged and resuspended in sodium dodecyl sulfate (SDS) lysis buffer for western blotting
analysis with the antibody against OPA1. (e) The histograms represent the means values ± SEM of the
relative expression of OPA1 oligomers (n = 3). Densitometric analysis was performed by Versa-Doc
imaging system BioRad, using Quantity One software. Student’s t test, *** p < 0.001; * p < 0.05. For
further details see under “materials and methods” section.
Numerous mitochondrial outer membrane proteins are modified with K48- and K63-linked
ubiquitin chains, including the mitochondrial fusion factors MFN1 and MFN2 and fission factors Fis1
and Drp1, triggering a cascade of events that result in mitophagy. According with previous results,
we found in CTNS−/− ciPTEC a significant increase in protein levels of the E3 ubiquitin ligase parkin
(2.92 ± 0.22 in CTNS−/− vs. 1.0 ± 0.04 in CTNS+/+, p = 0.001). MEA treatment did not change parkin
expression (Figure 4A). Ubiquitin carboxyl-terminal hydrolase 30 (USP30) mediates the removal of
the ubiquitin chains added by parkin to ubiquitilated forms of mitofusins, such as MFN2, therefore
we analyzed the expression of this deubiquitinating enzyme tethered to the OMM and showed in
CTNS−/− ciPTEC 62.9% decreasing compared to wild type cells (p < 0.001). Treatment with MEA
rescued USP30 expression in CTNS−/− ciPTEC by 87.9% (p = 0.037) (Figure 4B).
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Figure 3. Expression and ubiquitination of mitofusin 2 (MFN2) in untreated and MEA-treated CTNS+/+
and CTNS−/−. (a) Representative immunoblotting analysis of untreated and MEA-treated ciPTEC
CTNS+/+ and CTNS−/−. (b) The histogram of MFN2, n = 3, and (c) the histogram of ubiquitinated
MFN2 Ub-MFN2, n = 3, represent the mean values ± SEM of the relative expression normalized on actin
level. Densitometric analysis was performed by Versa-Doc imaging system BioRad, using Quantity
One software. Student’s t test, *** p < 0.001.
Figure 4. Parkin and ubiquitin carboxyl-terminal hydrolase 30 (USP30) proteins levels and MEA effect in
CTNS+/+ and CTNS−/−. (a) Immunoblotting analysis of untreated and MEA-treated ciPTEC CTNS+/+
and CTNS−/−. (b) The histogram represents the means values ± SEM of the relative expression of
Parkin normalized on actin level (n = 3). (c) The histogram represents the means values ± SEM of the
relative expression of USP30 normalized on actin level (n = 3). Densitometric analysis was performed
by Versa-Doc imaging system BioRad, using Quantity One software. Student’s t test, *** p < 0.001;
* p < 0.05.
2.2. Mitochondrial Cristae Organization Was Impaired in CTNS−/− ciPTEC
Comparative ultrastructural analysis of mitochondria in ciPTEC, by transmission electron
microscopy (TEM), showed the presence of smaller mitochondria in CTNS−/− ciPTEC compared
to CTNS+/+ ciPTEC (0.12 ± 0.01 μm2 in CTNS−/− vs. 0.26 ± 0.01 μm2 in CTNS+/+, p < 0.0001).
Mitochondrial area was completely recovered by MEA treatment (0.32 ± 0.04 μm2 in CTNS−/− +
MEA vs. 0.12 ± 0.01 μm2 in CTNS−/−, p < 0.0001). Moreover, TEM showed a substantial reduction
in number of cristae per mitochondrial section in CTNS−/− (5.1 ± 0.6 in CTNS+/+ vs. 1.6 ± 0.2 in
CTNS−/−, p < 0.0001). This parameter was rescued by MEA by 167.5% (p < 0.0001). Because evidences
underlined a critical role of cristae junction in mitochondrial function and organization, we measured
them. It was found an increase in cristae junction width (39.65 ± 4.83 nm in CTNS+/+ vs. 53.21 ±
10.05 nm in CTNS−/−, p < 0.0001) and cristae lumen width (29.68 ± 3.53 nm in CTNS+/+ vs. 37.04 ±
6.13 nm in CTNS−/−, p < 0.0003) partially rescued by cysteamine (Figure 5).
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Figure 5. Comparative ultrastructural analysis of mitochondria in ciPTEC. (a) Representative images of TEM
with magnification 16,000× of untreated and MEA-treated ciPTEC CTNS+/+ and CTNS−/−; scale bar = 1 μm.
As shown in high magnification cropped micrographs and in ad hoc schematic reconstruction, mitochondria
kept preserved ultrastructure in ciPTEC CTNS+/+ and in MEA-treated ciPTEC CTNS+/+ and CTNS−/−,
whereas ciPTEC CTNS−/− showed disruption of mitochondrial cristae and the disarrangement of the internal
structures; scale bar = 200 nm. (b–e) Quantitative analysis was performed with ImageJ v.1.52p in n ≥ 5
double-blind acquisitions for each experimental condition, red lines represent median with interquartile range.
(b) Evaluation of relative mitochondrial size measured as area of n ≥ 27 mitochondrial sections. (c) Average
number of cristae per mitochondrion in each cell (n ≥ 27 mitochondrial sections). (d) The measure of distance
of cristae junction near the inner membrane boundary and (e) the measure of cristae lumen, assessed on cristae
membranes that outline the lumen boundary, were assessed in n≥ 100 cristae. Non-parametric Mann-Whitney
test was applied, *** p < 0.001; * p < 0.05.
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3. Discussion
Nephropathic cystinosis is a rare inherited metabolic disorder, belonging to the group of lysosomal
storage diseases (LSD). The disease is the first cause of Fanconi syndrome in children, characterized by
loss of electrolytes, glucose, amino acid, low-molecular weight proteins in urine caused by proximal
tubule dysfunction [4,22]. The molecular mechanism at the basis of Fanconi syndrome in cystinosis is not
completely understood. Several mechanisms have been suggested to contribute to the pathogenesis of
cystinosis, including lysosomal overload, endo-lysosomal transport defect, altered chaperone-mediated
autophagy, mTOR signaling, transcription factor EB (TFEB) expression [11,13,23–27]. Cysteamine,
a cystine-depleting agent, which allows clearance of cystine from lysosomes, represents the only
specific treatment for cystinosis. However, cysteamine does not correct the above cited cellular
alterations and does not stop the progress of the Fanconi syndrome. Our recent studies have shown in
CTNS−/− ciPTEC a higher mitochondrial fragmentation index associated with lower mitochondrial
potential and mitochondrial cyclic AMP levels, rescued by 24 h treatment with 100 μM cysteamine
or with the cell-permeant analogue of cyclic AMP, 8-Br-cAMP [8]. cAMP, in fact, is one of the major
regulators of mitochondrial function [28–30] and dynamics [31]. In this contest, it should be noted
that MEA has been found to improve mitochondrial function in mitochondrial respiratory chain
diseases [32]. Mitochondrial dynamics is balanced between rates of fusion and fission that respond to
pathophysiologic signals. This finely regulated equilibrium is closely related to the quality control
system, which is mainly ascribed to the ubiquitin protease system (UPS) and to the intra-mitochondrial
proteolytic systems [33]. In our experimental model, no significant differences were observed on
protein levels of phosphorylated Drp1 at Ser-637. The PKA-dependent phosphorylation of Drp1
at Ser-637 is generally recognized to block Drp1 GTPase activity and to suppress mitochondrial
fission. However, and in agreement with data previously reported by Yu et al., Drp1pS637 did not
contribute substantially to mitochondrial fission regulation in CTNS−/− ciPTEC [18]. Several key
effector proteins of mitochondrial fusion (MFN1 and MFN2) and fission (Fis1, Mff) are located at the
OMM with their domains exposed at the cytosolic side of the membrane. This peculiar topology
allows selective removing of fusion or fission components exposed by the UPS, providing fine tuning
of this high-level regulatory processes. In mammalian cells, Fis1 accumulates in the mitochondrial
outer membrane during the fission process, whereas MFN1 and MFN2 are ubiquitinated and degraded
by the proteasome [34]. In this respect, we observed an increase in Fis1, ubiquitinated MFN2 and
of the E3 ubiquitin ligase Parkin in CTNS−/− ciPTEC, indicating the tendency to mitochondrial
fragmentation. The effect of MEA on the reduction of ubiquitilated MFN2 could be ascribed to
the modulation of USP30, a mitochondrion-localized deubiquitilase, which counteracts Parkin by
deubiquitilating OMM proteins and regulate mitophagy [35]. These findings are consistent with data
showing that an increase of parkin expression results in mitochondrial fragmentation [36] and is
associated with MFN2 ubiquitination [37]. In addition, the increase of FIS1, in cystinotic cell, might be
due to Sirt3 protein [38] that was found downregulated in the same cystinotic cell line [8]. OPA1, an
inner mitochondrial membrane GTPase protein, has gained attention because it regulates important
mitochondrial functions, including the balance between mitochondrial fusion and fission processes,
the stability of the mitochondrial respiratory chain complexes, the proapoptotic release of cytochrome
c molecules sequestered within the mitochondrial cristae and the maintenance of mitochondrial cristae
architecture [39]. The protein expression levels of OPA1 were not significantly changed in mutated
cells, compared to control ciPTEC cells (data not shown). However, the activity of OPA1 is also
controlled at the post-translational level by proteolytic and acetylation changes [31]. Various stress
conditions, including apoptotic stimulation, trigger the complete conversion of L-OPA1 into S-OPA1.
The pro-fusion activity of OPA1 depends on the balanced formation of L-OPA1 and S-OPA1 [40].
In this respect, we observed an alteration of OPA1 processing in CTNS−/− ciPTEC cells. In particular,
cystinotic cells were characterized by a significant increase of S-OPA1, associated with an increase in
the protease OMA1 activity, that was not prevented by MEA. In addition to its role as a fusion protein,
OPA1 controls the remodeling of mitochondrial cristae. Specifically, OPA1 forms oligomers in the
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inner mitochondrial membrane that keep the cristae junctions tight. During apoptosis, oligomers are
destabilized causing the opening of cristae and release of cytochrome c out of the mitochondria. OPA1
oligomers were decreased in cystinotic cells. MEA did not rescue this phenotype. This defect correlates
with increased cristae junction width that we observed in our TEM ultrastructural analyses.
In summary, our study shows deregulation of several proteins involved in mitochondrial dynamics
in CTNS−/− cells. We observed mitochondrial fragmentation in cystinotic cells associated with altered
proteolytic processing of OPA1, increased Fis1 and parkin protein levels. The deregulation of parkin
could result in increase of ubiquitination of MFN2. The cristae number was decreased while the
cristae lumen was increased in cystinotic cells, which parallels the previously reported bioenergetic
defects in these cells. The cristae junction width was increased in CTNS−/− cells, which is most likely
secondary to low OPA1 oligomerization levels. MEA treatment restored mitochondrial size, cristae
number, and lumen, but had no effect on cristae junction width, making tubular cells more susceptible
to apoptotic stimuli. In this contest, we highlight several cellular mediators of mitochondrial dynamics
that could be useful to develop new therapeutic interventions [41].
4. Materials and Methods
4.1. Cell Culture
Conditionally immortalized proximal tubular epithelial cells (ciPTEC), from healthy donor and
cystinotic patients were obtained from Radboud University Medical Center, Nijmegen, The Netherlands
and cultured as described in [42]. Cells were grown in a humidified atmosphere with 5% CO2 at 37 ◦C.
Where indicated, the cells were treated with 100 μM MEA or water (vehicle) for 24 h.
4.2. SDS-PAGE and Western Blotting
Monolayer cell cultures were harvested with 0.05% trypsin, 0.02% EDTA. After trypsinization,
cells were centrifuged at 500× g and resuspended in RIPA buffer (150 mM NaCl, 5 mM EDTA, 50 mM
Tris/HCl, 0.1% SDS, 1% Triton X-100, pH 7.4), in the presence of a protease inhibitor (0.25 mM PMSF).
Cell lysate proteins were subjected to SDS-polyacrylamide gel electrophoresis (PAGE), transferred
to a nitrocellulose membrane and immunoblotted with antibodies against OPA1 (Thermo scientific,
Waltham, MA, USA; Pierce Antibodies); Fis1, Mfn2 (Merck Millipore, Burlington, MA, USA); parkin,
USP30 (Santa Cruz Biotechnology, Dallas, TX, USA); OMA1 (Abcam, Cambridge, UK); Drp1, Mff (Cell
Signaling, Danvers, MA, USA) and actin (Merck, Kenilworth, NJ, USA). After being washed in TTBS,
the membranes were incubated for 1 h with anti-mouse or anti-rabbit IgG peroxidase-conjugate
antibody. Immunodetection was performed with the enhanced chemiluminescence (ECL) (Thermo
scientific, Waltham, MA, USA). VersaDoc imaging system (BioRad, Milan, Italy) was used for
densitometric analysis.
4.3. Analysis of OPA1 Oligomers
To investigate on OPA1 oligomerization, cell fresh pellets were treated with the cross-linker
bismaleimidohexane (BMH) 1 mM or with vehicle (DMSO) for 30 min at 37 ◦C. After incubation,
the samples were centrifuged, resuspended in SDS lysis buffer and then subjected to SDS-PAGE and
western blotting analysis with the antibody against OPA1.
4.4. Electron Microscopy
For routine EM the cells were grown in 12 well plates as a monolayer. At the end of the experiment
the cells were fixed with 1% Glutaraldehyde prepared in 0.2 M Hepes buffer. Then the cells were scraped,
pelleted, post-fixed in OsO4 and uranyl acetate and embedded in Epon as described previously [43].
From each sample, thin 60 nm sections were cut using Leica EM UC7 (Leica Microsystems, Vienna,
Austria). EM images were acquired from thin sections using a FEI Tecnai-12 electron microscope
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(FEI, Eindhoven, Netherlands) equipped with a VELETTA CCD digital camera (Soft Imaging Systems
GmbH, Munster, Germany).
Author Contributions: F.B. and D.D.R. conceptualization; A.S., E.D.L., E.V.P., A.F., R.R., and S.R. investigation;
F.B. and D.D.R. writing—original draft preparation; F.B., D.D.R., A.S., R.P., and F.E. writing—review and editing;
F.B. and D.D.R. funding acquisition. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by Cystinosis Research Foundation, grant number CRFF-2017-001 and by
Ricerca Corrente of the Italian Ministry of Health.
Acknowledgments: We thank Paolo Lattanzio for technical assistance and Manuela Colucci for statistical
analysis contribution.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
cAMP 3′,5′-cyclic adenosine monophosphate
Fis1 Mitochondrial fission 1 protein
IMM Inner Mitochondrial Membrane
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Abstract: This retrospective analysis investigated plasma oxalate (POx) as a potential predictor of
end-stage kidney disease (ESKD) among primary hyperoxaluria (PH) patients. PH patients with type
1, 2, and 3, age 2 or older, were identified in the Rare Kidney Stone Consortium (RKSC) PH Registry.
Since POx increased with falling estimated glomerular filtration rate (eGFR), patients were stratified
by chronic kidney disease (CKD) subgroups (stages 1, 2, 3a, and 3b). POx values were categorized
into quartiles for analysis. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for risk of
ESKD were estimated using the Cox proportional hazards model with a time-dependent covariate.
There were 118 patients in the CKD1 group (nine ESKD events during follow-up), 135 in the CKD
2 (29 events), 72 in CKD3a (34 events), and 45 patients in CKD 3b (31 events). During follow-up,
POx Q4 was a significant predictor of ESKD compared to Q1 across CKD2 (HR 14.2, 95% CI 1.8–115),
3a (HR 13.7, 95% CI 3.0–62), and 3b stages (HR 5.2, 95% CI 1.1–25), p < 0.05 for all. Within each POx
quartile, the ESKD rate was higher in Q4 compared to Q1–Q3. In conclusion, among patients with
PH, higher POx concentration was a risk factor for ESKD, particularly in advanced CKD stages.
Keywords: plasma oxalate; primary hyperoxaluria; estimated glomerular filtration rate; chronic
kidney disease; Urine Oxalate; end-stage renal disease
1. Introduction
Primary hyperoxaluria (PH) is a rare inherited autosomal recessive genetic disease caused
by defects in genes that encode proteins important for glyoxylate metabolism [1]. Currently,
three distinct forms are known—PH1 results from mutations in the enzyme alanine-glyoxylate
aminotransferase (AGT) which is encoded the AGXT gene, PH2 is caused by a deficiency of the
glyoxylate reductase/hydroxypyruvate reductase (GRHPR) enzyme encoded by GRHPR, and PH3
occurs when the mitochondrial enzyme, 4-hydroxy-2-oxoglutarate aldolase (HOGA) is deficient due to
mutations in the HOGA1 gene. Based upon current numbers in the Rare Kidney Stone Consortium
(RKSC) PH registry, approximately 70% of diagnosed patients are PH1, 10% are PH2, 10% PH3,
and 10% do not have an identified genetic cause [2].
The metabolic consequence of each of these enzyme deficiencies is a marked increase in hepatic
oxalate production. Since oxalate cannot be metabolized by humans, the excess released into the plasma
must be excreted by the kidneys, with less than 10% eliminated through the gastronintestinal tract.
Calcium oxalate stones and nephrocalcinosis can result from high urinary oxalate (UOx) excretion;
the latter can be associated with interstitial inflammation and fibrosis and may contribute to progressive
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chronic kidney disease (CKD) and end-stage kidney disease (ESKD) [3]. Once patients approach
ESKD, excess oxalate can no longer be eliminated by the kidneys, and it accumulates in the body,
potentially leading to systemic oxalosis. Among PH patients, there is wide variability in clinical course,
with some progressing to ESKD in early childhood, while other PH patients retain kidney function
into their fifth or sixth decade. Prediction of long-term outcomes using biomarkers is an important tool
for clinical management, particularly now that novel treatment strategies with the potential to reduce
hepatic oxalate production in PH are ready for clinical trials [4]. Patients with PH typically excrete
>0.7 mmol/1.73 m2/day [5], and we previously reported that higher UOx predicts future ESKD risk
within the PH patient group [2]. We also recently reported that plasma oxalate (POx) concentration
correlates with UOx excretion [6].
Since 24 h urine collections can be difficult to obtain, especially on a repeated basis or in younger
children, a blood biomarker that predicts UOx and other clinical features of PH could be clinically
valuable. Furthermore, in patients with advanced CKD, UOx may no longer reflect systemic oxalate
burden; in such cases, POx may represent a more accurate biomarker [7]. Therefore, we examined data
in the RKSC PH registry in order to determine whether POx represents a viable biomarker that predicts
the future loss of kidney function among patients with confirmed PH and at varying CKD stages.
2. Results
2.1. Baseline Characteristics
There were 227 patients who met the criteria for this study (Figure 1). During follow-up,
ESKD developed in nine of the 118 patients (7.6%) in the CKD 1 group, 29 of 135 (21.5%) of the CKD
2 patients, 34 of 72 (47.2%) in the CKD3a, and 31 of 45 (68.8%) in the CKD 3b. There was one death
in the CKD 1 group, nine deaths each in the CKD 2 and 3a groups, and 10 deaths in the CKD 3b
group. The proportion of patients with PH1 increased by CKD stage (Table 1), representing 56.8%
with CKD1, 73.3% with CKD2, 86.1% with CKD3a, and 84.4% with CKD3b. Due to the analysis plan,
the median age at PH diagnosis also differed according to which patients experienced each CKD stage,
from 5.4 years (CKD1) to 16.0 years (CKD3b). Median follow-up time was 5.3, 8.8, 6.6, and 1.8 years
for CKD stages 1–3b, respectively.
Figure 1. Flowchart of inclusion criteria for analysis cohort. From a total of 545 PH1 patients in the
Registry, 227 were eligible for this analysis.
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Table 1. Clinical characteristics of patients with primary hyperoxaluria who did not have ESKD at or
before diagnosis.
CKD Stage
Stage 1 (≥90) Stage 2 (60–89) Stage 3a (45–59) Stage 3b (30–44)
Characteristics n = 118 n = 135 n = 72 n = 45
Type of PH, % (n)
PH1 67 (56.8%) 99 (73.3%) 62 (86.1%) 38 (84.4%)
PH2 23 (19.5%) 16 (11.9%) 6 (8.3%) 5 (11.1%)
PH3 28 (23.7%) 20 (14.8%) 4 (5.6%) 2 (4.4%)
Sex, % (n)
Male 68 (57.6%) 76 (56.3%) 39 (54.2%) 23 (51.1%)
Female 50 (42.4%) 59 (43.7%) 33 (45.8%) 22 (48.9%)
Age at diagnosis, y 5.4 (2.7, 11.1) 7.9 (4.0, 23.9) 10.7 (4.6, 26.4) 16.0 (7.0, 41.7)
Follow-up time, y 5.3 (2.9, 10.0) 8.8 (3.1, 15.2) 6.6 (3.4, 12.8) 1.8 (1.0, 3.8)
Patients with follow-up Pox labs n = 50 n = 69 n = 37 n = 17
No. follow-up labs 2.5 (1,5) 3 (1,6) 3 (1,5) 1 (1,3)
Continuous variables are expressed as median with 25th, 75th percentiles. n, number; PH, primary hyperoxaluria;
PH1, primary hyperoxaluria type 1; PH2, primary hyperoxaluria type 2; PH3, primary hyperoxaluria type 3; y, years.
Baseline POx increased by CKD stage from (3.1 (2.1, 5.7) μmol/L in CKD1 (n = 38) to 14.4 (10.5, 20.0)
μmol/L in CKD3b (n = 17) (Table 2). The results were similar within the PH1 subset, increasing from
3.9 [2.4, 6.8] μmol/L in CKD1 (n = 24) to 14.9 (11.6, 21.5) μmol/L in CKD3b (n = 16). The numbers were
not sufficient for a similar sub-analysis in PH2 and PH3. The risk of incident ESKD was higher in
patients with PH1 compared to PH2 and PH3 in CKD2 and CKD3b; the results were similar albeit
non-significant in CKD1 (HR 7.45; 95% CI 0.92–60.2; p = 0.06) and CKD3a (HR 5.74; 95% CI 0.78–42.1;
p = 0.085) (Table 3).
Table 2. Baseline and follow-up POx quartiles, by CKD stage.
Oxalate Measure n Q1 Median Q3
Baseline
POx, umol/L
CKD stage 1 38 2.1 3.1 5.7
CKD stage 2 44 1.9 4.1 7.2
CKD stage 3a 25 2.9 4.8 8.2
CKD stage 3b 17 10.5 14.4 20.0
Follow-up
POx, umol/L
CKD stage 1 171 1.9 3.0 4.8
CKD stage 2 288 2.1 4.1 7.1
CKD stage 3a 165 4.2 7.0 12.9
CKD stage 3b 38 9.9 15.2 18.0
2.2. POx and ESKD
When treated as a continuous predictor, higher baseline POx values were significantly associated
with a higher risk of ESKD in CKD2 (HR 1.17; 95% CI 1.01–1.35; p = 0.033), CKD3a (HR 1.29; 95% CI
1.09–1.53; p = 0.004) and CKD3b (HR 1.24; 95% CI 1.08–1.42; p = 0.003) (Table 3). Baseline POx values
in Q4 compared to POx in Q1 were also associated with a higher risk of ESKD in CKD3a (HR 13.88;
95% CI 1.41–137; p = 0.024) and CKD3b (HR 42.1; 95% CI 3.29–539; p = 0.004) (Table 3).
During follow-up (Table 4), POx was significantly associated with ESKD risk across all CKD
stages: CKD1 (HR 1.12; 95% CI 1.02–1.24, p = 0.018), CKD2 (HR 1.17; 95% CI 1.08–1.25; p < 0.001),
CKD3a (HR 1.19; 95% CI 1.11–1.27; p < 0.001), and CKD3b (HR 1.12; 95% CI 1.04–1.21; p = 0.003).
When POx was considered by quartile, Q4 was a significant predictor of ESKD compared to Q1 across
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the CKD stages as well: CKD 2 (HR 14.2; 95% CI 1.76–115; p = 0.013), CKD3a (HR 13.7; 95% CI 3.02–62;
p < 0.001), and CKD3b (HR 5.19; 95% CI 1.10–24.5; p = 0.038). Within each POx quartile, the ESKD
rate was higher for the later CKD stages. Within each CKD stage, the ESKD rate was also higher in the
fourth POx quartile compared to the first three (Table S1 and Figure 2). Thus, the greatest ESKD rate
was for the CKD 3b subjects in the highest POx quartile (Figure 2).
Figure 2. ESKD rate by POx quartile during follow-up by CKD stage. ESKD rates were estimated for
each CKD stage group by dividing individual patient follow-up times into intervals based on the time
between the POx measures or last follow-up. Person-time and ESKD events were summed within
POx quartiles with the rate = [100 × (events/person-time)]; error bars represent 95% CI of the ESKD
rate (see Supplemental Table S1 for numerical values). ESKD rates were similar for the lower three
quartiles (Q) but increased for the highest POx quartile across CKD stages 2–3b (Q4 vs. Q1 HR 14.21;
95% CI 1.76–114.7; * p < 0.05 for CKD stage 2, HR 13.66; 95% CI 3.02–61.91; ** p < 0.001 for CKD stage
3a, and HR 5.19; 95% CI 1.10–24.5; * p < 0.05 for CKD stage 3b).
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2.3. UOX and ESKD
Risk of ESKD increased at higher UOx levels when follow-up UOx was employed as a continuous
time-dependent covariate, yielding an HR of 1.8 (95% CI 1.35–2.5) per each UOx increased of
1 mmol/1.73 m2/24 h (p < 0.001). When examined by follow-up UOx quartile (cut-off points of 0.77,
1.21, and 1.84 mmol/1.73 m2/24 h), UOx Q4 had a higher ESKD risk than Q1 (HR, 3.7; 95% CI 1.5–9.55)
(p < 0.01).
2.4. ESKD or 40% Sustained Reduction in eGFR
Results were similar when the combined endpoint of ESKD and a 40% sustained eGFR reduction
in eGFR were used for CKD progression. A higher baseline POx remained a significant predictor
of incident CKD progression at CKD3b (HR 1.27; 95% CI 1.09–1.48; p = 0.002). Higher POx values
during follow-up also remained a significant predictor of CKD progression in CKD2 (HR 1.15, 95% CI
1.07–1.23; p< 0.001) and CKD3a (HR 1.17, 95% CI 1.08–1.27; p< 0.001) when treated both as a continuous
predictor and when comparing POx Q4 to POx Q1 (HR 10.71; 95% CI 1.34–85.4; p = 0.025 and HR 8.15;
95% CI 1.74–38.2; p = 0.008; respectively). Follow-up time was shorter, and there were fewer laboratory
parameters available when considering this composite endpoint.
2.5. eGFR Slope
There were 59 patients with a total of 369 POx and eGFR laboratory measures obtained within
three months of each other throughout follow-up. The number of lab values per patient ranged from 1
to 20. After adjusting for follow-up time, eGFR was significantly lower among those with higher POx
(eGFR reduced by 1.27 mL/min/1.73 m2 per 1 μmol/L increase in POx; (p < 0.001).
3. Discussion
In the current study, we analyzed the predictive value of POx for the subsequent decline in eGFR
in PH patients, stratified by CKD stage. These data suggest that POx is a useful predictor of ESKD risk
across CKD stages 2–3b (Figure 2), with the effect most pronounced in CKD3b. These data and our
previous study [2] suggest that the use of POx and UOx could be complimentary, with UOx being
particularly informative across CKD stages 1–3b, and POx particularly informative in CKD stages 3a
and 3b.
The clinical management of PH is challenging due to the lifelong nature of the disease and the risk
for ESKD observed in a vast majority of PH1 patients, although this can occur at markedly variable
ages. The ability to predict long term outcomes using biomarkers facilitates the most effective use of
current treatments and also has the potential to provide an important outcome measure for clinical
trials of novel therapeutics. Newer treatment options, including the potential use of small inhibitory
RNA (siRNA) therapeutics to impact oxalate generating pathways in the liver are under current
development [8]. These newer approaches make it important to better understand the prognostic
features of PH, which could both identify patients who could be eligible candidates for clinical trials
and also potentially be used as surrogate endpoints in future studies.
In the current study, we examined whether POx is a useful prognostic marker for the future of
loss of kidney function. The data demonstrate that higher POx levels both at baseline and during
follow-up were significantly associated with loss of kidney function over time. When stratified by
quartile, those in POx Q4 were at increased risk of ESKD compared to POx Q1 across CKD stages 2–3b.
As expected, based upon previous prevalence data, patients that progressed to later CKD stages tended
to be older and more likely to have PH1. The current study also confirms our previous observation
that baseline UOx and UOx over follow-up predict ESKD, with those in the highest quartile at the
greatest additional risk [2]. Furthermore, the HRs for the subsequent ESKD of the highest UOx quartile
at baseline (2.5) and during follow-up (3.7) were similar to our previous work [2].
74
Int. J. Mol. Sci. 2020, 21, 3608
Much as the serum creatinine concentration is a net result of creatinine generation from muscle
and elimination by the kidneys, POx is the net result of oxalate generated in the liver and absorbed
from the GI tract and its elimination by the kidneys. Thus, higher POx can reflect higher hepatic oxalate
generation, greater gastrointestinal absorption, lower GFR, or some combination of these. Indeed, our
previous publications demonstrated that UOx excretion could be used to predict POx and eGFR [6].
Recent studies also suggest that higher UOx excretion predicts a higher renal tubular fluid oxalate
concentration at the S3 segment of the proximal tubule, the anatomic site of nephrocalcinosis in PH [9].
Thus, the results from our current study demonstrating the predictive value of POx across the CKD
stage 2–3b spectrum may reflect the fact that POx provides integration of oxalate generation and
elimination, and thus becomes a sensitive marker of oxalate burden at the level of the proximal tubule.
One issue with the widespread use of POx is the challenging nature of the available laboratory
assays [10]. Under normal circumstances, POx is present in micro-molar concentrations in blood.
Thus, sample handling, including prevention of ascorbate conversion to oxalate, is quite important.
In addition, methods for measuring oxalate, including sample type, preparation, and analysis, are not
interchangeable [10–12]. Our study benefitted from use of a single clinical laboratory over many
decades with data to support that POx results could be compared over that time period. However,
because of the barriers for analysis in routine laboratories, the POx measurement is not widely available.
Additionally, when GFR is normal or near-normal, POx concentrations typically are near or below
the limit of quantification in the general population [10]. However, due to a markedly increased
oxalate generation, POx is typically above the limit of quantification in most PH patients, even with
preserved eGFR [6], suggesting that with a consistent and sensitive assay, POx could be a useful
biomarker. Moreover, as GFR declines, POx values rise well within the quantification range with good
reproducibility in all PH patients.
The current study has several limitations. Due to the retrospective nature of this analysis based
on registry data, laboratory measures and follow-up were limited by availability, and variability in the
diagnosis and ability to recruit patients with this rare disease may have introduced bias. There was also
no controlled intervention to change POx values. Nevertheless, we were able to analyze a relatively
large cohort of over 200 PH patients with available POx values. Furthermore, comorbidities such as
obesity, dyslipidemia, hypertension, and albuminuria, which are important CKD risk factors, were not
available for multivariate analysis. However, many PH patients progress to ESKD at a very young age,
and thus these comorbidities likely play a relatively minimal role in CKD progression, in comparison
to common causes of CKD such as diabetic nephropathy in which vascular/microvascular injury and
dysfunction play a major role.
In conclusion, there is a need for improved knowledge regarding the utility of biomarkers to
predict ESKD risk in PH patients at various stages of CKD. The current study suggests that POx,
perhaps in combination with other risk factors, is a useful marker for this purpose.
4. Materials and Methods
Natural history and laboratory data from PH patients enrolled in the RKSC PH Registry were
used for analysis [13]. PH1, PH2, and PH3 patients were confirmed by mutations in the AGXT, GRHPR,
or HOGA1 genes, respectively. POx was measured in the Mayo Clinic Renal Testing Laboratory
(Rochester, MN, USA) by an oxalate oxidase (1991–6/2016) or ion chromatography (6/2016–2019)
based-assay per the standard Mayo Renal Testing Laboratory Protocol [10]. Detailed validation data
was available to determine that assay results could be compared over the course of this time period.
UOx was measured by oxalate oxidase also in the Mayo Renal Testing Laboratory or another accredited
clinical laboratory [10,14]. Data for subjects <2 years old were excluded from this analysis due to
potential confounding effects of renal maturation in very young children on GFR (and thus POx).
This project was approved by the Mayo Clinic Institutional Review Board (IRB 11-001702;
initial approval 16 August 2011). A total of 545 PH patients were identified in the Registry as of
March 31, 2019 (Figure 1). After excluding patients who met clinical criteria but had no detectable
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mutations of AGXT, GRHPR, or HOGA1, (n = 46), those with ESKD at diagnosis (n = 144), patients less
than two years old at ESKD or last follow-up (n = 22), and those patients without eGFR data after
diagnosis and older than two years before ESKD or death (n = 106), a total of 227 patients remained
in the final cohort for analysis. Since our previous study suggested an association between POx and
CKD stage [6], patients were then divided into four groups based on CKD stage (1, 2, 3a, 3b) in a
landmark-style analysis, such that a patient started in a given CKD stage subgroup on their first eGFR
observed in that range, while also remaining in any prior groups through all available follow-ups.
For instance, a patient whose eGFR measurements were 64, 72, 43, 47, 38, 29, and 21 mL/min/1.73 m2
would never be included in the CKD stage 1 group, would enter the eGFR 60–89 group with the date of
the eGFR = 64 mL/min/1.73 m2 measurement and be followed until kidney progression or censoring,
would enter the eGFR 30–44 group with the date of the eGFR = 43 mL/min/1.73 m2 measurement
and be followed until kidney progression or censoring, and would enter the eGFR 45–59 group with
the date of the eGFR = 47 mL/min/1.73 m2 measurement and be followed until kidney progression
or censoring.
Laboratory results were extracted from the registry data, and were from baseline (defined as
within one year prior to or within six months of entry into the CKD stage group and prior to kidney
progression) or follow-up (defined from six months after the entry into the CKD stage group and prior
to kidney progression). None of this patient cohort experienced acute kidney injury events during
follow-up. GFR was estimated via the CKD-EPI creatinine equation for adults greater than 18 years
old [15] and the Schwartz equation for those less than 18 years old [16]. POx values were manually
examined, and outlying transient results not fitting the clinical picture were removed from the analysis.
4.1. Statistical Methods
Plasma Oxalate
Progression to ESKD (eGFR < 15 mL/min/1.73 m2 or the start of dialysis or renal transplantation)
was selected as the primary endpoint. Sensitivity analyses were also performed using a combined
endpoint of ESKD or sustained 40% reduction in eGFR from baseline. The results were expressed in
terms of the median (25th, 75th percentiles) for continuous variables and as percentages for categorical
variables. To maximize available data, the diagnosis/baseline labs were defined as the closest reading
between one year before entry and up to six months after entry into a CKD stage group.
The percentage of patients who were free of renal progression (ESKD and > 40% decline in eGFR)
after entry into each CKD stage was estimated using the Kaplan–Meier method. The effects of baseline
clinical characteristics, as well as Pox on renal progression, were estimated by univariate analyses
using the Cox proportional hazard model with log-rank tests. The primary outcome of interest was
time to ESKD and was censored on death or loss to follow-up. Hazard ratios (HRs) and 95% confidence
intervals (95% CIs) are presented. A time-dependent Cox model was used to explore the effect of POx
concentration on renal outcome during follow-up. Times to ESKD by POx quartile during follow-up
were estimated for each CKD stage group by dividing individual-patient follow-up time into intervals
based on the time between POx measures or last follow-up. Person-time and ESKD events were
summed within the POx quartile with the rate = 100 × (Events/Person-time). The proportional hazards
assumption was checked for all models using martingale residuals. Generalized estimating equations
(GEE) adjusting for time were used to evaluate the association between POx and eGFR throughout
follow-up. The effect of follow-up UOx concentration on the risk of renal outcomes were also assessed
using a time-dependent Cox model.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/10/
3608/s1.
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Abstract: The complement cascade is part of the innate immune system whose actions protect hosts
from pathogens. Recent research shows complement involvement in a wide spectrum of renal disease
pathogenesis including antibody-related glomerulopathies and non-antibody-mediated kidney
diseases, such as C3 glomerular disease, atypical hemolytic uremic syndrome, and focal segmental
glomerulosclerosis. A pivotal role in renal pathogenesis makes targeting complement activation an
attractive therapeutic strategy. Over the last decade, a growing number of anti-complement agents
have been developed; some are approved for clinical use and many others are in the pipeline. Herein,
we review the pathways of complement activation and regulation, illustrate its role instigating or
amplifying glomerular injury, and discuss the most promising novel complement-targeting therapies.
Keywords: complement; alternative complement pathway; complement-targeting therapies; C3
glomerulopathy; hemolytic uremic syndrome; focal segmental glomerulosclerosis
1. Complement Cascade
The complement system consists of soluble or membrane-bound molecules, mostly zymogens,
activated through a tightly regulated proteolytic cascade [1,2]. Current understanding of complement
immune mechanisms include (1) functioning as opsonins; (2) producing chemoattractants to recruit
immune cells thereby enhancing site specific angiogenesis, vasodilation and coagulation cascade
regulator; and (3) functioning as an enhancing bridge to adaptive T and B lymphocyte responses [3].
Current research suggests that abnormal complement activation plays a role in autoimmune
inflammatory diseases and particularly in those targeting the kidney.
2. Complement Cascade Activation and Regulation
Complement activation proceeds via three pathways: the classical, alternative,
and mannitol-binding lectin (MBL). The pathways have both unique and overlapping proteins,
activated by a proteolytic cascade, that respond to pathogenic insults [3,4] (Figure 1). The classical
and MBL pathways are initiated by antibodies and bacterial mannose motifs binding to C1q and
mannose-associated serine proteases (MASPs), respectively [5,6]. Conversely, spontaneous hydrolysis
of C3 on cell surfaces produces constitutive alternative pathway (AP) activation [7], and is tightly
controlled by a number of regulators [8]. Decay accelerating factor (DAF) and membrane cofactor
protein (MCP) (CD46, murine homolog Crry) are cell surface-expressed complement regulators
that accelerate the decay of surface-assembled C3 convertases, thereby limiting amplification of the
downstream cascade. DAF restrains convertase-mediated C3 cleavage; MCP and factor H (fH) also
have a cofactor activity: together with soluble factor I (fI), they irreversibly cleave C3b into iC3b,
thereby preventing reformation of the C3 convertase.
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Figure 1. Overview of the complement cascade and principal complement targeting molecules. Three
pathways can initiate complement cascade: (1) The classical, (2) the mannose-binding lectin (MBL),
and (3) the alternative pathway. They all converge on C3 convertases formation which continuously
cleave C3; after they are activated, the C3 convertase from alternative pathway dominates within an
amplification loop that sustains the production of C3b (circular arrow). The three C3 convertases
associate with an additional C3b to form the C5 convertases, which cleave C5 into C5a + C5b.
C5b fragments recruits C6, C7, C8, and multiple C9 molecules to generate the terminal membrane
attack complex (MAC); MAC inserts pores into cell membranes to induce cell lysis or activation.
Anaphilotoxins C3a and C5a through their G protein-coupled receptors C3aR and C5aR, respectively,
can promote signaling, inflammation, chemotaxis of leukocytes, vasodilation, cytokine and chemokine
release, and activation of adaptive immunity. Dotted black arrows: inhibitor function of a complement
effector on its target. Red arrows emerging from balloons: inhibitor function of anti complement drug
on its target (bold drugs’ names are the FDA approved ones). Full arrow: consequential interaction
between complement fractions leads to the subsequent cascade step. Full bold arrow: final convergence
of the three complement pathways on same final target. MBL: Mannose binding lectin; MASP:
Mannose-binding lectin-associated serine protease; C4BP: C4 binding protein; C1-INH: C1 inhibitor;
DAF: Decay accelerating factor; CR1: Surface complement receptor 1; MCP: Membrane cofactor protein;
CD59: Protectin; fD: Factor D; fB: Factor B; fI: Factor I; fH: Factor H. Red balloons highlights complement
target drugs’ points of action (see Table 1).
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The three activation pathways converge in C3 convertases that continuously cleave C3 into C3a
and C3b. C3a signals on cell surface G protein-coupled receptor (GPCR) C3aR, while C3b forms
additional alternative pathways C3 convertases (even if initiated via the other pathways), as well as C5
convertases. C5 convertases produce the split products C5a and C5b. While C5a functions similarly
to C3a (but signals via C5aR) C5b, in conjunction with C6–C9, forms the membrane attack complex
(MAC) leading to cell lysis/activation [9]. Countering distal complement MAC formation is CD59,
a circulating complement inhibitor.
3. Effector Functions
Complement proteins promote inflammation and immune cell activity in multiple ways. C3a and
C5a ligate their transmembrane-spanning receptors, C3aR and C5aR, on immune cells, leading to the
production of proinflammatory cytokines and chemokines and promoting vasodilation. They also
mediate neutrophil and macrophage chemoattraction, activate macrophages to promote intracellular
killing of engulfed organisms, and contribute to T-cell and antigen-presenting cell (APC) activation,
expansion, and survival [10–13]. The more distal complement proteins (C5b-9) form MAC complexes
on cell membranes, promoting lysis of non-nucleated cells, such as red blood cells, or pathogens
lacking cell surface complement inhibitors, such as bacteria. MAC insertion into nucleated eukaryotic
cells generally does not result in lysis, but rather induces immune activation [14] and/or promotes
tissue injury [15]. C3b and other bound cleavage products function as opsonins binding to specific
surface-expressed receptors (complement receptors CR1, CR2, CR3, and CR4).
4. Complement in Glomerular Diseases
4.1. Diseases with Antibody-Mediated Complement Activation
The majority of circulating, or fluid-phase, complement components are produced by the liver.
Liver produced complement components are involved in auto-antibody initiated glomerulonephritis
(GN) through the classical and/or MBL pathways. Inadequate regulation of alternative pathway activity,
due to inherited and/or acquired abnormalities of complement regulators, can result in glomerular
injury from persistent C3 convertase activity with consequent excessive MAC activity. Complement can
also be produced by parenchymal (e.g., tubular cells in the kidney [16] and resident/infiltrating immune
cells, (e.g., T cells and APCs) [17–19]. The relative contributions of systemic or locally produced
complement in GN pathogenesis remains unclear.
4.2. IgA Nephropathy
IgA nephropathy (IgAN) is the most common form of GN worldwide [20,21]; its clinical
presentation varies, but it often includes proteinuria and hematuria. The disease is associated
with aberrant O-glycosylation of mucosal IgA1 with galactose-deficient IgA1 (Gd-IgA1) which plays a
pivotal role in the progression of IgAN [22]. They deposit in glomeruli and, subsequently, development
of circulating/in situ immunoglobulins (IgA or IgG) targeting glycosylated IgA takes place [23,24].
Mesangial IgA and immune complexes deposits are often observed and initiate glomerular injury.
In vitro and in vivo studies showed that polymeric mucosal IgA activates the complement system
through the alternative or MBL pathway [25], and glomerular MBL correlates with greater disease
severity and a worse prognosis [26]. Although C3 levels in plasma are usually normal, glomerular C3
deposits can be detected in approximately 85% of biopsies, with C5b-9 also often present along with C3
during infections [27]. MAC generated from complement activation attack on mesangial cells inducing
them to proliferate and over-produce oxidants, proteases, cytokines, growth factors (e.g., transforming
growth factor β and platelet-derived growth factor) and extracellular matrix material that together
result in the typical focal proliferative GN with mesangial matrix expansion characteristic of IgA
nephropathy [28].
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A genomic wide association study (GWAS) of IgAN in a cohort of 3144 cases of Chinese and
European ancestry, linked allele deletion polymorphisms of complement factor H-related proteins
one and three (CFHR1 and CFHR3) with less severe IgA nephropathy [29,30]. Since CFHR proteins
interfere with factor H complement regulation (Figure 1) their deficiency might reduce complement
activation and lessen IgAN. CFHR1, CFHR3, and CFHR5 especially have been studied for their role
in IgAN [29,31]; another study of 1126 Chinese patients concluded that circulating CFHR5 levels are
an independent risk factor for the disease: levels were higher in IgAN subjects compared to heathy
controls, and correlated directly with worst Oxford MEST pathology score, a lower glomerular filtration
rate (GFR), and hypertension [32].
4.3. Membranous Nephropathy
Membranous nephropathy (MN) is the second most commonly diagnosed GN, and the most
common cause for nephrotic syndrome in adults (20–50%) [33]. Disease progression varies greatly with
~1/3 of patients undergoing spontaneous remission, ~1/3 developing progressive renal insufficiency,
and ~1/3 maintaining normal GFR despite persistent proteinuria. MN is characterized by presence
of anti-podocyte antibodies in the subepithelial space of glomerular capillary loops and granular
deposits of IgG4 and C3. M-type phospholipase A2 receptor (PLA2R) has been found as the main target
podocyte antigen for autoantibodies in 70–80% of patients with primary MN, while antibodies against
thrombospondin type 1 domain-containing 7A (THSD7A) are detected in a minority of patients [34].
Although antibodies from IgG4 subclass are poor classical complement pathway activators, deposition
of C3 and breakdown of C4b products are detectable in almost all patients with a primary form of
MN [27]. Mannose binding lectin and MBL-associated serine protease expression (MASP-1, MASP-2)
are detected in PLA2R positive patients’ glomeruli, suggesting that complement activation proceeds
through this pathway [35]. Hypogalactosylated IgG (including IgG4) binds MBL and activates the
complement providing a possible explanation to the IgG4 conundrum [36]. Animal studies also
indicate a role for MAC insertion into podocytes; blocking their formation prevents disease [37].
Sublytic activation alters podocyte cytoskeletal structure crucial for slit diaphragm integrity and
function, leading to proteinuria [38,39].
4.4. Post Infectious Glomerulonephritis
Post infectious GN is a common cause of nephritic syndrome that develops after self-limited
bacterial infections (most commonly from streptococcal or staphylococcal species). It occurs mainly in
childhood, but can also be seen in adults. It is characterized by hypercellularity within the capillary
loops (caused by neutrophils infiltration and endothelial proliferation) and strong C3 staining, usually
in addition to IgG. Post infectious GN occurs due to passive glomerular trapping of circulating
immune complexes composed of nephritogenic bacterial antigens and IgG, complement activation,
and attraction of neutrophils responsible for glomerular injury [28]. However, levels of C1q and C4
deposition are lacking or low in most of the cases [40,41], suggesting contributions from lectin and
alternative pathway. This is eventually triggered from specific pathogens’ components; for example,
streptococcal pyrogenic exotoxin B is a possible alternative pathway activation [42]. Autoantibodies
with C3 nephritic factor (C3nef), activity that binds to and stabilizes C3 convertases, has also been
reported in post-infectious GN and may be associated with an enhanced cleavage of C3 [28]. In some
patients underlying genetic defects in the regulation of the alternative pathway, including mutations in
complement regulators (fH or CFHR5) and presence of C3Nef, lead to persistent glomerular deposition
of complement factors within the glomeruli and inflammatory infiltrates that resemble features of
a persistent proliferative glomerulonephritis [43]. Interestingly, in few cases, post infectious GN
evolved into C3 glomerulopathy (C3G) [44]: recent reports document repeat biopsies demonstrating
transformation of post infectious GN to C3G, including identical appearing early lesions of C3G and
initiation of C3G by streptococcal infection. Sethi et al. [43] described that most of the cases with
biopsy-proven persistent post-infectious GN had underlying genetic mutations and/or auto-antibodies
83
Int. J. Mol. Sci. 2019, 20, 6336
affecting regulation of the alternative complement pathway. These findings indicate that glomerular
injuries initiated by infection may transfer to C3G by imbalanced alternative complement pathway
activation: C3G is initiated by heterogeneous insults, leading to a final common pathway of alternative
complement dysregulation.
4.5. Immune Complex-Mediated Membranoproliferative Glomerulonephritis (MPGN)
Membranoproliferative glomerulonephritis (MPGN) is a histopathological pattern of glomerular
injury characterized by mesangial hypercellularity, capillary wall changes (i.e., “tram-tracking”),
and endocapillary proliferation found in 7–10% of biopsy-diagnosed glomerulonephritis [45]. MPGN
classification was based on electron micrograph ultrastructural findings but advances in our
understanding of underlying pathomechanisms produced a rethinking of MPGN and a classification
schema based on immunofluorescence findings; MPGN is caused by immune complex deposition,
C3 dysregulation, or thrombotic microangiopathy (TMA) [45]. Immune complex-mediated MPGN is
caused by immune complex deposition in the subendothelial space activating complement classical
pathways and causing glomerular injury. When not linked to a systemic disease, it is termed
‘idiopathic’ but secondary forms more commonly occur in association with infections (e.g., hepatitis B,
C, or tuberculosis), autoimmune diseases (e.g., Sjogren’s Syndrome or systemic lupus erythematosus
SLE), or monoclonal gammopathy. Clinical evidence of classical complement activation in immune
complex-mediated MPGN includes preferential consumption of plasma C4 (although C3 is often low as
well) and detection of C1q and terminal C5b-9 complex in glomeruli. This phase is followed by an influx
of leukocytes, promoted by formation of the C3a and C5a anaphylatoxins, leading to capillary damage
and proteinuria [46]. Activation of classical pathway through immunoglobulins is the most prominent
pathogenic process, but heterozygous mutations in alternative pathway complement regulators and the
presence of circulating C3nef factor are also identified in some patients with immune complex-mediated
MPGN, suggesting additional contributions from the alternative pathway [47]. These findings raise the
possibility that in individuals with genetic or acquired complement alternative pathway dysregulation,
immune complex deposition initially triggers injury through the classical pathway but chronic kidney
injury is sustained through the enhanced alternative pathway [46]. The complement also features
prominently in the two other dominant etiologies of MPGN: C3 glomerulopathies and TMA from
atypical Hemolytic Uremic Syndrome (aHUS), and these are discussed in detail later in this paper.
4.6. Anti-GBM Glomerulonephritis
Anti-glomerular basement membrane (GBM) is a rare life-threatening autoimmune disease,
caused by IgG autoantibodies against alpha 3 NC1 domain of collagen IV of the GBM. Antibody
binding to the GBM leads to injury characterized by strong complement activation, leukocyte infiltration,
and proteinuria; leading to crescent formation, scarring, and, frequently, end-stage renal disease (ESRD).
Evidence of complement pathogenic role comes from detection of complement components MBL,
C1q, factor B (fB), properdin, C3d/C4d, and C5b-9 in GBM, and circulating MAC levels that correlate
with kidney injury severity [48]. Local complement activation produces C3a- and C5a-mediated
inflammation, as well as MAC-dependent sublytic activation of glomerular cells, which together
enhance inflammation and extracellular matrix formation [49]. Pathways of complement activation in
anti-GBM disease have been studied in murine models by injection of heterologous antibodies against
GBM, where C3 and C4 deficiency prevented full manifestation of renal disease [46,50,51]. This evidence
supports involvement of, at least, both classical and alternative pathways in anti-GBM disease.
4.7. ANCA Induced Renal Vasculitis
Antineutrophil cytoplasmic antibody (ANCA) associated vasculitides commonly target the kidney,
with abundant complement component deposition in vessels and glomeruli without immunoglobulin
(pauci-immune). Current research supports that vascular injury is due to cytokine-primed
neutrophils displaying surface ANCA-binding antigens (myeloperoxidase and proteinase-3) that
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undergo degranulation while simultaneously activating alternative complement pathways which
potentiates neutrophil recruitment via C5a [8]. C5a generation functions as an amplification
loop for ANCA-mediated neutrophil activation, eventually culminating in the severe necrotizing
inflammation of the vessel walls. Studies in animal models have also shown complement contributes
to pathogenesis, and agents blocking C5 cleavage/C5a signaling or C5 and fB deficiency themselves are
protective; conversely, preventing MAC formation is ineffective, supporting the importance of C5a in
ANCA-mediated pathogenesis [52,53]. A recent trial of patients with ANCA vasculitis compared the
use of rituximab/cyclophosphamide in addition to either placebo and high-dose steroids, avacopan
(C5aR antagonist) plus reduced dose steroids, or avacopan and no steroids. Regimens with low or
absent steroids were non-inferior to traditional regimens; this illustrates complement’s essential role in
ANCA vasculitis and suggests C5aR antagonism as a feasible alternative in patients where steroids are
contraindicated [54].
4.8. Lupus Nephritis
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by antibodies to
self-antigens (e.g., anti-nuclear) leading to the formation of immune complexes that deposit in target
organs. Lupus nephritis (LN) is one severe complication of SLE. Up to 50% of patients with SLE have
clinically evident kidney disease at presentation, and up to 75% develop it during the course of the
disease [55]. The hallmark of renal pathology is simultaneous glomerular deposition of IgG, IgM, IgA,
C4, and C3, referring to the poker hand ranking, the “full house pattern” [55]. Complement deposition
is not merely a biomarker of LN, as it mediates direct glomerular injury: Immune complex-mediated
classical pathway plays a key pathogenic role through both intra capillary generation of neutrophil
and macrophage chemotactic factors (class II–IV) and formation of MAC (class V) [56]. Circulating C3
and C4 levels are reduced in more than 90% of patients with diffuse proliferative LN and their decline
often reflects a worsening in disease activity [57]. Extensive data from animal models also indicate a
significant role for alternative pathway activation: Deletion of regulators (i.e., fH) or activators (i.e.,
fB and fD) worsen or ameliorate, respectively, experimental LN [58–60]. In humans, plasma Bb levels
(but not C3) are associated with LN outcome and strongly correlated with MAC levels. In addition,
Bb co-localized with MAC in the glomeruli with LN, overall supporting the concept that activation
of MAC in LN reflects alternative pathway activation [57]. Experimental LN can be prevented by
blockade of all complement pathways through the administration of CR2-Crry fusion protein [61].
Data also show that the disease severity can be ameliorated by C5aR blockade [62] or anti-C5 mAb [63],
which suggests the potential clinical relevance of complement pathway intervention. A phase 1 human
trial with eculizumab (anti-C5) suggested preliminary efficacy, but the treatment period was too short
to draw definitive conclusions [64]. The complement system seems to have a paradoxical role in
SLE: genetically determined complement deficiencies or development of anti-complement antibodies
involving components of the classical pathway (anti-C1q or C1-INH) [65], are strong risk factors.
Susceptibility is likely due to a defective clearance of nuclear antigens released by injured and apoptotic
cells since experimental studies have shown that such deficiencies lead to autoantibody production
and glomerular injury [66].
5. Disease with Complement Activation in the Absence of Detectable Serum Antibodies
5.1. Atypical Hemolytic Uremic Syndrome
Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia,
thrombocytopenia and acute kidney injury. Renal pathology shows typically diffuse fibrin thrombi,
endothelial swelling and capillary lumens narrowed/collapsed (acute features), or reduplication of
GMB, mesangiolysis, and vessels recanalization (chronic phase). Typical forms of HUS are related
to infection by Shiga toxin (Stx) producing Escherichia coli (STEC), while aHUS) is a condition due to
defects in alternative complement activation. It has been associated with a predisposing genotype,
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usually an inherited heterozygous mutation [67,68], rather than an acquired mutation or loss of
complement proteins (e.g., fI, fH, MCP).
The first identified mutant gene encodes for fH [28], the most important alternative pathway
regulator in plasma and on cell surfaces. Subsequently, over 100 mutations were identified and
most commonly lead to normal levels of a protein that is unable to bind and regulate complement
components on endothelial cells [69].
Most complement genes mutations associated with aHUS result in an altered cell surface
regulation: MCP mutation and fI mutation prevent effective degradation of C3 convertase. Although
rarer, factors C3/C3b or fB gain of function mutations have been described [28]. Formation of blocking
antibodies direct against fH is also another possible pathogenic mechanism [46,68]. 3–5% of patients
with aHUS also carry heterozygous mutation of thrombomodulin (THBD), a molecule that normally
enhances fI function [70]. As discussed below, complement targeting therapies have been extremely
effective in treating this condition.
5.2. C3 Nephropathy
C3 nephropathy (C3N) is a rare nephritic disease, with a poor long-term outcome.
The membranoproliferative pattern is the most common (not unique) histological presentation of C3
nephropathy and is further divided in the two entities of: Dense deposit disease (DDD), with typical
ultrastructural evidence of intramembranous highly electron-dense osmophilic deposits with or
without IgG and C3 on immunofluorescence, and C3 glomerulonephritis (C3GN) diagnosed with C3
positive on IF while all others immunoglobulins are negative [71,72]. Low serum C3 and glomerular
deposits of C3 are emblematic of alternative pathway dysregulation.
A major subset of C3 glomerulopathies arises from C3Nef autoantibodies (present in 40% of
C3GN and 80% of DDD) stabilizing C3 convertases against complement regulatory proteins (CRegs),
or from other antibodies (former anti-fB, anti-fH) targeting directly CRegs [47]. C3 glomerulopathy
can be due to genetic missense or non-sense mutations, affecting genes that encode for complement
components or regulators [46,73]. The most important seems to involve fH, fI, and CFHR proteins
with loss of function [74]; C3 mutation with gain of function and resistance to fH is uncommon [75]
and when C5 genes are affected a less severe form of GN occurs [76]. fH/fI deficiency/resistance play a
critical role in developing the disease because the GBM does not express CRegs and therefore relies on
circulating ones (i.e., fH/fI) to prevent excessive local fluid phase AP activation.
Several cases of familiar C3 glomerulopathy have also been described when mutation of CFHR
gene cluster occurs; recently an autosomal dominant inheritance among some Cypriote families has
been described. In this nephropathy, CFHR5 has reduced affinity for surface-bound complement [77],
the glomeruli present with C3GN features but C3 levels in the serum tend to be normal suggesting that
improper complement activation occurs in the glomerulus rather than plasma [46,78–81].
6. Other Glomerular Diseases
Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS), is one of the leading causes of nephrotic syndrome
in adults. Patients with non-nephrotic proteinuria have good prognosis and about 15% progress
to ESRD over the course of 10 years, whereas 50% of patients with nephrotic-range proteinuria
progress to ESRD over 5–10 years [82]. In patients with massive proteinuria (10–14 g/d), the course
is malignant, resulting in ESRD by 2–3 years on average [82]. It is characterized by focal and
segmental obliteration of glomerular capillary tufts, with an increase in matrix. The sources of
podocyte damage are varied and not altogether known, but include circulating factors, genetic
abnormalities, viral infection, and medications that produce common deleterious effects on podocytes.
C3 and IgM glomerular deposition is typical, suggesting complement activation contributes to FSGS
pathogenesis [83]. Sclerotic lesions are significantly higher in patients with C3 deposition combined
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with IgM; they have worse renal dysfunction and limited response to therapy [84]. Murine models of
FSGS clarified that glomerular IgM deposits activate complement, suggesting that glomerular injury
simultaneously increases classical pathway activation by natural IgM, which binds to injury associated
epitopes, while also decreasing glomerular alternative complement regulating abilities [85]. Consistent
with a pathogenic role for IgM, B cell absence in murine FSGS models prevents IgM deposition and
albuminuria [85]. In humans, mutations in fH and C3 have been described in literature cases of biopsy
documented FSGS [86] and FSGS patient urine and plasma are enriched with complement fragments
C3a, C3b, Ba, Bb, C4a, sC5b-9 compared to samples from patients with other renal diseases [87].
7. Complement Inhibitory Drugs in Kidney Diseases
Identification of complement component contributions to renal pathogenesis recently spurred
pharmaceutical industry efforts to therapeutically target complement
Many available agents target terminal complement molecules and more proximal roles, such as
opsonization, remains preserved. Even so, since these agents are immunosuppressants, they convey
increased infection risk. More importantly, relevant to kidney diseases, many upstream elements
(e.g., C3a, C5a, and C3b) contribute to pathogenesis and are not effectively targeted by available
compounds. Currently, Food and Drug Administration (FDA) approved complement inhibitors
include the monoclonal anti-C5 antibody Eculizumab, and Cynrize an inhibitor of fragment C1
(C1-INH) [88–90].
7.1. Eculizumab
Eculizumab is a humanized murine monoclonal antibody to complement C5 that acts on the
terminal complement cascade preventing the formation of C5a, C5b, and C5b-9. The drug use
has been approved by European Medicines Agency’s (EMA) and FDA for treatment of paroxysmal
nocturnal hemoglobinuria (PNH) and aHUS [91]. The major side effect is predisposition to infections,
especially from gram-negative bacteria; as such, all patients are advised to be immunized for
meningococcus before receiving eculizumab. Eculizumab approval for aHUS treatment was given
based on results from two prospective trials: one involving 17 aHUS patients with thrombocytopenia
and the other with 20 aHUS patients requiring persistent plasma exchange (PE) [92]. Whole patients
from these cohorts no longer required PE and 88% reached normal hematological values after median
of 63 weeks of Eculizumab treatment. This medication has dramatically improved renal morbidity,
with consistent decreases in ESRD risk, but its clinical use is still limited by uncertainty over patient
selection, timing, and duration of treatment. An ongoing multi center single-arm trial is now testing the
safety Eculizumab discontinuation in patients with aHUS (NCT02574403). Eculizumab has also been
successfully used to prevent or treat recurrence of aHUS after kidney transplant [93–95], but appears
ineffective in preventing delayed graft function (NCT01919346) [96] in sensitized kidney transplant
recipients (NCT00670774, NCT01095887, NCT01327573) [97,98].
Eculizumab has successfully treated patients with DDD and C3GN highlighting its potential
with these rare diseases. Treatment of six patients (three C3GN and three DDD) resulted in complete
to partial remission in four patients at one year of follow-up [99]. This positive effect was limited
to patients with crescentic rapidly progressive C3 glomerulopathy as opposed to a more insidious
C3GN suggesting that it is specific to disease pathogenesis. Moreover, advantages are not seen so far
in C3GN recurrence after kidney transplantation [100]. Eculizumab use in patients with glomerular
diseases other than aHUS or C3GN/DDD is limited to case reports and of uncertain efficacy. The price
of eculizumab is a factor that limits its use. Competitors have in clinical development both similar
agents targeting C5 (e.g., Ravulizumab), as well as agents that affect complement component C5a
(i.e., Avacoban).
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7.2. C1 Inhibitor
Despite the potential advantages of terminal complement inhibition, these approaches may not be
sufficient in conditions stemming from more proximal complement activation. Classical complement
pathway activation occurs when C1q binds the Fc portion of antigen bound immunoglobulin.
Preventing this process is C1-esterase inhibitor and its absence or mutated function produces the
condition hereditary angioedema. Cinryze, a human serum derived C1 inhibitor (C1-INH) is FDA
approved for treatment of hereditary angioedema. C1-INH does not have approved indications
for kidney disease, but a phase I/II study was conducted on highly sensitized renal transplant
recipients randomized to C1INH or placebo. Antibody mediated rejection was prevented in all 10
patients receiving C1INH group and 9/10 only receiving placebo. Efficacy and safety of C1INH for
treatment of acute antibody mediated rejection in kidney transplantation is being evaluated in a
randomized double-blind study of donor-sensitized kidney transplants recipients (NCT02052141,
NCT02547220) [101]. Results may broaden its use to patients with antibody mediated rejection.
8. Conclusions
The complement system is a complex network of proteins that augment immune system
function and, in many cases, contribute to kidney disease pathogenesis. Increasing research
suggests that selective interventions to stop cascade activation can halt or even reverse renal disease.
Ongoing research, both translational and in animal models, will help delineate which pathway(s),
and at what level, intervention could be effective. Although infrequently a primary insult, common
mutations affecting complement regulation synergize with other pathological features perpetuating
inflammation and, ultimately, nephron loss. The advent of selective complement-targeting therapeutics
offers the opportunity for new treatment strategies for renal disease, an area in desperate need of
new options.
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Abstract: In April 2012, a group of nephrologists organized a consensus conference in Cambridge
(UK) on type II membranoproliferative glomerulonephritis and decided to use a new terminology,
“C3 glomerulopathy” (C3 GP). Further knowledge on the complement system and on kidney
biopsy contributed toward distinguishing this disease into three subgroups: dense deposit disease
(DDD), C3 glomerulonephritis (C3 GN), and the CFHR5 nephropathy. The persistent presence
of microhematuria with or without light or heavy proteinuria after an infection episode suggests
the potential onset of C3 GP. These nephritides are characterized by abnormal activation of the
complement alternative pathway, abnormal deposition of C3 in the glomeruli, and progression of
renal damage to end-stage kidney disease. The diagnosis is based on studying the complement
system, relative genetics, and kidney biopsies. The treatment gap derives from the absence of a robust
understanding of their natural outcome. Therefore, a specific treatment for the different types of C3 GP
has not been established. Recommendations have been obtained from case series and observational
studies because no randomized clinical trials have been conducted. Current treatment is based on
corticosteroids and antiproliferative drugs (cyclophosphamide, mycophenolate mofetil), monoclonal
antibodies (rituximab) or complement inhibitors (eculizumab). In some cases, it is suggested to
include sessions of plasma exchange.
Keywords: C3 glomerulopathy; Dense deposits disease; C3 glomerulonephritis; CFHR5 nephropathy
1. Introduction
Membranoproliferative or mesangiocapillary glomerulonephritis (MPGN) has been traditionally
classified based on the light and electron microscopy (EM) findings; here, there are three categories:
type I, characterized by the presence of immune deposits in the subendothelial space and mesangium of
glomeruli; type II, characterized by C3 deposits within the mesangium and in the basement membranes
highly osmiophilic on electron microscopy (dense deposits disease; DDD); and type III, which is
a variant of type I [1].
In August 2012, a group of experts in renal pathology, nephrology, complementology,
and complement therapeutics organized a consensus conference on the C3 glomerulopathy (C3
GP), meeting in Cambridge, UK [2]. Subsequently, new information on the complement system has
increased our understanding of the MPGN, which has been divided into two groups: (i) MPGN
caused by immune complexes (IC-MPGN) that can be caused by polyclonal or monoclonal IgG and (ii)
complement-mediated glomerulonephritis (Figure 1).
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Figure 1. Classification of the membranoproliferative glomerulonephritis (MPGN). Abbreviations:
IC-MPGN (immune complex MPGN); Ig (immunoglobulin); C3 GP (C3 glomerulopathy); DDD (dense
deposits disease); C3 GN (C3 glomerulonephrits); CFHR5 GP (complement factor H-related protein 5
glomerulopathy).
The term C3 GP includes a group of nephritides based on the abnormal control of the alternative
pathway of the complement system that causes a dominant accumulation of C3 fragments in glomeruli,
as evidenced by an intense staining of C3 with absence or low presence of immunoglobulins and
components of the classical complement pathway in the immunofluorescence pattern of a kidney
biopsy [3]. This form of nephritis can be detected in individuals with defects in the complement
activation that is induced by circulating factors or the presence of rare gene variants in complement
components of the alternative pathway.
In a recent classification proposed by Cook and Pickering [4], C3 GP was shown to be principally
composed of three major subgroups (Figure 1): (i) DDD is characterized by intramembranous
glomerular deposits of dense osmophilic material; (ii) C3 glomerulonephritis (C3 GN) is based on the
presence of less dense deposits of C3 in the mesangial, subendothelial, and subepithelial areas of
glomeruli; it also appears with the presence of circulating auto-antibodies against C3bBb, factor B
(FB), and factor H (FH); (iii) complement factor H-related 5 glomerulopathy (CFHR5 GP) is caused by
genetic variants of CFHR5. Differences in these three nephritides are based on the interpretation of
data obtained by light microscopy, immunofluorescence/immunohistochemistry and EM, laboratory
complement findings, and clinical data. However, in some cases, there is an overlap of clinical data
and laboratory findings, suggesting the possibility of a disease continuum based on the dysregulation
of the complement alternative pathway; this would be caused by acquired factors (autoantibodies) or
genetic variants of some complement components of the alternative pathway.
2. Pathogenesis
The complement system is the first cornerstone of innate immunity, and in the presence of various
infections, it induces the lysis of agents through the generation of the membrane attack complex
(MAC) [5]. Moreover, the system modulates adaptive immunity.
The complement system can be activated through three different pathways, as illustrated in
Figure 2.
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Figure 2. Complement system pathways.
The classical pathway is activated by circulating immune complexes, whereas the lectin pathway
is activated by bacteria or their membrane fragments. Both pathways cleave C3 into C3a and C3b.
C3a is an anaphylatoxin with a proinflammatory effect, whereas C3b binds a fragment of factor B (Bb),
thus forming the C3 convertase (C3bBb). Additional production of C3b promotes the formation of
the complex C3bBbC3b (C5 convertase), which cleaves C5 into C5a and C5b and combines with C6,
C7, C8, and C9, thus forming the membrane attack complex (C5b-9) that induces the lysis of cellular
membranes and the glomerular basement membrane (GBM).
The alternative pathway is continuously activated by the C3 tick-over at a low rate with the constant
generation of C3b, which here is rapidly degraded. In this physiological process, C3 is hydrolyzed to
C3(H2O) and combines with fB the complex C3(H2O)B. Then, this complex cleaves C3, generating
C3b, which combines with Bb and forms the C3 convertase of the alternative pathway (C3bBb). In the
presence of further C3b, the formed C5 convertase (C3bBbC3b) activates C5 with the sequential
induction of the terminal complement pathway (C5b-9).
The three pathways of the complement system are modulated by proteins that regulate the
system in the blood (fluid phase) and on the surface of cells (surface phase). In the fluid phase,
the C1-inhibitor (C1-INH) downregulates the classical and lectin pathways; the C4 binding protein
(C4bp) downregulates the classical pathway; clusterin and vimentin regulate C5b-9. The regulators of
the complement in the surface phase system are the membrane cofactor protein (MCP, named CD46),
CD59 that is a regulator of MAC formation, the decay accelerating factor (DAF, named CD55), and the
complement receptor 1 (CR1).
The alternative pathway is regulated by properdin, FB, FI, FH, and FH-related proteins. Properdin
enhances the formation of C3 convertase and stabilizes it; thus, properdin prevents the action of FH.
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FH is the principal regulator of the alternative pathway both in the fluid phase and on the cellular
surface; it inhibits the binding of C3b with FB, enhances C3 convertase dissociation, and the activity of
FI, which cleaves C3b into inactivated C3b (iC3b). A dysregulated control of C3 convertase (C3bBb)
can be caused by the abnormal activity of FH, as illustrated in Figure 3. The regulatory activity of
this factor can be inhibited by the presence of genetic FH deficiency or autoantibodies against FH,
which have been found in patients with C3 GP [6–9].
Figure 3. Schematic dysregulation of the C3 activation in C3 GP.
The activity of FH is regulated by the group of CFHRs that activate the alternative pathway by
binding C3b and the activity of C3bBb convertase. CFHRs also compete with FH when attempting to
bind to C3b deposited on the cellular surfaces. Therefore, the competition between FH and CFHRs
influences the degree of C3b by inhibiting (predominant FH binding) or allowing (predominant FHR
binding) to this process. The CFHR system is composed of five proteins that are coded by genes
(CFHR1 to CFHR5) located near the CFH gene. CFHR genes may have rearrangements because the
deletion or duplication of the first two consensus repeats with the presence of altered activity of
CFHR proteins. Abnormal rearrangements include intragenic duplication in CFHR1 and CFHR5 and
the presence of hybrid CFHR2-CFHR5 and CFHR3-CFHR1 genes. A deletion of the CFHR1 gene is
associated with the abnormal activity of FH and reduced control of the activation of the alternative
complement pathway in the circulation system.
CFHR5 interacting with CFHR1 and CFHR2 may generate abnormal CFHR proteins that impact
the function of C3 and/or C5 convertases in the fluid phase or on the glomeruli, causing C3 GP. More
than 20 different mutations have been identified in the CFH-CFHR gene family of patients affected by
C3 GP, as reported by Xiao et al. [10] and Merinero et al. [11]. A recent review on the process of CFH
deregulation that is responsible for the C3 activation has been published by Barbour et al. [12].
An excessive activation of the alternative pathway may be caused by the presence of autoantibodies
against the C3 convertase of the alternative pathway (C3NeF) and C3 convertase of the classical pathway
(C4NeF) (Figure 3). In 1969, NeF was detected for the first time in a case of MPGN with persistent
hypocomplementemia [13]. The serum of this patient was able to break down into C3 when it was
incubated with normal human serum. The activity of NeF was attributed to the stabilization of the
alternative complement pathway convertase (C3bBb), and it was named C3NeF [13,14]. Then, further
studies [15–18] described various types of NeF stabilizing different convertases, thus preventing their
cleavage and causing continuous activation of the complement system. Marinozzi et al. [19] detected
a C3NeF that stabilizes the C5 convertase of the alternative pathway (C5NeF). C4NeF was first detected
in a case of patients with postinfection glomerulonephritis and who had persistent low levels of C3
and C5 [20], and it was also discovered in a case of MPGN. C3NeF and C4NeF may coexist in the
same patient [21], but plasma C3, consumption, and disease severity do not always correlate with
the presence and activity of C3NeF in individuals with MPGN [22]. Other autoantibodies related to
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complement components, such as FB, FH, and C3b have been detected in a smaller percentage of
patients [23]. A recent review regarding the use of diagnostic tools to detect and characterize NeFs was
published by Donadelli et al. [24].
In conclusion, various autoantibodies enhance the activity of the alternative pathway in different
ways. C3NeF binds and stabilizes the C3 convertase in the presence of properdin. C4NeF binds and
stabilizes C3 convertase (C4bC2a) of the classical pathway, thus causing more production of C3b and
C3bBb. Autoantibodies against factor H eliminate the regulatory function of this factor [25], whereas
autoantibodies against factor B stabilize the enhancing function of factor B [26,27]. The presence of one
of these autoantibodies is responsible for the development of C3 GP caused by an abnormal control of
alternative complement pathway activation with reduced C3 degradation and increased C3 fragment
deposition in the GBM.
3. Epidemiology
C3 GP is a rare disease, so its frequency can only be approximately calculated. Cohort studies and
an analysis of data from C3 GP registry have estimated an annual incidence of biopsy-proven DDD
and C3 GN of one to two cases per million, with both sexes being affected equally [28]. The prevalence
has been calculated as less than five cases per 1,000,000 in the United States and ~0.2–1.0 cases per
1,000,000 among the European population [25,29].
Instead, for CFHR5 GP, which was first observed in patients from Cyprus, data of incidences are
lacking, while the prevalence value has been estimated at 140 cases per 1,000,000 Cypriot individuals [30].
4. Clinical Manifestations
Because of the low frequency of C3 GP, patient cohort studies are important and can provide
valuable information regarding clinical presentation, pathological and laboratory features, and their
correlation with disease outcomes.
Table 1 shows the clinical and laboratory data of patients affected by C3 GP in different cohorts, as
described by many investigators [23,25,29,31–36]. C3 GP involves mainly children and young people
and may develop after an infectious episode (i.e., streptococcal infection) of the upper respiratory tract.
However, the presence of rare variants linked to C3 and other components of the alternative pathway
predisposes an individual to C3 GP susceptibility.
The onset of the disease is characterized by micro- or macroscopic hematuria, light or heavy
proteinuria, and a progressive reduction of renal function. Microhematuria is present in 90% of
individuals, and episodes of gross hematuria may occur in 20% of patients in concomitance with upper
respiratory tract infections. At the beginning of the disease and mainly in adults, light proteinuria
may be present, which then becomes heavy over the course of the disease. The impairment of renal
function is more frequent in adults and elderly subjects.
These clinical manifestations are common in all subtypes of C3 GP based on the aberrant control
of the alternative complement pathway and sequential deposition of C3 in glomeruli. Therefore, renal
biopsy remains the main approach for diagnosis.
In DDD, the onset is characterized by nephrotic syndrome in 50% of the patients and acute
nephritic syndrome in the other 50%. Hypertension may be present at the onset of the disease or
detected during the course of the disease. These clinical manifestations are preceded by an acute
episode of upper respiratory tract infection.
In a few cases, DDD shows at the fundus oculi drusen bodies that are electron-dense deposits of
complement factors between the Bruch’s membrane and the retinal epithelium. This abnormality may
be present at all ages and comes with a modest risk of progressive visual loss.
In some cases, patients with DDD may show acquired partial lipodistrophy that is characterized
by the absence of subcutaneous fat in the face, but can also be present in the arms and upper portions
of the trunk. However, partial lipodistrophy is more frequent in MPGN.
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The outcome of DDD patients is poor, given that 50% of individuals progress to end-stage kidney
disease (ESKD) within 10 years of diagnosis.
In C3 GN, the onset of the disease is characterized by microhematuria associated with hypertension
in one-third of patients and nephritic syndrome in another third. The percentage of patients with
ESKD is similar to that of patients with DDD. The disease involves mainly children and young adults.
Microhematuria is present in 90% of individuals, and episodes of gross hematuria may occur in 20% of
patients, along with upper respiratory tract infections. At the beginning of the disease light proteinuria
that becomes heavy during the course of the disease is present but mainly in adults. The impairment
of renal function is more frequent in adults.
CFHR5 glomerulopathy (CHFR5 GP) has been described in family studies; here, the abnormal
activity of the complement factor H-related (CFHR) proteins or deregulation of CFH caused by CFH
gene polymorphisms segregates in some members of the family [33,37,38]. Individuals with these
genomic abnormalities show persistent microscopic hematuria that may be associated with proteinuria.
The development of chronic renal failure progressing to ESKD is more frequent in men with proteinuria.
In other patients, the usual presentation may be macroscopic hematuria in the concomitance of upper
respiratory tract infection, as in IgA nephropathy, which mainly occurs in children.
However, familial cases of C3 GP have been observed in the presence of CFHR3-1 protein
abnormalities [39] or the internal duplication of CFHR1 [40] or CFHR5, specifically in members of
a Cypriot family [41].
5. Renal Biopsy
A renal biopsy is essential to identify C3 GP because it is the correct approach for distinguishing
the different subtypes of MPGN.
5.1. Immunofluorescence Microscopy
The diagnosis of C3 GP is based on an immunofluorescence (IF) technique, which reveals C3
dominant staining, with C3 being the only positive immunoreactant or with others (IgG, IgA, IgM,
C1q) but C3 at least 2 + stronger [42].
In DDD, C3 deposits are arranged in a ribbon-like (“garland”) pattern in the glomerular basement
membranes with sometimes ring-shaped mesangial deposits (Figure 4a). Broad linear tubular basement
membranes (~60%) (Figure 4b) and Bowman capsule deposits (~30%) can also be present in DDD.
In C3 GN, prominent granular C3 deposits are seen in the mesangium and/or glomerular basement
membranes (Figure 4c,d).
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Figure 4. (a) Ribbon like pattern of C3 deposition along glomerular basement membrane in a patient
with DDD (×400). (b) Linear C3 deposition along tubular basement membrane in DDD (×400). (c)
Granular mesangial C3 deposits in a patient with a mesangial proliferative C3 GN (×400). (d) Coarsely
granular mesangial and glomerular capillary wall C3 deposits in a patient with membranoproliferative
pattern of C3 GN (×400). (e) Glomerulus with segmental mesangial proliferation in a patient with C3
GN (PAS). (f) Glomerulus with global membranoproliferative pattern of injury in a patient with C3 GN.
Several aspects of glomerular basement membrane double contours (black arrows) are present (Jones
silver stain). (g) Glomerulus with thickened strongly PAS positive glomerular basement membranes
with several double contours (black arrows) (PAS) in a patient with DDD. (h) Silver negative glomerular
basement membrane in a patient with DDD (white arrows). Glomerular basement membranes
appear eosinophilic and refractile (Jones silver stain). (i) Highly osmiophilic electron dense deposits
permeating lamina densa in a patient with DDD (TEM, ×8900). (j) Mesangial electron dense deposits
(black arrows) in a patient with mesangial proliferative C3 GN (TEM, ×11000). (k) Subendothelial
electron dense deposits (black arrows) with newly formed lamina densa (i.e., double contours) and
cellular interposition (white arrow) in a patient with membranoproliferative patter of C3 GN (US:
urinary space, CL: capillary lumen) (TEM, ×8900).
The absence of C4d in the kidney biopsy from proliferative GN has been found to be helpful,
as noted by Sethi et al. [43], in distinguishing C3 GP from Ig complex-mediated and postinfection
glomerulonephritis. Although helpful, this feature has been questioned by other studies [44].
C3 GP has now been included among the possible manifestations of monoclonal gammopathy of
renal significance (MGRS) because 30–50% of patients >50 years of age with C3 GP have a detectable
monoclonal Ig [45]. For this reason, careful examination of a renal biopsy and searching for a monoclonal
Ig or light chain is mandatory. Failing to detect a monoclonal protein using an immunofluorescence
technique from fresh frozen tissue should prompt reprocessing to formalin-fixed-paraffin-embedded
tissue after pronase digestion. Actually, 10–20% of patients with a serum monoclonal component and
finding of C3 GP on immunofluorescence have a proliferative GN with masked monoclonal deposits [45].
It is important to distinguish C3 deposition in C3 GN from other forms of glomerulonephritis,
such as postinfection glomerulonephritis, in which immunoglobulin deposition occurs in the first
phase of the disease and then disappears. In this case, persistence of heavy proteinuria and/or double
contours on light microscopy (LM) may suggest the occurrence of C3 GP.
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5.2. Light Microscopy
LM can vary greatly, presenting with different morphologic patterns. Mesangial proliferative
glomerulonephritis (Figure 4e) and membranoproliferative glomerulonephritis (Figure 4f) are the most
common patterns found, respectively, 33.3% and 50.8% of a cohort of 114 patients with C3 GP from
the Mayo Clinic [23]. The membrane proliferative pattern in light microscopy is not different from
that seen in idiopathic forms with Ig deposits. It is characterized by the thickening of glomerular
basement membranes with double contours and cellular interposition. The features of exudative
glomerulonephritis with endocapillary hypercellularity with or without polymorphonucleates are
observed in 10–20% of cases. Extracellular proliferation with a crescent formation can also be present.
In chronic phases of injury focal, segmental and/or global glomerulosclerosis and a fibrous crescent can
be found. Fibrinoid necrosis is uncommon.
In DDD, glomerular basement membranes appear eosinophilic and refractile and stain brightly
with periodic acid-Schiff (PAS) and poorly with a Jones silver stain (Figure 4g,h).
5.3. Electron Microscopy
EM studies have refined the G3 GP classification into further categories (DDD and C3 GN) based
on the appearance of deposits.
In DDD (formerly MPGN type II), EM shows highly osmiophilic dense deposits in the lamina
densa of the glomerular basement membranes, resulting in an electron-dense appearance (Figure 4i).
These deposits can also be found in the mesangium, Bowman capsule, tubular basement membranes,
and small vessel walls.
In C3 GN, the “usual” electron-dense deposits are found in various locations: the mesangial
(Figure 4j), subendothelial (Figure 4k), and intramembranous areas. Subepithelial humps can be found
both in DDD and C3 GN.
6. Diagnosis
A single algorithm cannot define the diagnostic approach to C3 GP, which is based on the
interpretation of individual cases through the integration of the information provided by the renal
biopsy together with clinical, serological, and genetic assessments.
Because the clinical presentation of C3 GP in its different forms may vary from asymptomatic
hematuria to nephrotic syndrome and acute kidney injury, a diagnosis of C3 GP should be taken into
consideration virtually in all patients presenting features of glomerulonephritis (proteinuria, hematuria,
renal failure, or active urine sediment).
The clinical and laboratory work-up for the diagnosis of C3 GP is illustrated in Figure 5. After
collecting the medical history and providing an accurate examination of the physical status, the patient
usually undergoes general laboratory evaluation, looking at immunity (measurement of the serum
levels of immunoglobulins and detection of serum cryoglobulins) and the complement system
(hemolytic assay of the classical and alternative pathway). In the presence of the specific activation of
the alternative complement pathway (i.e., reduced C3 and normal C4 serum levels) C3 GP is highly
suspected although not yet determined. The diagnosis of C3 GP is exclusively made based on renal
histological findings. In particular, as previously shown, LM is not specific enough for C3 GP, but IF
and EM are necessary to make a diagnosis of C3 GP and to distinguish between C3 GN and DDD.
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Figure 5. Clinical and Laboratory Work-up for diagnosis of C3 glomerulopathy.
C3-dominant glomerulonephritis is defined as C3 deposition in renal tissue of at least two orders
of magnitude greater than that for any other immunoreactant (including Ig, C4, C1q, etc.). However,
even when a C3 prevailing deposition is found, only a suspected diagnosis of C3 GP may be formulated,
while the definitive diagnosis might require an ultra-structural analysis by EM.
Once the histological diagnosis of C3 GP has been realized, additional laboratory tests should be
done to evaluate the serum levels of other components of the complement system, such as FH, FB, C5,
and other complement regulatory proteins. Then, the work-up proceeds to a differential diagnosis
and excludes secondary forms of glomerulonephritis. Investigations of the medical history should
include a possible familial story of glomerulonephritis, unclear renal insufficiency, prior episodes
of hematuria and/or proteinuria, and secondary causes, such as infections, autoimmune diseases,
and paraproteinemia. Particular attention should be paid to recent infective episodes that may represent
a trigger for complement activation. Moreover, all patients (especially if the age is more than 50 years)
should be screened for the presence of paraproteins by serum electrophoresis-immunofixation and
serum-free light chain measurement. Indeed, it has been shown that monoclonal gammopathy may be
common in patients with a histological diagnosis of C3 GP [46]. If paraproteins are present, the patient
should be referred to hematology consultation because in these cases, a clone-guided treatment might
improve renal outcomes.
If secondary forms of complement activation are unlikely or excluded, all patients with C3 GP
should undergo a comprehensive evaluation of the complement system, which includes measurements
of the complement hemolytic activity, screening for circulating autoantibodies and genetic studies,
which can help in defining the diagnosis and choosing the therapeutic approach [47].
The evaluation of the overall complement activity may be performed by evaluating the total
complement hemolytic activity (CH50), the complement alternative pathway activity (AP50), or the
complement FH functional activity [48]. Although functional tests may be considered the gold standard
for studying the complement activity, they may actually have a significant rate of false-negative results,
and their use still needs to be validated.
Moving to the specific details, serological studies of the complement AP should include the
quantification of individual complement components, here bearing in mind that the results of these
studies may change over the course of the disease. The most important complement components to
evaluate are C3 and C4. Low C3 is found in a substantial number of patients with C3 GN (40–75%) and
DDD (60%), while serum C4 levels are usually normal [23]. Moreover, serum FB, FH, FI, properdin,
104
Int. J. Mol. Sci. 2020, 21, 525
and membrane cofactor proteins (MCP or CD46) should also be tested, considering that a deficiency of
these factors, often accompanied by low C3 levels, can be associated with altered AP activation [49].
However, complement activation may also be detected by measuring the decay products of complement
activation; when elevated, they may reflect an increased turnover of C3 (C3a, C3d), C5 (C5a), and FB
(Bb) [50]. Finally, considering that the activation of all complement pathways leads to the generation of
the membrane attack complex (C5b-9), soluble levels of C5b-9 should be evaluated as an additional
marker of complement activation [49]. Interestingly, it should be noted that small differences in
complement biomarkers between C3 GN and DDD exist. For example, in C3 GN, the plasma properdin
reduction and soluble C5b-9 elevation tend to be higher than in DDD. Thus, a complement component
evaluation may also provide an indication of the disease in the differential diagnosis between C3GN
and DDD.
Serological studies in patients with C3 GP should also include screening for autoantibodies,
which may constitute the acquired causes of C3 GP. C3NeF and C5NeF are the most frequently
identified autoantibodies (Figure 5). Various diagnostic tools can be used to detect NeFs [51]. Three
of these tools are functional and hemolytic assays. The first method consists of the measurement of
C3 fragments in the serum’s patient by two-dimensional immunoelectrophoresis, immunofixation
electrophoresis, or Western blotting. The second test is based on a hemolytic assay that measures
the lysis of sheep or rabbits erythrocytes after incubation with the serum or plasma of the patient.
Finally, the presence of NeFs can be detected through the quantification of C3a and C5a anaphylotoxins.
NeFs can be measured by binding assays that detect C3NeF by various ELISA techniques. Actually,
they encompass a heterogeneous group of IgG and IgM autoantibodies that stabilize the alternative
pathway of C3 and C5 convertase (C3bBb and C3bBbC3b, respectively), prolonging their survival
and promoting massive C3 or C5 consumption [51]. C3NeF is found in 80% of patients affected by
DDD and in 50% of patients affected by C3 GN. Detecting C3NeF can be done in many different ways,
including ELISA, C3 convertase surface assay, and electrophoresis [52]. In addition, C4 nephritic factor
(C4NeF), which stabilizes the C3 convertase of the classical and lectin pathways, has been identified in
a small subset of patients with C3 GP, even if its role remains unclear [53]. Antifactor H antibodies
are another group of auto-antibodies described in patients affected by C3 GP; they may be detected
using an enzyme-linked immunosorbent assay and have been related to the presence of monoclonal
gammopathy [54]. Finally, anti-FB antibodies have rarely been described, but their detection remains
confined to research laboratories [26].
Because genetic factors have been reported in cohorts of patients with C3 GP, genetic testing
should be considered in these patients [32] (Figure 5). In particular, genetic screening should include
the evaluation of the C3, FB, FH, MCP, CFHR1-5, and FI genes to detect single nucleotide changes,
small insertions and deletions, or more complex rearrangements, such as copy number variations [34].
However, the interpretation of a genetic analysis in C3 GP is often difficult for several reasons. First,
genetic defects have been identified only in a small number of patients with C3 GP. Second, the actual
pathogenetic and functional meaning of many mutations is still not defined. Finally, most genetic
variants have a low penetrance, and combined variants may coexist, which also involves other
genes, such as thrombomodulin (THBD) and diacylglycerol kinase-epsilon (DGKE) [55]. Thus, it is
necessary to cautiously analyze the detected gene alterations to determine if they are specifically
disease associated.
A different situation is found in the familial forms of C3 GP, where disease-specific gene mutations
have been characterized. This is the case of patients affected by CFHR5 GP and who are of Cypriot
origin, in which an internal duplication in the CFHR5 gene has been described as causative [37].
Interestingly, other forms of familial C3 GP have been related to rearrangements of the CFHR2-CFHR5
hybrid gene and abnormalities in CFHR1 and CFHR5 [39,40], suggesting that the CFHR1-5 gene family
should be carefully assessed in all C3 GP cases. A detailed description of the methods to quantify the
CFHR proteins in the serum and detect circulating autoantibodies has recently been published by
Sanchez-Corral et al. [56].
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In any case, although the precise value of genetic testing remains to be defined in a general
clinical setting for C3 GP, a genetic cause of the disease should be taken into consideration, and genetic
screening should be offered to all the family members of affected patients who carry a potentially
causative mutation.
7. Differential Diagnosis
A differential diagnosis should be done in the presence of diagnosed C3 GP on either a native
or transplanted kidney. In this case, it is necessary to investigate the concomitant presence of low
plasma levels of C4, occurrence of C4NeF (C4bC2a), and paraproteins (i.e., monocolonal gammopathy)
because in this case, the patient is affected by MPGN type 1.
C3 GP must be differentiated from other types of glomerulonephritides that have excessive
activation of the C system in the presence of circulating immune complexes, causing postinfection
glomerulonephritis or secondary glomerulonephritides (lupus nephritis, essential cryoglobulinemia,
and others) [1]. Because the clinical presentation in these cases is similar, it is suggested that an
accurate study of the complement system and genetic tests in specialized laboratories be carried out.
However, a kidney biopsy is diriment in these patients because it shows a prevalent deposition of
immunoglobulins, which is the characteristic pattern of these nephritides. In addition, postinfection
glomerulonephritis should be differentiated from C3 GP when there is no spontaneous resolution of
the disease within one to two months.
G3 GP can be diagnosed in the presence of false-negative staining for immunoglobulins by
immunofluorescence on the frozen renal tissue sections of patients with essential cryoglobulinemia.
In these cases, it is suggested to investigate the presence of C4 in a kidney biopsy to discover the
potential occurrence of the low serum levels of circulating immune complexes or cryoglobulins.
In many cases, the prognosis of C3 GP is severe when it comes to the progression of renal damage
to ESKD [28,32]. It is less severe in CFHR5 GP.
8. Recurrence or De Novo C3 GP after Kidney Transplatation
Patients with C3 GP are at high risk to develop the disease after kidney transplantation. Therefore,
post-transplant monitoring and available optional therapies are necessary for improving the outcome
of the patients. The recurrence is at high rate for both DDD and C3 GN. The recurrence of CHFR5
GP has been observed in the kidney allograft of patients, allowing for a family with CFHR gene
abnormalities [57]. C3 GP occurs in over 50% of patients with native C3 GP [58]. The timing and clinical
presentation may be different with DDD recurrence in later post-transplant time. The appearance of
hematuria, proteinuria and reduction of eGFR is a strong indicator of C3 GP recurrence. However, LM,
IF, and EM studies are necessary for a correct diagnosis. A recent report [59] suggests that aggressive
renal lesions in native kidney and hybrid CFHR3 1 gene-related C3 GN contribute to more recurrence
of the disease in the post-transplant time.
The approach to therapy has not been established because different treatments have been used
in these patients. Recent data from Bomback et al. [60] in a prospective open-label, uncontrolled
trial and by other investigators [61–63] suggest the administration of eculizumab which induces
reduction of proteinuria and stabilization of the renal function. However, the heterogeneous treatment
response suggests the opportunity to design a larger multicenter study in C3 GP patients after
kidney transplantation. For this reason in 2017, a group of researchers across Europe and North and
South America initiated the post-TrANsplant GlOmerular (TANGO) disease study, an observational
multicenter cohort study with the aim to enroll patients who arrived to ESKD for different forms of
glomerulonephritis, mainly C3 GP [64].
If eculizumab represents a successful therapy in atypical hemolytic uremic syndrome (AHUS) [65],
the response rate is heterogeneous in patients with C3 GP [66]. The different response is due to the
correct blockage of the terminal complement pathway in AHUS, whereas this therapy is questionable
in patients with C3 GP because the disease is characterized by abnormal activation of the alternative
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complement pathway, abnormal cleavage of C3 and continuous deposition of C3 split products in
glomeruli. This provides different response rate between the two diseases.
Some considerations should be done on the use of anti-CD 20 (rituximab) that has been used in
a small number of cases with different response to the treatment. This drug is correctly indicated in
patients with kidney graft who develop MPGN with monoclonal IgG deposits caused by dysregulated B
cells or plasma cells alone without hematologic malignancy [67]. However, sporadic use of rituximab in
association with immunosuppressive drugs has shown failure in the treatment of many cases [62,68,69].
Recurrence or de novo C3 GP may receive other therapies that are under trough evaluation as (i)
compostatin that is a C3 inhibitory peptide; (ii) CP40 is a compostatin analog [70]; (iii) monoclonal
antibodies against C3b [71], FB [72] and properdin [73]. Moreover, soluble complement receptor 1(CR1))
may prevent the dysregulated alternative pathway caused by abnormal production of C3 convertase.
All these drugs can block the dysregulated alternative complement pathway induced by
autoantibodies or genetic mutations.
9. Therapy
The current gap in the treatment of C3 GP derives from the absence of a robust understanding of its
natural outcomes. Therefore, a specific treatment for different types of C3 GP has not been established.
Recommendations have been obtained from case series and observational studies [12] because there
are no randomized clinical trials for treatments. Current treatment is based on the inhibition of
factors that activate the complement pathways, which is done by administering the available drugs as
corticosteroids and antiproliferative drugs (cyclophoshamide, mycophenolate mofetil), monoclonal
antibodies (rituximab), or complement inhibitors (eculizumab).
Children and adults with C3 GP in presence of mild or moderate proteinuria should receive
supportive therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Patients with nephrotic syndrome and a decline in renal function should receive oral CYC or MMF plus
a low dose of daily or alternate-day corticosteroids [33]. If despite this treatment nephrotic syndrome
persists or the renal function impairs, tacrolimus or RTX can be considered although the percentage of
its beneficial effect is very low [35,70].
Treatment with chemotherapeutic agents, immune-suppressive drugs, and complement inhibitors
confer infection risks. Indeed, Koopman et al. [71] suggest vaccination prophylaxis against Streptococcus
pneumonia, Neisseria meningitis, and Hemophilus influenzae.
In patients with C3 GN with abnormal deposition of C3 because of persistent activation of the
alternative complement pathway, it is suggested that treatment with eculizumab (monoclonal anti-C5
antibody) may be administered. A prospective clinical trial in which six patients with native or
post-transplant recurrent DDD or C3 GN received eculizumab therapy was the first clinical study
to evaluate the benefit of this monoclonal antibody [60]. Other case reports described by Barbour
et al. [12] have shown complete or partial remission of the clinical findings (significant reduction of
serum creatinine and/or proteinuria). Recently, Le Quintrec et al. [36] evaluated a cohort of 26 patients
(13 children/adolescents) with C3 GP who were treated with eculizumab. At the initiation of eculizumab,
40% of the patients had chronic kidney disease, while about 30% had a rapidly progressive disease.
After eculizumab treatment, six (23%) patients achieved a complete clinical response, defined as a >50%
decrease in serum creatinine and proteinuria, while six (23%) and 14 (54%) had partial or no response,
respectively. Interestingly, at the time of diagnosis, patients who had a complete clinical response,
when compared with others, presented a more severe disease associated with more extracapillary
proliferation on kidney biopsy, suggesting that different response profiles to eculizumab treatment
among C3 GP patients could be recognized.
In individuals with monoclonal gammopathy that causes C3 GP (proteinuria and decline of renal
function), a retrospective study of 50 patients with various types of monoclonal gammopathy [72]
demonstrated that chemotherapy reduced proteinuria and improved renal function in 74% of patients,
mainly in patients who had a reduction of gammopathy. Moreover, the hazard of ESRD was 83%
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lower in patients with reduced gammopathy. The same improvement was observed in other patients
who received chemotherapy [23] in the presence of gammopathy because of lymphoproliferative
disorders [73,74]. Many patients have shown an improvement in the clinical course, which is
characterized by a reduction of proteinuria and improvement of renal function. However, the role of
eculizumab remains to be defined. C3 GP remains the ideal disease in which anticomplement drugs
(compostatin, monoclonal antibodies against C3, FB, properdin) can be tested [75–78].
Plasma exchange removes autoantibodies such as NeFs and mutated proteins, but it must be
associated with immunosuppressive therapy for blocking antibody production. This approach has
been used successfully in patients with CFH mutations [79–81]. The Consensus Report on C3 GP [2]
concluded that an international pathology registry is necessary to define the different spectra of this
disease and to divide patients into appropriate subgroups. Thus, the combination of well-defined
clinical studies associated with a robust complement study would be ideal before enrolling patients
in clinical trials. The final aim will be to treat homogenous cohorts before enrolling patients in
clinical trials.
10. Conclusions
C3 GPs are orphan diseases of which the understanding of the pathophysiology of the complement
system has improved laboratory and clinical diagnosis. However, a multidisciplinary approach that
involves nephrologists, renal pathologists, and geneticists is helpful for a correct diagnosis and for
choosing optimum therapeutic plans. More comprehensive genetic and biomarker studies are needed
to refine our diagnostic approach. We should continue to improve the clinicopathological phenotype
for designing correct multicenter trials that will give more information on the clinical course of the
disease and the effect of new drugs. Treatment with a combination of immune-suppressive drugs or
anticomplement agents can induce complete or partial remission in 50% of patients. Remission is more
frequent in C3 GN than in DDD, whereas spontaneous remission is very rare. These diseases lead to
ESKD in 50% of patients; some of them have persistent heavy proteinuria that is nonresponsive to
therapy, ranging from ACEi-ARB to immunosuppressive drugs. Older age reduced renal function,
and nephrotic syndrome at presentation are unfavorable prognostic factors. The recurrence of
these diseases in patients after kidney transplantation is very frequent; therefore, post-transplant
monitoring and available treatment options should be taken into consideration. Newer therapies such
as monoclonal antibodies and recombinant proteins may be promising strategies in the near future.
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Abstract: The abnormal deposition of calcium within renal parenchyma, termed nephrocalcinosis,
frequently occurs as a result of impaired renal calcium handling. It is closely associated with
renal stone formation (nephrolithiasis) as elevated urinary calcium levels (hypercalciuria) are a key
common pathological feature underlying these clinical presentations. Although monogenic causes of
nephrocalcinosis and nephrolithiasis are rare, they account for a significant disease burden with many
patients developing chronic or end-stage renal disease. Identifying underlying genetic mutations
in hereditary cases of nephrocalcinosis has provided valuable insights into renal tubulopathies
that include hypercalciuria within their varied phenotypes. Genotypes affecting other enzyme
pathways, including vitamin D metabolism and hepatic glyoxylate metabolism, are also associated
with nephrocalcinosis. As the availability of genetic testing becomes widespread, we cannot be
imprecise in our approach to nephrocalcinosis. Monogenic causes of nephrocalcinosis account for a
broad range of phenotypes. In cases such as Dent disease, supportive therapies are limited, and early
renal replacement therapies are necessitated. In cases such as renal tubular acidosis, a good renal
prognosis can be expected providing effective treatment is implemented. It is imperative we adopt a
precision-medicine approach to ensure patients and their families receive prompt diagnosis, effective,
tailored treatment and accurate prognostic information.
Keywords: nephrocalcinosis; nephrolithiasis; hypercalciuria; monogenic; precision medicine
1. Introduction
Nephrocalcinosis can broadly be defined as the deposition of calcium, either as calcium phosphate
or calcium oxalate, within the interstitium of the kidney [1]. Whilst Oliver Wrong’s original
classification sub-divided nephrocalcinosis into being either molecular, microscopic or macroscopic,
in clinical practice the term commonly refers to macroscopic nephrocalcinosis that can be detected
radiologically [2]. Rarely, asymmetric presentation of nephrocalcinosis localised to the renal cortex
may represent calcium release from tissue breakdown, for example in renal transplant rejection or
renal infarction [3]. However, in the majority of cases, nephrocalcinosis affects the renal medulla
and can be detected as bilateral, symmetrical increased echogenicity within the renal pyramids on
ultrasound imaging [4]. This non-invasive imaging modality is utilised either as a screening tool, or as
a method of assessing disease progression/response to treatment, as medullary nephrocalcinosis can be
reliably graded (Grade I–III) according to the extent of increased echogenicity affecting the medullary
pyramids [5].
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Whilst the exact pathogenesis of nephrocalcinosis remains under investigation, it is acknowledged
medullary nephrocalcinosis is a consequence of hypercalciuria. Increased urinary calcium load arises
either through increased calcium absorption (extra-renal causes) or impaired calcium reabsorption
within the renal tubule [2]. The majority of calcium reabsorption (~65%) occurs in the proximal tubule,
whilst ~25% is reabsorbed in the thick ascending limb of the loop of Henle [6] and ~5% is reabsorbed
from the cortical collecting duct [2]. Identification of monogenic causes of nephrocalcinosis affecting
these areas has provided valuable insights into the pathogenesis of this heterogeneous condition.
Interestingly, although a further ~7–10% of calcium is reabsorbed within the distal convoluted tubule,
no monogenic causes of nephrocalcinosis have been identified which affect this section of the renal
tubule [2].
Hypercalciuria, in addition to being part of the underlying pathological process for
nephrocalcinosis, also predisposes patients to renal stone formation (nephrolithiasis). Nephrocalcinosis
and nephrolithiasis will therefore commonly co-exist within the phenotypes of these rare monogenic
conditions, and nephrolithiasis onset at a young age may prompt investigations for nephrocalcinosis
and uncover an inherited condition [7].
Nephrocalcinosis in itself is a rare disorder, and consequently monogenic forms affect even smaller
numbers of the population. For those individuals affected by nephrocalcinosis, however, a tailored,
individualised approach to their initial diagnostic work-up is imperative. Presentation at a young age,
a family history of an affected individual or carrier, or a history of consanguinity in the family is often
suggestive of an inherited tubulopathy. Several factors, including recessive inheritance patterns and
varied phenotype presentation, dictate that a family history is often not present, and suspicion of a
monogenic cause should not be dismissed simply due to absence of the above factors.
The morbidity associated with nephrolithiasis and nephrocalcinosis is widely accepted [8]. Whilst
an overall approach may focus upon slowing progression of associated chronic kidney disease
(CKD), specific treatment strategies, such as dietary modifications or use of thiazide diuretics, will
vary depending upon the underlying disease process. Widespread adoption of precision medicine
within this field is likely to have significant advantages for both current and future patients. Several
monogenic causes of nephrocalcinosis are associated with rapid progression of CKD, often requiring
initiation of renal replacement therapies before adulthood. Early diagnosis of a monogenic cause
is vital for providing accurate prognostic information for the patient and their family, including
the opportunity to screen other family members or offer pre-implantation genetic diagnosis (PGD)
testing for subsequent pregnancies. Perhaps most significantly, a prompt diagnosis may also avoid
the individual being exposed to unnecessary or harmful treatments. For example, a patient with
OCRL mutations (Dent disease 2) was reported to receive immunosuppressive therapies including
corticosteroids and cyclophosphamide, based on a misdiagnosis of nephrotic syndrome, before
their inherited tubulopathy was correctly identified [9]. Commonly used medications may easily
inadvertently worsen the condition of patients with other inherited tubulopathies: loop diuretic use
can potentiate hypercalciuria and worsen nephrolithiasis/nephrocalcinosis burden, whereas use of
potassium-sparing diuretics should be avoided in patients with distal renal tubular acidosis [10].
Furthermore, in cases where a proactive approach to personalised genetic medicine has been taken,
next generation sequencing has identified CLCN5 mutations (Dent disease 1) in patients for whom
only low-molecular weight proteinuria was present at diagnosis, i.e., before the full phenotype had
emerged [11]. Finally, given the current paucity of treatment options for nephrocalcinosis, it is
potentially from the study of these rare monogenic causes that key future therapeutic targets may
emerge which could revolutionise our management of the condition (Table A1).
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2. Monogenic Causes of Nephrocalcinosis
2.1. CLCN5 Mutations
The proximal tubule represents the site of greatest calcium reabsorption within the renal tubule,
and it is mutations in the ClC-5 chloride transporter in this region, encoded by CLCN5, that give rise to
Dent disease type 1 [12]. This condition demonstrates an X-linked recessive pattern of inheritance;
affected males usually display a triad of low molecular weight (LMW) proteinuria, hypercalciuria
and nephrocalcinosis, although the triad may be incomplete at initial presentation [11]. Female
carriers are usually asymptomatic, but may occasionally have LMW proteinuria, hypercalciuria or
nephrolithiasis [12].
Dent disease 1 (CLCN5 mutations) accounts for 60% of Dent disease cases. OCRL mutations,
which may result in a spectrum of phenotypes ranging from Dent disease 2 to the more severe Lowe
oculocerebrorenal syndrome, account for a further 15% of cases, whilst the underlying genetic mutation
remains unascertained in 25% of cases [12]. The varied phenotypes of Dent disease may also include
a partial Fanconi syndrome as the initial clue indicating proximal tubular dysfunction [13], whilst
nephrolithiasis or haematuria can also feature alongside the cardinal LMW proteinuria [11]. Although
genetic conditions with a Fanconi syndrome, including Lowe oculocerebrorenal syndrome (OCRL
mutations) and cystinosis (CTNS mutations) may also feature nephrocalcinosis [14,15], it remains more
commonly associated with Dent disease 1 (CLCN5 mutations) [16].
Patients with Dent disease carry a poor prognosis in terms of renal function: 30–80% of males
develop end-stage renal disease (ESRD) by middle-age [12]. The development of CKD has been
hypothesised to be linked to nephrocalcinosis, although this theory does not explain Dent disease
patients without nephrocalcinosis who also develop progressive CKD, and it is probable more than
one mechanism exists [16,17].
Treatment options for Dent disease are limited. Early diagnosis is crucial in order to prioritise
preservation of renal function for as long as possible and offer accurate prognostic information [11].
Patients should undergo careful CKD monitoring with control of variables such as blood pressure.
A strategy to try and reduce nephrocalcinosis development is to reduce urinary calcium excretion;
thiazide diuretics may be used but in some patients their role is limited by unacceptable side effects
including hypokalaemia, muscle cramps and dehydration [12]. The majority of patients will reach
ESRD by the age of 40 [18]; renal transplantation offers the best outcomes as there is no recurrence in
the renal allograft due to the donor kidney not carrying the causative mutation [12].
2.2. CYP24A1 Mutations
Nephrocalcinosis occurs as a result of impaired renal calcium handling; disorders of vitamin D
metabolism can result in elevated calcium levels and represent a different pathway predisposing to
nephrocalcinosis formation. The second stage of vitamin D activation takes place within the kidney,
resulting in production of the active metabolite 1,25-dihydroxyvitamin D3. Mutations in CYP24A1,
which encodes 1,25-hydroxyvitamin-D3-24-hydroxylase, result in an inability to catabolise this active
vitamin D metabolite [19]. CYP24A1 mutations were first detected following reports of a small cohort
of babies developing adverse effects (including hypercalcemia and nephrocalcinosis) as a result of
the public health intervention to routinely supplement formula milk with vitamin D [20]. Following
further analysis, two distinct phenotypes resulting from CYP24A1 mutations have been recognised,
both of which frequently include nephrocalcinosis [19].
The first phenotype, idiopathic infantile hypercalcaemia (IIH) presents in childhood, and is
classified as hypercalcaemia, infantile 1 (HCINF1). Affected infants often present with symptomatic
hypercalcaemia, severe dehydration, vomiting and failure to thrive [21]. Nephrocalcinosis is
often detectable on ultrasound imaging at diagnosis [21]. Management of these patients focusses
upon removing exogenous sources of vitamin D (e.g., supplements), fluid resuscitation and future
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conservative measures (high fluid intake, dietary adjustments, avoidance of tanning beds) to prevent
further nephrolithiasis/nephrocalcinosis formation.
A second, later-onset, phenotype has also been demonstrated in adults who present with
nephrolithiasis, hypercalciuria or incidentally detected nephrocalcinosis [22]. This phenotype is usually
less severe, and a history of vitamin D supplementation is not universally present. Treatment strategies
focus upon low calcium and oxalate diet, avoidance of vitamin D supplementation and excessive
sunlight exposure [19]. Use of azole antifungal agents (fluconazole, ketoconazole) have shown benefit
as non-specific P450 enzyme inhibitors which inhibit 1α-hydroxylase (encoded by CYP27B1), thereby
reducing production of the active form of vitamin D [19,23]. However, lifelong treatment with these
agents may be undesirable owing to their side effect profile, including hepatotoxicity. Recently,
rifampicin was demonstrated to reduce hypercalcaemia and effectively control 1,25-dihydroxyvitamin
D3 levels in patients with CYP24A1 mutations [24]. Rifampicin acts upon an alternative vitamin D
catabolism pathway as a potent inducer of CYP3A4 [24]. This provides an alternative therapy that may
be better tolerated as a lifelong treatment.
2.3. SLC34A1 Mutations
Autosomal recessive inheritance of mutations in the sodium-phosphate co-transporter NaPi2a,
encoded by SLC34A1, cause idiopathic infantile hypercalcaemia (IIH), classified as hypercalcaemia,
infantile 2 (HCINF2), in a subgroup of patients without CYP24A1 mutations [25]. In addition to
the classic biochemical features associated with IIH of hypercalcaemia, hypercalciuria and high
levels of 1,25-dihydroxyvitamin D3, patients with SLC34A1 loss-of-function mutations exhibit
hypophosphatemia [26]. This hypophosphatemia arises as a result of renal phosphate wasting
within the proximal tubule, driving excessive production of 1,25-dihydroxyvitamin D3 and subsequent
hypercalcaemia and hypercalciuria.
Nephrocalcinosis is a common phenotypical feature in patients with SLC34A1 mutations [27].
In the acute presentation, where patients may have classical features of IIH such as failure to thrive,
dehydration and vomiting, they should be fluid resuscitated and may receive loop diuretics (furosemide)
to induce calciuresis [27]. Similar to patients with CYP24A1 mutations, an azole antifungal agent
(ketoconazole or fluconazole) may be used to inhibit 1α-hydroxylase, thereby reducing the high calcium
levels predisposing to nephrocalcinosis through reduction in levels of 1,25-dihydroxyvitamin D3 [26].
The long-term management of these patients, however, should focus upon a low calcium diet and
avoidance of vitamin D supplementation or heightened vitamin D exposure, in order to minimise the
risk of nephrocalcinosis.
2.4. CLDN16 and CLDN19 Mutations
The thick ascending limb (TAL) of loop of Henle, where ~25% of calcium reabsorption [6] and
~60% of magnesium reabsorption usually takes place [28], is the site of two rare autosomal recessive
channelopathies affecting calcium and magnesium absorption. Mutations in CLDN16 and CLDN19,
which encode the tight junction proteins claudin-16 and claudin-19 respectively, give rise to the
condition familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) [29].
Patients are symptomatic from a young age, although initial presenting features may be non-specific
such as polyuria/polydipsia, failure to thrive and vomiting. The biochemical profile of FHHNC
phenotypes includes excessive loss of calcium and magnesium in the urine, with normal serum
calcium levels and low serum magnesium levels [28]. Importantly, serum hypomagnesaemia is not
universally present, and a fractional excretion value of magnesium (FeMg%) should be calculated using
serum magnesium, serum creatinine and urinary magnesium levels to ensure diagnostic accuracy [30].
Nephrocalcinosis is a universal feature which develops early in the disease course of FHHNC, and
hypercalciuria is one predisposing factor for this [30]. A further predisposing factor for nephrolithiasis
and nephrocalcinosis in FHHNC is hypocitraturia, which removes the protective effect of urinary
citrate against precipitation of calcium salts in the urine [30]. The renal prognosis for FHHNC is poor;
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many patients progress to ESRD during adolescence [28]. Rapid progression of CKD in these patients
may not be attributable solely to nephrocalcinosis, as their renal dysfunction is more severe/presents
earlier than that observed in other tubulopathies predisposing to nephrocalcinosis such as primary
distal renal tubular acidosis or Bartter syndrome [30]. CLDN19 mutations are associated with severe
ocular abnormalities as claudin-19 is also expressed in the retinal epithelium [28].
Treatment strategies for FHHNC patients focus initially on supportive measures aimed at reducing
hypercalciuria and replacing magnesium; thiazide diuretics and oral magnesium supplements are
used for this respectively, although their impact on total urine calcium and serum magnesium levels
is not always significant [28,30]. Overall, these supportive treatments do not negate the progression
of renal dysfunction, and renal replacement therapies are commonly necessitated before adulthood.
Renal transplantation is the ideal option: the loss-of-function channelopathy is not present in the
renal allograft so renal calcium and magnesium handling are normalised and there is no disease
recurrence [31].
2.5. Bartter Syndromes
The Bartter syndromes describe five channelopathies affecting thick ascending limb (TAL)
transporter proteins involved in sodium chloride (NaCl) re-absorption. Autosomal recessive inheritance
of these gene mutations results in salt-losing tubulopathies characterised by excessive urinary sodium
losses, with corresponding hypokalaemia, metabolic alkalosis and secondary hyperaldosteronism [32].
Nephrocalcinosis has been described in all Bartter syndromes but is most frequently associated
with Bartter I, II and V [2]. The pathogenesis of nephrocalcinosis in Bartter syndromes is not
fully understood, although it is most probably a consequence of hypercalciuria seen within the
Bartter syndrome phenotypes [33]. Early identification of the Bartter syndrome genotype is clinically
advantageous, especially given the fact nephrocalcinosis and other renal manifestations are not
uniformly represented across the different Bartter syndrome phenotypes. Several clinical features,
including age of onset, presence of transient hyperkalaemia, severity of hypokalaemia, sensorineural
deafness and renal impairment may provide vital clues about the likely underlying genotype which
can guide genetic testing.
Bartter syndromes I and II, caused by mutations in SLC12A1 and KCNJ1 respectively, usually
present during the antenatal/postnatal period, and have been traditionally referred to as antenatal
Bartter syndromes (aBS). Polyhydramnios, premature birth and low-birth weight are classic features of
aBS, and nephrocalcinosis is frequently already detectable at this young age [34]. KCNJ1 mutations,
encoding the ROMK potassium channel, often display transient hyperkalaemia in the neonatal period
prior to development of classic hypokalaemia [32]. Early treatment to correct electrolyte disturbance,
rehydrate patients and minimise growth retardation is necessitated [35]. Cyclo-oxygenase inhibitors
(e.g., indomethacin), which target the elevated prostaglandin levels seen within aBS, are an effective
treatment and can lead to effective catch-up growth [33,35].
Our understanding of Bartter syndrome II has recently expanded to include a late-onset phenotype
following case reports of two adults found to have KCNJ1 mutations after incidental nephrocalcinosis
detection. Both patients had nephrocalcinosis and mild renal impairment at diagnosis, and were treated
with oral potassium supplementation, and either a potassium-sparing diuretic or angiotensin-converting
enzyme inhibitor respectively [33,35].
Bartter syndrome III occurs as a result of mutations in CLCNKB which encode the chloride
channel ClC-Kb. The syndrome often has a milder phenotype with later-onset of symptoms, although
presentations within the neonatal period have been reported [32]. Patients with Bartter III often
have a more severe hypokalaemic alkalosis which is the most likely clinical clue to their underlying
genotype [32]. Hypercalciuria and nephrocalcinosis are less frequently associated with the Bartter III
phenotype compared to Bartter I and II [32].
Mutations in BSND, which encode Barttin (a chaperone protein for ClC-Ka and ClC-Kb) account
for Bartter syndrome IV. Sensorineural deafness is part of the Bartter IV phenotype [36]. An association
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between Bartter syndrome IV and renal impairment has been reported. Patients frequently develop
CKD at a very young age, and may not respond to indomethacin, in contrast to those with other aBS
genotypes [36].
Although the term Bartter syndrome V is sometimes used in the literature to describe
gain-of-function mutations in CASR encoding the calcium-sensing receptor (CaSR), according to
OMIM classification Bartter syndrome V instead refers to mutations in the MAGED2 gene, causing
an X-linked recessively inherited transient antenatal BS [37]. To avoid this nomenclature issue, CaSR
mutations are described separately in the section below.
2.6. CASR Mutations
The calcium-sensing receptor (CaSR), expressed in the parathyroid gland and kidney, responds
to changes in serum calcium levels, acting to inhibit parathyroid hormone (PTH) secretion and renal
tubular calcium reabsorption [38]. A total of 112 mutations of the CASR gene have been reported,
of which 48 are gain-of-function mutations, including those associated with autosomal dominant
hypocalcaemia (ADH)/autosomal dominant hypocalcemic hypercalciuria (ADHH) [38].
Patients with ADH exhibit a biochemical phenotype which includes serum hypocalcemia,
low-normal levels of PTH, hypercalciuria, and polyuria [39]. It is essential to distinguish these patients
from those with hypoparathyroidism: ADH patients given vitamin D supplementation are likely to
develop worsening hypercalciuria, nephrocalcinosis and renal impairment as 1,25-dihydroxyvitamin
D upregulates transcription of the CASR gene [40]. Instead, a low-normal serum PTH (in contrast to
a very low or undetectable level) and low urinary calcium levels in a hypocalcemic patient should
prompt clinicians to screen for CASR mutations [40]. Patients with ADH should receive treatment
for their hypocalcemia only if it is symptomatic, and should aim for symptom control rather than
normalised serum calcium levels [40]. Gain-of-function CASR mutations that inhibit activity of NKCC2
and ROMK channels in the thick ascending limb (TAL) of loop of Henle have been reported to produce
a Bartter-like phenotype, which may include hypokalaemia and hyperreninemic hyperaldosteronism,
in addition to hypocalcemia [41,42].
2.7. ADCY10 Mutations
Mutations in ADCY10, which encodes the soluble adenylyl cyclase gene, have been linked
to familial idiopathic hypercalciuria, also known as Absorptive Hypercalciuria, 2 (HCA2) [43].
HCA2 displays autosomal dominant inheritance, with a phenotype including frequent calcium
nephrolithiasis [44]. The underlying aetiology of the condition has not been fully delineated, but it
is known increased intestinal calcium absorption is responsible for the hypercalciuria seen in these
patients. Alongside the common clinical finding of calcium nephrolithiasis, increased renal calcium
handling predisposes these patients to nephrocalcinosis formation [44].
2.8. Primary Distal Renal Tubular Acidosis
In distal renal tubular acidosis (dRTA), affected patients have a hyperchloremic normal anion-gap
metabolic acidosis and alkaline urine (pH > 5.3) [10]. This characteristic biochemical profile arises as a
consequence of type A intercalated cells in the collecting duct failing to acidify the urine [45].
Under normal physiological conditions, H+ and HCO3− are produced within the type A
intercalated cells. Mutations in either the vacuolar H+-ATPase pump, which excretes H+ into the urine,
or the chloride bicarbonate counter transporter anion exchanger (AE1), which reabsorbs HCO3− into the
circulation, account for 85% of known causes of primary dRTA [10]. Mutations in the B1 and A4 subunit
of the vacuolar H+-ATPase pump, encoded by ATP6V1B1 and ATP6V0A4 respectively, demonstrate
autosomal recessive transmission and produce a phenotype frequently associated with sensorineural
hearing loss as well as the commonly recognised biochemical abnormalities [45]. Mutations in SLC4A1,
which encodes AE1, can occur with either autosomal dominant or autosomal recessive transmission:
autosomal recessive cases are associated with earlier age of symptom onset and a more severe
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phenotype [10]. Red blood cell abnormalities may also form part of the phenotype for patients with
SLC4A1 mutations [45]. More recently, mutations in Forkhead box protein Il (encoded by FOXI1) and
WD repeat-containing protein 72 (encoded by WDR72) have been recognised as alternative underlying
genetic mutations in a small number of families with autosomal recessive inheritance of dRTA [46,47].
At present the underlying genetic defect remains unknown in approximately 15% of cases of primary
dRTA [10].
Nephrocalcinosis is an extremely common feature within the phenotype of primary dRTA
patients [48]. Calcium phosphate precipitates at higher pH; the alkaline urine of dRTA patients acts as
a predisposing factor for nephrolithiasis and nephrocalcinosis formation [45]. In addition, chronic
metabolic acidosis leads to excessive bone demineralisation often resulting in hypercalciuria: this also
increases the likelihood of nephrocalcinosis developing if patients do not receive early diagnosis and
treatment [48].
Treatment strategies for dRTA focus primarily on correcting the underlying metabolic acidosis;
patients are maintained on oral potassium citrate which must be taken at regular intervals given its
short half-life. This treatment may soon become less cumbersome for patients, as a controlled-release
preparation of potassium bicarbonate and potassium citrate designed to be taken twice daily is
undergoing phase three trials [10]. Primary distal renal tubular acidosis carries a good prognosis
providing prompt diagnosis and treatment initiation are achieved. In patients on treatment with a
corrected metabolic acidosis, it has been noted nephrocalcinosis does not progress and their renal
function usually remains preserved [10]. However, potassium citrate treatment cannot reverse
nephrocalcinosis if already present. Long-term follow-up of dRTA patients should include annual
ultrasound screening to monitor for nephrocalcinosis and nephrolithiasis, as well as monitoring of
their renal function [45].
2.9. Primary Hyperoxaluria
Primary hyperoxaluria describes a group of inborn errors of metabolism where defective liver
enzymes involved in glyoxylate metabolism result in excess production of oxalate [49]. The predominant
route of oxalate excretion is via the kidneys, with enteric excretion also playing a role when renal function
is impaired [50]. In primary hyperoxaluria, excessive oxalate levels supersaturate renal excretion
mechanisms, leading initially to calcium oxalate deposition within the kidney, and subsequently
systemic oxalosis (deposition of oxalate within other systems) affecting the skeleton, heart, liver and
other organs [49].
Currently there are three known types of primary hyperoxaluria which all display autosomal
recessive inheritance. Reports of phenotypically similar cases with no proven monogenic cause
increase the likelihood of further pathogenic mutations being discovered over time [49]. Recurrent
calcium-oxalate nephrolithiasis and nephrocalcinosis are a central feature of primary hyperoxaluria
phenotypes. Treatment options and renal prognosis vary considerably between the three genotypes
however, making early genetic diagnosis imperative.
Primary hyperoxaluria type 1 (PH1) is the commonest form of primary hyperoxaluria and displays
the most severe phenotype, with 50% of patients developing ESRD before the age of 25 [51]. Mutations
in AGXT, which encode the hepatic alanine-glyoxylate aminotransferase (AGT) enzyme, result in an
inability to break down glyoxylate into glycine. Instead, glyoxylate is converted to oxalate, leading to
pathological hyperoxaluria [49]. Pyridoxine (vitamin B6) is a co-factor for AGT, and therefore offers
a therapeutic target unique to PH1. An estimated 10–40% of PH1 patients respond to pyridoxine
supplementation, which can delay progression to ESRF and allow consideration of isolated renal
transplantation rather than simultaneous liver/kidney transplantation providing the patient is fully
pyridoxine sensitive [51,52]. Early initiation of conservative measures such as high fluid intake and use
of potassium citrate may reduce the incidence of nephrolithiasis and delay progression to ESRD [51].
However, due to the risk of systemic oxalosis, renal replacement therapy (RRT) must be initiated once
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plasma oxalate levels > 30–45 μmol/L, often resulting in patients commencing dialysis at much higher
GFR levels than for other renal conditions [52].
PH1 is far more prevalent in developing countries (likely related to higher consanguinity rates)
meaning access to liver transplantation is limited [51]. Even in countries where transplantation is more
accessible, it carries significant risks for the patient [52]. The evolution of our treatment of this condition
therefore hinges upon identifying therapeutic targets which do not necessitate organ transplantation to
replace the defective enzyme. Trials utilising the oxalate-metabolising bacterium Oxabacter formigenes
to increase gut excretion of oxalate and reduce urinary oxalate excretion reached phase II/III trials
but did not significantly reduce urinary oxalate excretion [50]. Animal studies have shown oxalate
decarboxylase enzymes can effectively reduce urinary oxalate levels, providing an alternative potential
future therapy for reduction of calcium-oxalate nephrocalcinosis in primary hyperoxaluria [53,54].
Primary hyperoxaluria type 2 (PH2) occurs as a result of mutations in GRHPR which encodes the
glyoxylate reductase/hydroxypyruvate reductase enzyme. PH2 exhibits a less severe phenotype, with
lower incidence of nephrolithiasis and nephrocalcinosis. It is rare for PH2 patients to progress to ESRD
or develop systemic oxalosis [51].
Primary hyperoxaluria type 3 (PH3) account for only 10% of PH patients [49]. Mutations in
HOGA1, which encodes the hepatic enzyme 4-hydroxy-2-oxoglutarate aldolase, underlie the condition.
PH3 has a milder phenotype, with lower nephrolithiasis burden, and nephrocalcinosis and renal
impairment being less common
2.10. GDNF Mutations
Medullary sponge kidney (MSK) is a congenital disorder resulting in ectatic collecting ducts
within one or both kidneys. The clinical sequelae of nephrolithiasis, nephrocalcinosis, recurrent
urinary tract infections and urinary acidification defects are often not apparent until adulthood [55].
The underlying pathogenesis of MSK is yet to be fully elicited. Whilst once considered a sporadic
disorder, evidence of MSK cases showing likely autosomal dominant inheritance have emerged,
intensifying the search for underlying genetic causes [56]. Identification of mutations in GDNF, which
encodes glial cell-derived neurotrophic factor, have now been identified in some MSK patients and
may account for the underlying pathophysiological process in a subset of MSK patients [57].
3. Other Genetic Conditions That May Feature Nephrocalcinosis within Their Clinical Phenotype
Hypercalciuria acts as a predisposing factor for medullary nephrocalcinosis formation; any
condition associated with excess urinary calcium excretion may lead to cases of nephrocalcinosis.
Hypercalciuria and nephrocalcinosis have been described in association with the inherited conditions
Wilson’s disease, Williams-Beuren syndrome and cystic fibrosis.
Wilson’s disease, a rare autosomal recessive condition characterised by ATP7B mutations leading
to defective copper excretion, can feature a renal Fanconi syndrome [58,59]. In Wilson’s disease patients
exhibiting hypercalciuria, nephrolithiasis and nephrocalcinosis have been described [59].
Williams-Beuren syndrome is a developmental disorder occurring as a result of a microdeletion
on the q arm of chromosome 7. The classical phenotype includes a distinctive facial appearance,
intellectual disability and cardiovascular problems. However, patients with this syndrome have
been found to be at increased risk of hypercalcaemia; the combination of resulting dehydration and
hypercalciuria have led to cases of nephrocalcinosis being described [60].
Cystic fibrosis, caused by mutations in the CFTR gene, has been associated with hypercalciuria
and microscopic nephrocalcinosis. However, the patients described did not demonstrate any signs of
renal dysfunction associated with their microscopic nephrocalcinosis [61].
Amelogenesis Imperfecta describes a group of inherited enamel defects; there have been case
reports of nephrocalcinosis detection in some of these patients in association with a distal renal tubular
acidosis. However, in contrast to Wilson’s disease, Williams-Beuren syndrome and cystic fibrosis, these
patients have not demonstrated hypercalciuria, indicating different underlying pathophysiology [62].
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4. Conclusions
Monogenic causes of nephrocalcinosis account for a rare set of conditions with a low population
frequency. However, the clinical course for affected patients is very different depending on their
underlying genotype. Accurate, prompt diagnosis allows early initiation of conservative measures,
which in some cases can halt nephrocalcinosis or delay progression of renal impairment. Establishing
the underlying genetic mutation also allows accurate prognostic information to be given and can help
facilitate screening of other family members. As our understanding of these rare inherited conditions
increases, it is hoped further treatment targets that address underlying enzymatic/protein defects will
emerge. However, at present for the majority of cases treatment strategies focus upon supportive
treatments to correct biochemical parameters, and careful monitoring of disease progression.
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Abstract: IgA Nephropathy (IgAN) is a primary glomerulonephritis problem worldwide that
develops mainly in the 2nd and 3rd decade of life and reaches end-stage kidney disease after 20 years
from the biopsy-proven diagnosis, implying a great socio-economic burden. IgAN may occur
in a sporadic or familial form. Studies on familial IgAN have shown that 66% of asymptomatic
relatives carry immunological defects such as high IgA serum levels, abnormal spontaneous in vitro
production of IgA from peripheral blood mononuclear cells (PBMCs), high serum levels of aberrantly
glycosylated IgA1, and an altered PBMC cytokine production profile. Recent findings led us to focus
our attention on a new perspective to study the pathogenesis of this disease, and new studies showed
the involvement of factors driven by environment, lifestyle or diet that could affect the disease. In
this review, we describe the results of studies carried out in IgAN patients derived from genomic
and epigenomic studies. Moreover, we discuss the role of the microbiome in the disease. Finally, we
suggest a new vision to consider IgA Nephropathy as a disease that is not disconnected from the
environment in which we live but influenced, in addition to the genetic background, also by other
environmental and behavioral factors that could be useful for developing precision nephrology and
personalized therapy.
Keywords: IgA Nephropathy; microbiome; virome; environment
1. Introduction
IgA-Nephropathy (IgA-N) is the most common form of primary glomerulonephritis worldwide.
It is characterized by the manifestation of mesangial IgA deposits in the glomeruli leading to frequent
episodes of intra-infectious macroscopic hematuria or continuous microscopic hematuria and/or
proteinuria. The aberrant synthesis of deglycosylated IgA1, selective mesangial IgA1 deposition with
ensuing mesangial cell proliferation and extracellular matrix expansion lead to renal fibrosis, with
molecular mechanisms still poorly understood. Approximately 40% of patients older than 20 years
develop end-stage renal disease within 20 years after the renal biopsy-proven diagnosis [1,2]. The
prevalence of IgA-N ranges widely worldwide, from 16.7% in the USA to 48.7% in Australia of all
patients with biopsy-proven primary glomerulonephritis as reported in regional biopsy registries. The
frequency of the disease increases from the Western (USA 16.7%) to the Eastern regions of the world
(Japan 47.4%) [2,3]. IgAN is the most common glomerulonephritis in Asia, where it accounts for 40%
of glomerulonephritis; it is also very common among the native Americans in Manitoba, the Zuni
and the Australian aborigines; it is rare in African native populations and in the Indian [2–7]. The
family aggregation has been widely described in the world, in sibling pairs, in families and in extensive
pedigrees belonging to geographically-isolated populations [8–10]. The difference in percentages in all
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countries may be only partially attributed to late referral to nephrologists, routine screening of urine
in some countries, and disparities in the indication to perform a kidney biopsy in individuals with
permanent urinary abnormalities.
Several studies describe immunological abnormalities involving B and T lymphocytes throughout
the clinical course of the disease [11]. Naive B cells express surface IgM/IgD and have to go through
a process of clonal expansion, isotype switching, affinity maturation, and differentiation before IgA
plasma cells develop. During the process of class switching, recombination occurs by looping out and
deletions of segments of DNA. In IgA-N patients, B cells not only seem to be increased in number in both
bone marrow and tonsils [12–14], but also show reduced susceptibility to Fas-mediated apoptosis with a
marked expression of BCL-2 [12]. In addition, B cells produce polymeric IgA1 abnormally glycosylated
in response to a variety of antigens that initiate the formation of IgA immune complexes [15,16].
The regulation of IgA production by B cells is regulated in both a T cell-dependent and a T
cell-independent manner, through molecular signals involving the TNF-Receptor superfamily, which
is expressed on the surface of dendritic cells. In both cases, dendritic cells are thought to play a critical
role in this process. A functional defect of these cells has been observed in the nasal mucosa of IgA-N
patients, thus inducing dysregulation of the immune response [16].
Mucosal immunity is largely involved in the pathogenesis of the disease, as the exposure of the
upper respiratory tract to bacteria or virus is often associated with recurrent episodes of macroscopic
hematuria. There is increasing support for the hypothesis of altered cell homing in IgAN patients,
in which there is a displacement of mucosal derived plasma cells and a secretion of mucosal-type
antibodies in the systemic compartment [17,18]. In particular, CD4+ T cells represent a key component
of the mucosal immune defense against pathogens, altered homing from mucosal to systemic sites,
and excessive activation of this leukocyte subset has been demonstrated by Batra et al. [19].
Numerous observations point towards an important role for alterations in IgA biology in
the pathogenesis of the disease. Deposited IgA is predominantly polymeric IgA (pIgA) of the
IgA1 subclass [20] and has been shown to be differently glycosylated [21], since there is a reduced
galactosylation of the O-linked glycans in the hinge region of serum IgA1 and in IgA1 located in the
mesangial deposits. Levels of plasma IgA1 are elevated in about half of the IgA-N patients [21]. This is
the result of a higher production of deglycosylated IgA1 by plasma cells in the bone marrow and by
tonsillar lymphocytes [22,23]. IgA1 glycosylation takes place in the Golgi apparatus of the B cells. These
IgA1 proteins with altered glycans represent an autologous antigen recognized by ubiquitous, naturally
occurring antibodies, mostly of the IgG isotype with anti-glycan or anti-glycopeptide specificities [24].
Thus, the presence of glycan-specific anti-IgA1 antibodies promotes the formation of circulating
immune-complexes which are relatively large [25]. Because of their size, they are not efficiently cleared
from the circulation, and thus tend to deposit in the renal mesangium. Deposited immune-complexes
and/or polymeric IgA1 aggregated for their de-glycosylation stimulate mesangial cell proliferation and
production of cytokines (IL-6 or TGFβ) [26]. Continuous deposition of circulating IgA1-IgG immune
complexes induces activation of mesangial cells and of the innate immune system with the attraction of
macrophages that produce inflammatory mediators leading to renal damage. Interstitial infiltration by
T cells at the renal level causes tubular injury and sets in motion irreversible interstitial fibrosis leading
to end-stage renal failure. Hence, a dynamic constellation of B and T lymphocytes and their soluble
mediators participate at all levels in disease pathogenesis: Initiation, perpetuation, amplification,
regulation, disease relapse, and tissue and organ destruction.
2. Genetics Involvement in IgAN
IgA-N may occur in a sporadic or a familial form according to the clinical evidence that one or
more subjects belonging to the same family are affected by biopsy-proven IgA-N. The routine urinalysis
carried out in first-degree relatives frequently evidences the occurrence of urinary abnormalities. Such
abnormalities have been detected in 25% of first-degree relatives of IgA-N patients as compared to 4%
of unrelated subjects [27]. Moreover, first-degree relatives have a higher risk of developing the disease,
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with an odds ratio (OR) of 16.4 (95% CI 5.7–47.8), than second-degree relatives (OR = 2.4; 95% CI
0.7–7.9) [10]. Three loci linked for familial IgA-N have been found by our group [8,9] (7,8), and some
genetic variants which may predispose individuals to sporadic IgA-N have been identified [28]. The
IGAN 1 locus is located on chromosome 6q22-23, with a LOD score of 5.6 [9]. IGAN 2 and 3 loci are
located on chromosome 4q26-31 and 17q12-22, respectively [8]. These chromosomal traits may contain
causative and/or susceptibility genes for familial IgAN which may be involved in the development of,
or susceptibility to, overt IgA-N.
Advancements in the field of knowledge on the genetics of IgAN have recently been achieved
by the application of genome-wide association studies (GWAS) on large cohorts of IgAN cases and
controls. GWAS is an approach aimed at providing comprehensive coverage of the entire genome in
order to find variants associated with susceptibility to developing the disease. The major limitation of
GWAS is that they only identify common variants of susceptibility, and these obviously have only
a modest effect. However, a well-conducted GWAS can offer additional bias-free knowledge on the
biology of a human disease that could be clinically relevant, allowing for the identification of new
unknown pathways and of potential targets of innovative drug therapies. What is needed for an
informative GWAS is the collection of very large numbers of sporadic patients affected by IgAN and
healthy controls, comparable in age, sex and geographical origin. The recent GWAS have allowed the
discovery of common susceptibility variants to IgAN development. To date, several GWAS related to
IgAN have been published and, overall, have led to the identification of 15 disability susceptibilities
due to illness.
Regarding classical genetics, several hypotheses have been made on the type of inheritance in the
course of family IgAN. The autosomal recessive transmission would seem to be the most unlikely. Many
families have affected members in different generations of the pedigree; moreover, a high incidence
of the disease in children of consanguineous parents has not been found. An X-linked transmission
was considered, given that IgAN is more frequent in males; however, this hypothesis can be excluded
as the male-male transmission has also been observed. An autosomal dominant transmission with
complete penetrance has been excluded because, in the pedigrees there are numerous examples of
subjects that should be obligated carriers but that are healthy. Autosomal dominant transmission
with incomplete penetrance would seem to be the most plausible hypothesis as it would be a suitable
model to explain most pedigrees. This model would explain the presence of cases in many arms of
the pedigree and the recurrence of the disease in subsequent generations. Incomplete penetrance
may justify the presence of another genetic factor or environmental exposure. The other model that
would explain this type of family aggregation is the hypothesis of a multifactorial etiology in which
the combined effect of more genes and/or environmental factors is necessary for the development of
the disease in each individual [29].
The three major GWAS on IgAN, performed between 2010 and 2012, had shown a strong
contribution of the MHC locus in determining the risk of developing the disease; in addition to this
locus, the studies had identified 4 additional non-HLA susceptibility loci (chromosome 1q32, containing
the CFH cluster; chromosomal 8p23, comprising the DEFA gene cluster, codingα-defensin; chromosome
17p13, including TNFSF13; chromosome 22, including HORMAD2) [8,9,30]. Cumulatively, these 9
loci are responsible for around 5% of the risk of developing IgAN. In addition, the variation in the
frequency of risk alleles is able to explain a substantial proportion of the variation observed in the
various ethnic groups with regard to the prevalence of the disease, with the risk alleles showing a
higher frequency in Asians compared to Europeans.
The 3 loci in the MHC region (with the strongest signal at the HLA DQB1/DQA1/DRB1 locus)
suggested pathways involved in antigen processing and presentation [31]; a locus on chromosome 1q32
containing the Complement Factor H (CFH) gene cluster, suggested a metabolic pathway involved
in regulating the activation of the complement pathway. However, the locus on chromosome 22
(HORMAD2) is active in the regulation of mucosal immunity, through the regulation of IgA levels.
Moreover, the two regions on chromosome 17p13 and 8q23, containing respectively the TNFSF13
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genes (Tumor Necrosis Factor ligand superfamily member 13, encoding a protein which plays an
important role in the development of B cells) and DEFA (coding a protein, defensin, which has natural
antimicrobial properties, having a role in innate immunity) were also involved in the regulation of
mucosal immunity [31,32]. TNFSF13 codifies for APRIL, a potent B-cell stimulating cytokine that is
stimulated by intestinal bacteria and leads to CD40-independent IgA class switching [33]. APRIL
concentrations are high in patients with IgAN [34] and may upregulate intestinal IgA production [32]
(Table 1).
Table 1. Evidence of Potential Relationship with Environmental and Alimentary Hit in IgAN.
References Loci Chormosomes Year





TRIM27 and DUSP3 and the hyper-methylation of
VTRNA2-1 lead to the overexpression of TGFβ and to a
reduced TCR signal strength of the CD4+ T-cells, with a
consequent T helper cell imbalance
DUSP3 17q21.31
VTRNA2-1 5q31.1




The TLR9 loss in IgAN may result in impaired elimination
of mucosal antigens, prolonged antigen exposure to B cells
and an increase in immunologic memory leading to deal
with a continuous antigenic challenge that triggers the






MHC class II molecules are critical for antigen presentation
and adaptive immunity. MHC class II molecules participate
in the regulation of intestinal inflammation and IgA
production. VAV3 may modulate the intestinal
inflammation, IgA secretion, the glomerular inflammation,
the phagocytosis, and the clearance of immune complexes.
CARD9 may intervene in the regulation of bacterial




ITGAM-ITGAX 16p11 Integrins codified by ITGAM and ITGAX are expressed in
intestinal dendritic cells and bring to T-cell independent IgA
class-switch.
Kiryluk [39] HLA-DR– HLA-DQ 6p21 2012
There are four independent classical HLA alleles associated
with IgAN at this locus; two risk alleles (DQA1*0101,
DQB1*0301) and two protective alleles (DQA1*0102,
DQB1*0201). Some class II alleles have a permissive role in
autoimmunity, and thus may be associated with a greater
risk of antiglycan response
Yu [32] DEFA 8p23 2012
TNFSF13 codify for APRIL, a potent B-cell stimulating
cytokine which is stimulated by intestinal bacteria and lead




HLA-DP are MHC class II molecules, less well studied
compared with HLA-DQ and HLA-DR. Some class II alleles
have a permissive role in autoimmunity, and thus may be
associated with a greater risk of antiglycan response.
HLA-DPA1-DPB1-DPB2 6p21
TAP1-PSMB9 6p21
CFHR3-CFHR1 del 1p32 Elevated expression of TAP2, PSMB8, and PSMB9, may lead
to a proinflammatory intestinal state. HORMAD2 regulates
mucosal immunity, through the control of IgA levels.HORMAD2 22q12
Feehally [40] HLA-DR– HLA-DQ 6p21 2010
These data, however, suggested the possible existence of additional loci of susceptibility to
developing the disease. For this reason, new GWAS larger than the previous ones were performed [38].
In addition to replicating the 9 loci described in the previous GWAS, including the loci on chromosome
6p21 (HLA-DQ–HLA-DR, TAP1-PSMB8 and HLA-DP), on chromosome 1q32 (CFHR3-CFHR1), on
chromosome 8p23 (DEFA), on chromosome 17p13 (TNFSF13) and on chromosome 22q12 (HORMAD2),
new signals were identified, 4 of which in three new loci [38]: Integrin alpha M- Integrin alpha X
(ITGAM-ITGAX) on the 16p11 chromosome, implicated in the adhesion and migration of leukocytes
and in phagocytosis complement-mediated by monocytes and macrophages and associated with
the development of erythematous systemic lupus; CARD9, on chromosome 9q34, implicated in
the activation of nuclear factor NF-κB in macrophages, which gives an increased risk of ulcerative
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colitis and Crohn’s disease; and VAV3, on chromosome 1p13, implicated in the development of
B and T lymphocytes and in the antigen presentation process. PSMB8 and PSMB9 constitute
interferon-inducible immunoproteasome mediating intestinal NF-κB activation in inflammatory bowel
diseases (IBD) [41,42]. The TAP gene encodes a protein involved in the transport of antigens from
the cytoplasm to the endoplasmic reticulum for association with MHC class I molecules. Elevated
expression of TAP2, PSMB8, and PSMB9 may lead to a proinflammatory intestinal state [42]. Moreover,
two new independent signals (HLA-DQB1 and DEFA, respectively) were identified in previously
known regions (Table 1).
Some case-control association studies identified the C1GALT1 as an important gene for the
pathogenesis of IgAN and highlighted some C1GALT1 genetic variants associated with the IgAN
pathogenesis in the Italian and Chinese populations [43,44]. C1GALT1 codifies for the enzyme core
1,b1,3-galactosyltransferase 1 that adds a galactose to the IgA1 heavy-chain hinge region. In IgAN,
IgA1are aberrantly glycosylated, since the hinge-region O-linked glycans of the IgA1 heavy-chain lack
galactose. This contributes to the kidney mesangial deposition of IgA1.
In particular, these studies associated the disease to a C1GALT1 SNP (rs1047763) in the gene
promoter region. This variant was also correlated with a decreased C1GALT1 expression in homozygous
people [43]. Interestingly, the SNP is contained within the gene region binding the microRNA miR-148b
that was found regulating the C1GALT1 expression and the IgA1 O-glycosylation [45–47]. We do not
know whether this SNP effectively influences the disease pathogenesis, but probably it can affect the
miR-148b binding to C1GALT1.
Overall, the identified loci seem to be implicated in critical mechanisms for the development
of IgAN: The maintenance of the intestinal mucosal barrier, the synthesis of IgA at the mucosal
level, the modulation of the signal by NF-kB, the defense against intracellular pathogens and
complement activation. The innovative finding is that most of these loci are directly associated with
the risk of developing inflammatory bowel disease (HLA-DQ, HLA-DR, CARD9, and HORMAD2), or
maintenance of intestinal epithelial barrier integrity and response to various pathogenic pathogens
(DEFA, TNFSF13, VAV3, ITGAM-ITGAX, and PSMB8) (Table 1). In fact, abnormal glycosylation
mainly consists of polymeric IgA1, which is generated by mucosal IgA1-secreting cells. Also,
107 Immunocompetent B cells can migrate to the gut mucosal lamina propria, where they mature into
IgA-secreting plasma cells. These plasma cells can release dimeric IgA1, which can form dimeric IgA
or polymeric IgA proteins. The risen levels of polymeric IgA1 in the circulation may be the result
of ‘spillover’ from mucosal sites to the vascular space. Instead, the preponderance of the IgA that
achieves the circulation from the bone marrow is predominantly in a monomeric form [48,49].
VAV proteins are guanine nucleotide exchange proteins crucial for adaptive immune function
and NF-κB triggering in B cells, stimulating IgA production [50]. They are necessary for appropriate
differentiation of colonic enterocytes and avoiding natural ulcerations of intestinal mucosa [50].
Moreover, VAV3 may modulate the intestinal inflammation, IgA secretion, the glomerular inflammation,
the phagocytosis, and the clearance of immune complexes. DEFA genes codify for α-defensins that
are antimicrobial peptides keeping innate immunity against microbial pathogens. α-defensin 1 and
3 are synthesized in neutrophils, whereas α-defensin 5 and 6 (DEFA5 and DEFA6) are synthesized
by the intestinal Paneth cells. Whether DEFA IgAN risk alleles constitute a risk haplotype per se or
are associated with close variants of DEFA5 or DEFA6 genes is not clear. Anyway, the DEFA locus
may probably regulate intestinal microbial pathogens and inflammation. CARD9 codifies for a protein
necessary for the assemblage of a BCL10 signaling complex. It triggers NF-κB, which is involved in
both innate and adaptive immunity [51]. CARD9 intervenes in intestinal repair, T-helper 17 responses,
and regulation of bacterial infection after intestinal epithelial injury in mice [52].
ITGAM and ITGAX codify for integrins αM and αX that, together with the integrin β2 chain,
constitute leukocyte-specific complement receptors 3 and 4 (CR3 and CR4, respectively). High
quantity of these integrins, expressed in intestinal dendritic cells bringing to T-cell independent IgA
135
Int. J. Mol. Sci. 2020, 21, 189
class-switch [53,54]. In addition, ITGAM and ITGAX are also present in macrophages and contribute
to the phagocytosis process (Table 1).
Indications on the involvement of genes correlated with environmental factors or eating habits
have also come from studies on copy number variations (CNV) in IgAN patients. Ai Z. et al. identified
CNV of DEFA locus, including DEFA1A3, DEFA3 [36], and Sallustio et al. identified GALNT13,
COL11A2, and TLR9 loci that are associated with susceptibility to and progression of IgAN [37]
(Table 1). In particular, a TLR9 loss has been found associated with IgAN progression and renal
dysfunction. TLR9 is expressed in immune system cells such as B cells, dendritic cells, macrophages,
natural killer cells, and other antigen-presenting cells [55]. TLR9 preferentially binds unmethylated
CpG dinucleotides (CpG DNA) released by bacteria and viruses and triggers signaling cascades
that lead to a pro-inflammatory cytokine response [56,57]. In IgAN, the TLR9 CNV loss may lead
to the failure of CpG to induce the proliferation of memory B cells because of the lower expression
levels of TLR9, thus exacerbating IgA class switching in naive B cells via BCR. This may result in
impaired elimination of mucosal antigens, prolonged antigen exposure to B cells, and an increase
in immunologic memory leading to deal with a continuous antigenic challenge that triggers the
production of nephritogenic IgA1 [58–61].
Taken together, these data seem to suggest that IgAN is an inflammatory disease with an
autoimmune genesis that involves or perhaps even originates in the intestine. GWAS study of the
Gharavi group also showed that the frequency of the 15 identified genetic risk factors reflects the
different distribution of IgAN frequency in the various areas of the world. It was confirmed that the
loci of susceptibility to develop IgAN were, in fact, more frequent in Asian populations, which have
the highest incidence of disease, and less frequent in African populations, which have the lowest
incidence [38]. This data strongly suggested that the distinctive geographic pattern of IgAN risk alleles
could have been modeled by an adaptation to the local environment.
The environmental influence on IgAN is supported also from DNA methylation studies showing
that aberrant DNA methylation in IgAN patients influences the expression of some genes involved
in the T-cell receptor signaling, the pathway that transfers the signal of the presence of antigens and
that activates the T-cells [35]. In particular, the hypo-methylation of TRIM27 and DUSP3 and the
hyper-methylation of VTRNA2-1 lead to the overexpression of TGFβ and to a reduced TCR signal
strength of the CD4+ T-cells, with a consequent T helper cell imbalance. DNA methylation studies are
important because the structural modifications of the DNA can be established through environmental
programming. Moreover, the DNA methylation can be dynamic and potentially reversible [62]. For
these reasons, further studies about the DNA methylation in IgAN will be needed to better understand
environmental influences on this disease.
The last GWAS study of the Gharavi group suggested that the distinctive geographical pattern of
IgAN risk alleles could have been modeled by adaptation to the local environment [38]. It was also able
to better define potential environmental factors able to explain such an adaptation process. The authors
carried out an association analysis of the genetic risk score to develop IgAN with some ecological
variables present in the populations enrolled in the study, reflecting the local climate, pathogenic load,
and dietary factors. A strong positive association emerged between the score of genetic risk for IgAN
and the diversity of local pathogens such as viruses, bacteria, protozoa, helminths. The strongest
correlation was the diversity of parasitic worms (helminths), which often infest the intestine. The
increased incidence of IgAN in some geographical areas, therefore, could be the accidental consequence
of a protective adaptation from intestinal worm mucosal invasion. Helminth infection has been an
important source of morbidity and mortality in human history, and still occurs in 25% of the world’s
population, with the highest global burden of soil-transmitted helminth infections (geo-helminthiasis)
in Asia, where it contributes significantly to pediatric mortality. Schistosomiasis, a common helminthic
infection that is a long-known cause of secondary IgAN, further supports this hypothesis.
On the other hand, it is known that host-pathogen interactions have exerted a critical influence on
the genetic architecture of IBD. According to these data, IgAN susceptibility loci appear to be either
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directly associated with the risk of IBD or encode proteins involved in maintaining the intestinal
mucosal barrier or in regulating the mucosal immune response. Thanks to these latest studies it is
possible to link inflammatory diseases of the intestinal mucosa, including IBD, with the risk of IgAN,
and to explain why these two diseases occur simultaneously more often than expected. These data are
also consistent with the clinical observations that mucosal infections often trigger episodes of acute
nephritis during IgAN, with the key role of IgA in defense at the mucosal surface level.
3. Microbiota and IgA Nephropathy: The “Chicken or Egg” Question
The ensemble of bacteria, bacteriophages, fungi, protozoa, and viruses that live in the digestive
tract of humans, called microbiota, is in contact with the gut epithelium and plays a role in the
development of the mucosal-associated lymphoid tissue (MALT) and, reciprocally, the composition of
the commensal microbiota depends on MALT function [63,64]. In humans, the MALT is the primary
source of IgA [65], and numerous studies indicate that IgA Nephropathy (IgAN) is closely associated
with alterations in the gut microbiota [34,66,67]. To date, it is unclear whether dysbiosis precedes the
disease or if the IgAN can lead to gut dysbiosis.
A transgenic mouse model of IgA nephropathy that overexpresses the B cell activation factor of
the TNF family (BAFF) fails to develop glomerular IgA deposits when raised in germ-free conditions
until gut microbiota are introduced [34].
In a cross-sectional study, Gesualdo et al. [66] identified reduced fecal microbial diversity in
patients with progressive IgAN compared to those with non-progressive IgAN and healthy subjects.
IgAN patients have been found to have microbial dysbiosis with an increased Firmicutes/Bacteroidetes
ratio. Specifically, in the fecal samples of IgAN patients, a high level of Firmicutes has been found. They
are characterized by high percentages of some genera/species of Ruminococcaceae, Lachnospiraceae,
Eubacteriaceae, and Streptococcaeae. Instead, healthy controls presented a higher level of Clostridium,
Enterococcus and Lactobacillus genera.
4. Microbiome Modulation in IgAN: “State of the Art”
In the context of detection of microbiota dysbiosis in IgAN patients, restoring some microbial
gaps could lead to new supportive therapeutic strategies, such as the use of antibiotics or dietary
implementation with prebiotics and/or probiotics, or through fecal microbiota transplantation (FMT).
In this scenario, the first therapeutic approach was conducted by Monteiro et al. [67]. The authors
have demonstrated that antibiotic treatment (ampicillin, vancomycin, neomycin, and metronidazole)
of a double transgenic mice model of IgAN reverses the phenotype of the disease; but this antibiotic
cocktail may have other collateral effects on the gut and weight. Moreover, it is not feasible to give to
patients a broad-spectrum antibiotic mix, and it could generate resistant strains of bacteria.
The use of probiotics, prebiotics or symbiotics may prove to be a viable and low-risk therapeutic
strategy in the future. Probiotics have anti-inflammatory, anti-oxidative, and other favorable
gut-modulating properties [68]. Especially species from the Lactobacilli and Bifidobacteria genera
were shown to support the humoral immune responses against environmental toxins and antigens [69].
The use of probiotics or symbiotics in patients with chronic kidney disease has been shown to have
some beneficial effects on the uremic toxins, blood urea nitrogen, oxidative stress, and markers of
inflammation also by enhancing barrier function [70–73]. In that regard, the study of Soylu et al. [74]
showed that the administration of Saccharomyces boulardii, which is able to decrease intestinal
inflammation through modulation of the T-cell [75], reduced systemic IgA response and protected
induced IgAN mice from the disease.
Another future weapon against the IgAN could be the FMT. This approach consists of stool
transfer from a selected healthy donor to the gastrointestinal tract of a recipient patient suffering
from microbial dysbiosis [76]. Currently, FMT is recommended as the most effective therapy for the
recurrent Clostridium difficile infection [77]. Although there is no strong evidence that supports the
use of the FMT in IgAN, promising studies are focusing on revealing whether this therapeutic option
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may play a role in the management of this disease. Indeed, an interesting interventional ongoing study
(clinical trial NCT03633864) aims to determine the safety and efficacy of FMT in IgAN patients not
responding to the standard treatment or not responding to immunosuppressive treatments.
5. The Interplay between the Microbiome and Virome: A New Vision of Human Metagenome
The human gut microbiome is a complex ecosystem that begins with colonization at birth and
continues to alter and adapt throughout the life of an individual [78]. The bacterial and archaeal
communities of the microbiome provide their host with an array of functions, including immune
system development, synthesis of vitamins, and energy generation [79]. The bacterial components are
characterized by high temporal stability in a healthy subject but can be transiently affected by events
such as travel, sickness, and antibiotic usage [80].
Recently, the scientific community focused attention also on the human virome. The human
virome consists of both the viral component of the microbiome, dominated by bacteriophages [80],
and a variety of DNA viruses that directly infect eukaryotic cells [81]. Viruses access the human body
through mucosal surfaces, where they interact with the host immune defense, commensal bacteria
included. Bacteria of microbiota interact with viruses to eliminate or reduce their infectivity, ensuring
the homeostasis of the mucosal sites, but viruses had mechanisms to take advantage of the microbiota,
and thereby evade the immune system [82]. The concept of the virome as a stable part of the human
metagenome has been raised from studies on chronic viral infections. During a chronic viral infection,
a dynamic relationship between the host and viral agents occurs, creating a continuous state of immune
surveillance. This immune system dynamism is neutral for the host, but it has a critically important
role in shaping the “normal” human immune system [83]. The virome is one of the most variable
components of the human gut microbiome, changing from childhood to adult life [84] in response
to different environments, lifestyles or infections. A number of cross-sectional population studies
reported disease-specific alterations of the gut virome in a number of gastrointestinal and systemic
disorders, such as inflammatory bowel disease [85,86], AIDS [87], diabetes [88], and malnutrition [89].
However, to date, interpretation of these data is inconsistent, due to the very high variability in the
virome composition and the lack of exact taxonomic classification and biological properties of several
viral groups [80].
Recent studies have shed light on how resident enteric viruses may affect host physiology beyond
causing disease [90]. Despite the partial picture of the taxonomic composition of the mammalian
virome, recent investigations showed that the preponderance of viruses residing in the intestine are
bacteriophages, which infect bacteria and can be released from them in response to stress signals [91].
As a consequence of the lysis of bacteria by phages, bacterial cell wall components and bacterial
and phage DNA can trigger pattern recognition receptors in intestinal or immune cells, influencing
intestinal homeostasis and immunity [92,93]. This hypothesis has been investigated in several studies
with discordant results. In fact, some in vitro studies showed that phages were internalized by
phagocytosis or endocytosis in lysosomes of lymphocytes and degraded without inflammation [94].
A different study performed on mice showed activation of myeloid differentiation primary response
88 (MyD88)-dependent pathway, with consequent involvement of TLRs [95]. Despite controversial
results, it is clear that enteric phages have a key role in the modulation of the bacterial microbiome on
the intestinal mucosal surface [90].
It is known that IgAN and other glomerulonephritides are clinically associated with viral infections,
such as hepatitis B virus [96], respiratory syncytial virus [97] or HIV [98]. Most viral pathogens for
mammals produce double-stranded RNA (dsRNA) incidental to viral replication. dsRNAs are
recognized by TLR3, which is expressed on the cellular membrane surface of many immune cells [99].
TLR3 binds primarily to dsRNA and induce antiviral and inflammatory responses, mediated by the
TNFs system and NFkB [100,101].
Yamashita et al. investigated the cellular podocyte response to dsRNA [102]. Cell cultures of human
or murine podocytes were cultured and stimulated with Polyinosinic-polycytidylic acid (Poly(I:C)),
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a synthetic double-stranded (ds) RNA. RT-PCR, immunoblotting, phenotype characterization and
functional assays were then performed to study alterations in podocyte marker expression or cellular
functions. They found that human and murine podocytes expressed TLR3 and other proteins of its
correlated activation pathway. Stimulation with synthetic dsRNA led to the activation of the TLR3
signaling, and exposed podocytes showed alteration in migration processes and defective expression of
proteins podocyte-specific such as nephrin, podocin or CD2AP, and increased transepithelial albumin
flux [102]. Although these results need to be validated by in vivo experiments, they support the
hypothesis that dsRNA exposure can contribute to glomerular injury associated with immune complex
deposition and could be associated with the progression of IgAN.
The group of He L. et al. [103] offered more direct evidence of the involvement of dsRNA in IgAN.
In this paper, human leukocytes, isolated from tonsil tissue and whole blood, were cultured with
or without poly(I:C) for 1–7 days. They also analyzed lymphomonocyte, urine, kidney and spleen
samples from rats administered with or without poly(I:C) in the presence or absence of IgAN. In both
in vivo and in vitro experiments, theTLR3-dependent BAFF expression was upregulated after a viral
infection, especially in IgAN patients or animals. The TLR3 crosstalk with BAFF plays a vital role in
the over-production of IgA and in the Recombinant Class Switch to IgA in IgAN. Thus, the inhibition
of TLR3/BAFF axis activation could be an interesting option for preventing IgAN progression [103].
These studies demonstrated that exposure to viral products can directly influence the IgAN
progression. However, to date, there are no data available about a direct role of the virome in the
modulation of IgAN pathogenesis and/or progression. Specific studies aimed to study the influence of
virome in healthy and pathological processes are in very early stages, and efforts must be made to
improve our knowledge in this challenging field.
6. Conclusions
The GWAS and the other whole-genome genomic studies, thanks to technological developments
in the field of genetics, have allowed researchers to identify multiple susceptibility loci for the IgAN
and, consequently, they have shed new light on the pathogenesis of this disease, revealing the
close connections with multiple environmental, alimentary and behavioral factors. Nevertheless,
these studies have made possible the correlation of the genetic risk to develop IgAN with the
geo-epidemiological aspects of the disease. These findings focalize attention on a new perspective to
study the IgAN pathogenesis and show the involvement of factors driven by environment, lifestyle, or
diet affecting the disease (Table 1). These factors may represent the missing link in IgAN pathogenesis.
Many steps forward have been taken in the characterization of IgAN, and new studies through an
integrated genomic approach will be needed to deepen the etiopathogenetic mechanisms and to
suggest new potential therapeutic targets. Nevertheless, recent data suggest a new vision to consider
the IgA Nephropathy as a disease which is not disconnected from the environment in which we live
but influenced by, in addition to the genetic background, other environmental and behavioral factors
that could be useful for developing precision nephrology and personalized therapy.
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Abstract: Pseudoxanthoma elasticum is a rare disease mainly due to ABCC6 gene mutations
and characterized by ectopic biomineralization and fragmentation of elastic fibers resulting in
skin, cardiovascular and retinal calcifications. It has been recently described that pyrophosphate
(a calcification inhibitor) deficiency could be the main cause of ectopic calcifications in this disease
and in other genetic disorders associated to mutations of ENPP1 or CD73. Patients affected by
Pseudoxanthoma Elasticum seem also prone to develop kidney stones originating from papillary
calcifications named Randall’s plaque, and to a lesser extent may be affected by nephrocalcinosis.
In this narrative review, we summarize some recent discoveries relative to the pathophysiology of
this mendelian disease responsible for both cardiovascular and renal papillary calcifications, and we
discuss the potential implications of pyrophosphate deficiency as a promoter of vascular calcifications
in kidney stone formers and in patients affected by chronic kidney disease.
Keywords: pseudoxanthoma elasticum; pyrophosphate; kidney; Randall’s plaque
1. Introduction: Pseudoxanthoma Elasticum and Related Diseases
1.1. Clinical Manifestations
Pseudoxanthoma elasticum (PXE; OMIM #264800, prevalence 1/25,000 to 1/50,000) is an autosomal
recessive disease resulting mainly from mutations in ABCC6 gene [1,2]. PXE is characterized by the
fragmentation of elastin fibers, elastorrhexis, and calcifications of soft tissues involving mainly skin,
arteries and retina [3,4]. The 2/3 female to 1/3 male ratio in patients diagnosed with PXE remains
unexplained to date.
The disease may present during infancy but is classically discovered in teenagers or young adults,
because of cutaneous manifestations [3–6].
Xanthoma-like papules may be sparse or form coalescent plaques and folds of esthetic concern.
They give the name to the disease and predominate in flexion zones and neck. Skin biopsy and
histopathological examination reveal calcifications with destruction of the elastic fibers [7]. It remains
uncertain whether elastorrhexis precedes calcifications or whether calcified elastin fibers are broken in
a second step.
PXE also affects retina, inducing fragmentation and rupture of calcified elastin fibers of the Bruch’s
membrane. The examination of the fundus of the eye reveals a typical “peau d’orange” aspect in
Int. J. Mol. Sci. 2019, 20, 6353; doi:10.3390/ijms20246353 www.mdpi.com/journal/ijms147
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PXE patients, with angioid streaks and choroidal neovascularization leading to hemorrhages [8,9].
When affecting the macula, these lesions lead to the loss of central vision.
Cardiovascular calcifications are a hallmark of PXE but clinical manifestations are relatively
delayed, predominating after the fourth decade of life, and their severity is extremely variable among
PXE patients [5]. Peripheral arterial disease is frequent and there is a significantly increased risk
of stroke [10,11]. Coronary calcifications are also frequent but the risk of cardiac infarction seems
only mildly increased (if any) in comparison to the general population [5,12]. The earliest arterial
calcifications observed in PXE affect elastic fibers of the medial layer, and predominate in medium
and small-sized musculo-elastic arteries. Cardiovascular remodeling in large and medium sized
musculo-elastic arteries is characterized by an increased intima-media thickening [13,14]. The arterial
lesions affecting PXE peripheral arteries differ from those due to aging, hypertension or classic
atherosclerosis and share similarities with calcifications and remodeling observed in chronic kidney
disease [5,15].
To date, there is no specific curative or preventive therapy for PXE patients. Bisphosphonates such
as Etidronate seem promising to prevent cardiovascular calcifications and anti-Vascular Endothelial
Growth Factor (VEGF) intraocular injections limit neoangiogenesis [9,16,17].
Two other autosomal recessive mendelian diseases share phenotypic similarities with PXE:
the generalized arterial calcifications of infancy (GACI), caused by mutations of the ectonucleotide
pyrophosphatase phosphodiesterase NPP1 encoded by the ENPP1 gene (OMIM 208000) and Arterial
calcification due to deficiency of CD73 (ACDC, OMIM 211800), due to mutation of the NT5E gene
encoding CD73, an ecto 5’-nucleotidase adenosine (ADO)-generating enzyme [18–21] GACI is an
extremely severe but fortunately rare disorder characterized by extensive arterial calcification and
stenosis affecting young children leading to heart failure. In some cases, the disease is less severe and
patients with ENPP1 mutations may present with the PXE phenotype. ACDC has been discovered more
recently in a few families and is also characterized by cardiovascular calcifications and stenosis [19,20].
In addition to phenotypic resemblances, these three diseases share a common pathophysiological
link: pyrophosphate (PPi) deficiency.
1.2. Pathophysiology of PXE, GACI and ACDC: Pyrophosphate Deficiency
During decades, the mechanism responsible for ectopic calcifications in PXE patients remained a
mystery. ABCC6 mutations are responsible for most of the PXE syndromes diagnosed. ABCC6 encodes
an adenosine triphosphate (ATP)-binding cassette transporter mainly expressed in the liver and to a
lesser extent in kidney proximal tubular cells [1,22,23]. This specific expression raised the hypothesis
that PXE would be a metabolic disease responsible for distant manifestations, i.e., connective tissue
calcifications [24]. Due to its structure, close to other ABC-type transporters, ABCC6 could promote the
efflux of calcification inhibitors from hepatocytes and tubular cells toward the systemic circulation [24].
A role for vitamin K has been suggested by several observations [25]. First, antivitamin K
therapy is associated with vascular calcifications and sometimes calciphylaxis in hemodialyzed
patients [26]. Second, GGCX mutations cause a PXE-like calcification phenotype and are associated
with deficiency in vitamin K clotting factors [25]. The GGCX gene encodes a gamma-glutamyl
carboxylase which catalyzes the conversion of glutamate residues to gamma-carboxyglutamate
residues (gamma-carboxylation). This posttranslational modification process uses vitamin K as an
essential cofactor. Gamma-carboxylation is necessary to activate multiple vitamin K-dependent
proteins including coagulation factors (Factors II, VII, IX and X) and proteins such as Matrix Gla
Protein (MGP). Third, PXE patients have lower serum levels of vitamin K in comparison with a control
population [25]. Finally, MGP is a vitamin K-dependent mineralization inhibitor. MGP homozygous
mutations are responsible for Keutel syndrome, characterized by cartilage calcification and pulmonary
artery stenoses [27]. Nevertheless, administration of vitamin K was not efficient to reduce clinical
manifestations in patients or to improve significantly the ectopic calcification which also occur in
Abcc6−/− mice [28,29].
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A major breakthrough in the field of calcifying diseases has been the identification that the hepatic
(and probably tubular) ABCC6 transporter promotes the release of extracellular adenosine triphosphate
(ATP), which serves as a substrate for NPP1 in the vasculature to generate adenosine monophosphate
(AMP) and PPi, a potent anticalcifying molecule [30,31]. This process is the main source of circulating
PPi, that counteracts the formation of calcium phosphate ectopic calcifications. PPi inhibits the
crystallization and the growth of calcium phosphate crystalline phases such as hydroxyapatite [32].
Patients with PXE and GACI as well as Abcc6−/− and Enpp1 mutant (tiptoe walking: ttw/ttw) mice have
a reduced plasma PPi level, explaining, at least in part, their mineralization disorder [22]. Of note,
PPi treatment is sufficient to prevent ectopic mineralization in both Abcc6−/− and Enpp1ttw/ttw murine
models [33–35].
Moreover, ABCC6 and NPP1 combined activity generates AMP in addition to PPi. AMP is rapidly
converted into adenosine by CD73, which exerts a tonic inhibition on tissue non-specific alkaline enzyme
(TNAP). In ACDC, mutations in NT5E/CD73 lead to insufficient adenosine levels, increasing TNAP
activity: TNAP degrades PPi to generate inorganic phosphate and eventually promotes hydroxyapatite
precipitation in ectopic tissues [22,33,35].
Thus, ABCC6, NPP1 and CD73 increase PPi systemic synthesis and decrease endogenous PPi
degradation through TNAP inhibition (Figure 1).
 
Figure 1. Systemic Pyrophosphate (PPi) synthesis. ABCC6 (expressed in hepatocytes and proximal
tubular cells) and NPP1 (in arteries and capillaries) combined activity generates AMP in addition
to PPi. AMP is rapidly converted into adenosine by CD73, which exerts a tonic inhibition on tissue
non-specific alkaline enzyme (TNAP). TNAP degrades PPi to generate inorganic phosphate and
promotes hydroxyapatite precipitation in ectopic tissues. ANK allows PPi externalization from cells,
its role in ectopic calcifications is unclear.
2. Pseudoxanthoma Elasticum and Kidney Calcifications
2.1. Nephrocalcinosis and Kidney Stones: Preliminary Reports
A few preliminary and sparse reports have suggested that PXE patients may be affected by kidney
stones [36]. In addition to kidney stones, the presence of typical nephrocalcinosis has been reported in a
few patients affected by PXE [37–39]. When exposed to a procalcifying diet (high phosphate, vitamin D
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and low magnesium), Abcc6−/− and Enpp1−/− mice develop rapidly a nephrocalcinosis consisting in
multiple calcium phosphate tubular plugs [40].
2.2. High Prevalence of Kidney Stones in PXE Patients
In a recent PXE cohort study that was not specifically designed to record kidney stone prevalence,
observations suggested that nephrolithiasis was an unrecognized but a prevalent feature of PXE,
affecting at least 10% of patients [11]. To better characterize the prevalence of kidney stones among
patients with PXE, we conducted a retrospective study in 170 patients participating in the Angers PXE
cohort [41]. Among the 164 patients who received the survey, 113 fulfilled the questionaire (33 men and
80 women). Among these patients, 45 (39.8%) declared they had a past medical history of kidney stones
(asymptomatic stones in four patients or renal colic in 41 patients). Although this type of study may be
biased, as patients affected by kidney stones may be more prone to fulfill the survey, the prevalence of
kidney stones and renal colic in PXE patients appears to be extremely high. As a matter of comparison,
the lifetime expected incidence of kidney stones is nearing 10% in the general population. Usually,
urolithiasis is more frequent in males than females but in PXE patients approximately two thirds of the
patients are women. This is consistent with the higher prevalence of PXE in women.
The analysis of six computed tomography (CT)-scans from PXE patients revealed the presence
of papillary calcifications, Randall’s plaques, the first step of kidney stone formation in five of
them [41]. This is remarkable as only the presence of massive plaques can be determined by imaging.
These calcifications affected rather the tip of the renal papilla than the renal medulla. One patient
had both papillary calcifications and medullary calcifications, i.e., nephrocalcinosis. CT scans had
been performed in patients with a past medical history of kidney stones, but one may hypothesize
that patients with PXE and without a past medical history of urolithiasis may also be affected by
asymptomatic papillary calcifications. We examined a limited number of CT-scans so that we cannot
estimate the prevalence of papillary calcifications/Randall’s plaque and nephrocalcinosis in PXE patients.
A few stones from PXE patients have been analyzed and presented Randall’s plaque fragments made
of carbonated apatite, suggesting that stone formation in these individuals was initiated by these
plaques. No specific study dedicated to the biological risk factors of kidney stone formation in PXE has
been performed to date. In the same way, chronic kidney disease (CKD) is not a classic feature of PXE
and we still ignore whether some PXE patients affected by kidney stones and papillary calcifications
may be at risk to develop CKD.
2.3. Abcc6−/− Mice: A Murine Model of Randall’s Plaque
Abcc6−/− mice recapitulate many of the phenotypical characteristics of the human PXE disease [42].
Mice are affected by ectopic calcifications involving aorta, heart, retina and vibrissae and their PPi serum
level is lower than in control mice. As renal cortical and medullary calcifications had been described in
these animals, especially after an “acceleration diet”, we hypothesized that papillary calcification could
develop in this model [40]. Aging Abcc6−/− mice actually developed kidney calcifications electively
at the tip of the papilla, mainly in the interstitial tissue, round shaped and surrounding the loops
of Henle and the vasa recta: they differed from the tubular plugs observed after an acceleration
diet. These calcifications were made of carbonated apatite spheres as evidenced by scanning electron
microscopy and Fourier transform infrared microspectroscopy [41]. At the nanometer scale, by using
transmission electron microscopy coupled to electron energy loss spectroscopy, we evidenced that
incipient calcifications were made of concentric layers containing calcium and phosphate alternating
with organic compounds, as described in incipient human calcifications forming the Randall’s plaque.
Remarkably, the renal calcification observed in aging Abcc6−/− mice met the four essential criteria of
Randall’s plaque: (i) interstitial deposits surrounding tubules and vasa recta, (ii) electively located
at the tip of the renal papilla, (iii) made of carbonated apatite, and (iv) forming nanometer-scale
elementary structures made of minerals and organic compounds.
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Abcc6−/− mice had also a lower urinary excretion of PPi than control mice, and as previously
described lower serum levels of PPi [41]. Abcc6−/− mice expressing a functional human ABCC6
protein in the liver had an increase in serum PPi circulating levels and were protected against kidney
calcifications at 18 months of age [33]. It seems therefore very likely that the systemic PPi deficiency in
these mice was at the origin of calcium phosphate supersaturation at the tip of the papilla, leading to
papillary calcification.
3. The Mystery of Randall’s Plaque Formation: A Role for Calcification Inhibitors and Pyrophosphate?
3.1. Randall’s Plaque: the Origin of Renal Calculi
Randall’s plaque is the first step of calcium oxalate stone formation in many cases. Alexander
Randall proposed its original theory in 1936 when he claimed the identification of the origin of renal
calculi [43]. He performed extensive forensic studies and observed, at the tip of the renal papilla,
whitish deposits made of calcium phosphate and carbonate, originating from the renal interstitium.
In some cases, these lesions disrupted the urothelium cellular barrier and brown calcium oxalate stones
were attached to these “Randall’s” plaques, forming a heterogeneous nucleation process. He identified
that the calcium oxalate stones had an umbilication due the shape of the papilla and that calcium
phosphate remnants, fragments of Randall’s plaque, were present in this umbilication once the stone
was passed, identifying the origin of the stone. Other authors performed similar studies during this
period [44]. It has been postulated early that the high concentration in calcium in renal papilla could
be at the origin of the plaque. The interest in Randall’s plaque has grown during the last decades,
as the development of endourology evidenced the presence of stones attached to Randall’s plaque in
situ. Randall’s plaque was found in stone formers in 57%–99% of patients when reno-ureterocopy was
performed. The prevalence seems lower in France than in North American studies [45–49]. Although
Randall’s plaques seem to be very frequent, common papillary calcifications are usually too small to be
evidenced by CT-scan (unlike PXE patients).
3.2. Determinants of Randall’s Plaque Formation
The main risk factors responsible for calcium oxalate supersaturation and crystals or
stone formation are relatively well identified: low diuresis, hypercalciuria, hyperoxaluria and/or
hypocitraturia [47,50]. However, the origin of the Randall’s plaque itself is less understood.
The prevalence of calcium oxalate stones is increasing worldwide [47,51]. As there is no longitudinal
study taking into account stone morphology or papillary plaque coverage, the role of Randall’s
plaque in this epidemic is difficult to assess. However, we identified that the proportion of stones
with a papillary umbilication and typical plaque remnants was three times more frequent in recent
years than three decades ago, especially in young adults [52]. In 2003, Evan et al. analyzed papilla
biopsies and identified that incipient Randall’s plaque at the tip of the renal papillae were made of
subepithelial apatite deposits surrounding the loop of Henle [53]. These observations suggested that
apatite droplets formed in around the loop of Henle in contact with basement membrane could spread
in the interstitium and form plaques. It has been suggested that calcium phosphate supersaturation
in the thin limb of the loop of Henle could promote calcium phosphate particle precipitation and
that some of these particles attached to epithelial cells could migrate by endocytosis to the interstitial
tissue and form plaques [54,55]. We performed analyses of incipient Randall’s plaque in dozens of
healthy papillae and identified that early calcifications could also appear around vasa recta at the
tip of renal papilla, as previously highlighted by Stoller et al. [56,57]. This suggests that calcium
phosphate supersaturation should be extremely high in this environment. Kuo et al. have identified
that hypercalciuria, low diuresis and low urine pH correlated with the surface of Randall’s plaque in
kidney stone formers [58]. More than seven decades ago, Vermooten had performed forensic studies in
South Africa and identified Randall’s plaque in 17% of whites and only in 4% of the local native Bantus,
known to have low calciuria and to be rarely affected by calcium-related stones [44,59]. Hypercalciuria
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could therefore be involved first in Randall’s plaque formation and several years or decades later in
calcium oxalate stone formation, once plaque has developed and eroded urothelium locally.
3.3. Randall’s Plaque and Calcification Inhibitors
Calcium concentration is predicted to be extremely high at the tip of the renal papilla, especially
around vasa recta [60,61]. Considering (i) that phosphate concentration is certainly significant, although
reabsorbed partly in the proximal tubule, and (ii) that papillary pH should stand within physiological
range (7.4), calcium phosphate supersaturation should be extremely high at the tip of the papilla.
This suggests that calcification inhibitors play a key role to prevent Randall’s plaque formation. A very
large number of low-weight and macromolecular calcification inhibitors have been studied in the field
of urolithiasis [62]. Currently, there is no monogenic mendelian disease responsible for calcification
inhibitor deficiency and kidney stone formation, maybe with the exception of distal renal tubular
acidosis, which is responsible for hypocitraturia and nephrocalcinosis [63]. Interestingly, ABCC6
mutation in PXE patients and Abcc6 knock-out murine models are sufficient to induce papillary
calcification [41]. This monogenic defect responsible for PPi deficiency is clearly not compensated
by other calcification inhibitors. This observation is remarkable as the development of kidney tissue
calcifications is extremely difficult to achieve in rodent models. We previously tried to induce Randall’s
plaque in Sprague Dawley rats exposed to vitamin D and calcium supplementation for 6 months.
These animals developed tubular plugs and stones but none of them developed papillary interstitial
calcifications [64]. Similar observations have been performed in the genetic hypercalciuric stone
forming rat extensively studied by Bushinsky et al. [65]. These data confirm that calcification inhibitors,
especially PPi, play a major role to prevent Randall’s plaque formation.
Further studies are required to assess whether kidney stone formers affected by Randall’s plaque
have lower urine (or serum) PPi levels than kidney stone formers without Randall’s plaque or than
general population. Of note, seminal studies had previously highlighted that kidney stone formers
may have lower urinary PPi excretion than matched subjects [66]. However, this field of research has
probably been limited during the last decades by the lack of reliable methods to measure PPi, due to
pre-analytic pitfalls and to the very low concentration of PPi in biological fluids.
3.4. The Abcc6−/− Murine Model: A Tool to Identify Randall’s Plaque Determinants and New Therapeutics
Abcc6−/−mice expressing a functional human ABCC6 protein in the liver or supplemented with PPi
were protected against kidney calcification [33,34]. It has been shown that oral PPi is partly absorbed in
human subjects and increases serum PPi circulating levels. Taken together, these data suggest that PPi
or drugs increasing PPi synthesis could potentially be used as a treatment against kidney calcifications
and Randall’s plaque.
Abcc6−/− mice can also be used to test whether drugs or dietary factors could influence Randall’s
plaque formation. We hypothesized that the increased proportion of stones grown on Randall’s plaque
during the past decades could, at least partly, be explained by the widespread use of vitamin D
supplementation in the general population [52]. Although the question is extremely controversial,
some studies highlighted a relationship between vitamin D intakes, especially in addition with calcium
supplementation, and stone formation [67]. Abcc6−/− and wild-type mice were exposed to vitamin D
supplementation, with or without a calcium-rich diet, to promote the formation of Randall’s plaque.
The combined administration of vitamin D and calcium accelerated significantly Randall’s plaque
formation in Abcc6−/− mice, although the animal did not develop hypercalcemia or even a significant
increase in urine calcium excretion [68]. This model raises some concerns regarding the potential role
of long-term vitamin D supplementation and calcium intakes in predisposed individuals.
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4. Pyrophosphate Deficiency, the Common Link between Vascular Calcifications, Kidney Stones
and Chronic Kidney Disease?
Epidemiological studies have highlighted an association between nephrolithiasis and systemic
conditions including cardiovascular diseases but the underlying mechanisms remain unidentified [69].
Vascular calcifications are highly associated with cardiovascular mortality. Kidney stone formers,
even young patients, have an increased carotid intima-media wall thickness and an increased arterial
stiffness in comparison with matched populations [70,71]. Kidney stone formers have a higher degree
of aortic calcification than age- and sex-matched non-stone formers and more severe coronary artery
calcification, suggesting that vascular calcifications and kidney stones may have a common underlying
mechanism [72].
The potential implication of PPi in vascular calcification is not a novel hypothesis, as Schibler et al.
have reported in 1968 that PPi and polyphosphate can inhibit the induction of aortic calcifications by
vitamin D, but the recent evidence that PXE patients are affected by both cardiovascular calcifications
and kidney stones and Randall’s plaque suggests that PPi deficiency could be involved in the
development of vascular calcifications in kidney stone formers [41,73]. Here again, further studies
based upon a reliable assay of serum PPi levels would be necessary to assess whether PPi deficiency is
the missing link between kidney stone/Randall’s plaque and vascular calcifications.
Moreover, a relative deficiency in PPi could be involved in the vascular calcifications observed in
patients affected by CKD, responsible for an increased cardiovascular morbidity and mortality [74].
TNAP activity is increased in uremic rats, reducing PPi/inorganic phosphate ratio and ABCC6
expression is reduced in uremic mice and rats [75,76]. Exogenous PPi could in theory be of help to
protect against vascular calcifications in CKD.
5. Conclusions
An increased prevalence of kidney stones has been reported recently in patients affected by PXE,
a disease characterized by low circulating PPi levels and vascular calcifications. These patients are
affected by massive Randall’s plaques and in some cases by nephrocalcinosis. In clinical practice,
patients affected by PXE should be aware that they are at high risk to form kidney stones, and preventive
measures should be considered, as for any kidney stone former (increased diuresis, decreased urine
calcium excretion, etc.). These observations from a rare monogenic disease evidence that PPi probably
prevents the development of Randall’s plaque and, in the long term, the formation of kidney stones,
a disease with a lifetime incidence nearing 10% of the population. Further studies are required
to assess whether PPi deficiency is involved in Randall’s plaque and kidney stone formation in
the general population, but also whether administration of PPi could be protective in that setting.
Abcc6−/− mice can also be used as a model of Randall’s plaque to test new drugs or identify potential
determinants of plaque formation or worsening. In addition, PPi could be a missing link between
kidney stones and the high prevalence of cardiovascular calcifications observed in kidney stone formers,
a deficiency in PPi and potentially in other calcification inhibitors could promote both papillary and
vascular mineralization.
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Abbreviations
PXE Pseudoxanthoma elasticum
VEGF Vascular Endothelial Growth Factor
GACI Generalized arterial calcification of infancy
(E)NPP1 ectonucleotide pyrophosphatase phosphodiesterase
ACDC Arterial calcification due to deficiency of CD73
PPi Pyrophosphate
CT Computed Tomography
CKD Chronic kidney disease
TNAP Tissue nonspecific alkaline phosphatase
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